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 i 
Abstract 
Infection with Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB), remains 
responsible for at least 1.5 million deaths annually. While the discovery of effective antibiotics 
and extensive global control programs have reduced this rate, the close association between the 
TB disease and human immunodeficiency virus (HIV) infection, in addition to the emergence 
of drug-resistant strains of M. tuberculosis, has greatly hindered the progress of eradicating the 
disease. Bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis closely 
related to M. tuberculosis, is the only currently licensed anti-TB vaccine. The protective 
efficacy of BCG, however, has been reported to vary between 0 and 80% in adults. The long-
term control of TB will require the development of more effective anti-TB vaccines. Subunit 
vaccines are an attractive anti-TB vaccine strategy to boost BCG or as primary vaccines. 
Although subunit vaccines, including DNA and recombinant protein vaccines, have 
demonstrated promising immunogenicity and protection against experimental M. tuberculosis 
infection, their efficacy must be increased. In this study, several strategies have been explored 
to enhance the immune response generated by subunit vaccines against TB. 
Co-stimulation is pivotal for the induction of T cell responses. The effects of exogenous 
co-stimulation signals during DNA immunisation on the resulting vaccine-specific T cell 
responses and protective efficacies were explored. Plasmids encoding soluble, multimeric 
forms of the co-stimulatory molecules, CD40L or GITRL, were tested in combination with the 
anti-TB DNA vaccine candidate DNA3-Ag85B-64, encoding a mycobacterial fusion antigen of 
Ag85B and MPT64190-198. Co-immunisation with plasmids encoding the dodecameric CD40L 
or the dodecameric GITRL resulted in increased antigen-specific CD4+ and CD8+ T cell 
responses, however the enhanced antigen-specific T cell responses did not translate into 
increased protective immunity against M. tuberculosis infection. 
 ii 
Recombinant adeno-associated viruses (rAAV) are able to transduce a wide range of 
dividing and non-dividing cells, resulting in sustained long-termed expression of the encoded 
transgene. This property and the attenuation of rAAV’s have made them an attractive vector 
for genetic transfer or as vaccine vectors. rAAV encoding the mycobacterial antigen fusion 
Ag85B-MPT64190-198-ESAT was generated by triple plasmid transfection, purified and used to 
immunise mice either alone or as heterologous boost for a DNA vaccine. Mice immunised with 
rAAV2-Ag85B-64-ESAT developed antigen-specific CD4+ and CD8+ IFN-γ T cell responses, 
but the persistent antigen expression afforded by the rAAV vector did not stimulate protective 
efficacy against M. tuberculosis. Further, boosting a DNA vaccine with the rAAV vaccine 
expressing the same antigen construct did not increase the level of protective immunity against 
M. tuberculosis provided by the DNA immunisation alone. 
Interleukin-12 (IL-12) is essential for the development of optimal IFN‐γ T cell 
responses against M. tuberculosis. Co‐delivery of plasmid DNA encoding IL‐12 during DNA 
or BCG vaccination has been proven to increase the protective efficacy of these vaccines 
against TB infection. To determine if prolonged IL-12 expression would be more effective, a 
rAAV expressing murine IL‐12 was developed and evaluated as an adjuvant for DNA 
vaccination. The genes for murine IL‐12p35 and p40 chains (mIL‐12) were cloned into a rAAV 
vector under the control of Rous Sarcoma Virus (RSV) promoter, and this vector demonstrated 
to express functional IL-12. C57BL/6 mice co-immunised with DNA3-Ag85B-64-ESAT and 
rAAV-mIL-12 developed increased antigen-specific, IFN‐γ-secreting CD4+ and CD8+ T cell 
responses compared to mice immunised with the DNA vaccine alone. In addition, co-
immunisation with rAAV2-mIL-12 and the DNA vaccine partially restored vaccine-induced T 
cell responses in IL-12p40-/- mice. However, co-immunisation with rAAV2-mIL-12 and 
DNA3-Ag85B-6-ESAT did not increase the protective efficacy of the DNA vaccine alone. 
 iii 
Subunit vaccines have an excellent safety profile compared to live anti-TB vaccine 
candidates, such as attenuated M. tuberculosis or BCG, and may be used in immuno-
compromised individuals. MPT83 (Rv2873) is a secreted mycobacterial lipoprotein expressed 
on the surface of M. tuberculosis. rMPT83 was expressed and found to elicit strong IFN-γ T 
cell responses during human and murine M. tuberculosis infection. Immunisation with MPT83, 
either as a recombinant protein with monophosphoryl lipid A (MPLA) in dimethyl-dioctadecyl 
ammonium bromide (DDA) liposomes or as DNA-MPT83, stimulated strong antigen-specific 
T cell responses.  The T cell epitopes in MPT83 were examined in immunised C57BL/6 and 
BALB/c mice by peptide scanning, and in particular, MPT83127–135 was identified as the 
dominant H-2b-restricted CD8+ T cell epitope within MPT83. Further, immunisation of 
C57BL/6 mice with rMPT83/MPLA/DDA or DNA-MPT83 stimulated significant levels of 
protection in the lungs and spleens against aerosol challenge with M. tuberculosis. Interestingly, 
immunisation with rMPT83 in MPLA/DDA primed for stronger IFN-γ T cell responses to the 
whole protein following challenge, while DNA-MPT83 primed for stronger CD8+ T cell 
responses to MPT83127–135. Therefore MPT83 is a protective T cell antigen commonly 
recognised during human M. tuberculosis infection and should be considered for inclusion in 
future TB subunit vaccines. 
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1.1 Tuberculosis – The Global Burden 
Tuberculosis (TB) in humans remains one of the leading causes of death by a single infectious 
agent globally and is second only to Human Immunodeficiency Virus (HIV)/Acquired Immune 
Deficiency Syndrome (AIDS). Currently, TB is estimated to kill approximately 1.5 million 
individuals annually. It is estimated that 2 billion people are infected with the causative 
pathogen, Mycobacterium tuberculosis, resulting in more than 9 million new cases each year 
(World Health Organization., 2011). The lifetime risk of these individuals to develop active TB 
is relatively small, around 5-10%. The majority of the infected population experiences a latent 
infection, which is generally accepted as a state of equilibrium between pathogen and the 
host’s immune system. This latent. TB infection (LTBI) can reactivate into full-blown active 
disease with waning of the host’s cellular immune response and results in pulmonary TB, the 
major form of active disease in adults. Active pulmonary M. tuberculosis infection is capable 
of spreading by close contact and droplet transmission, and is proving to be a major health 
concern in developing countries where the majority of cases occur. The highest incidence rates 
are in the Asian (55%) and African (30%) regions. In addition, malnutrition, poor public health 
infrastructure caused by socio-political instability and other circulating infections in these 
regions, such as measles, are also contributing factors to the re-emerging TB epidemic. In 1993, 
the World Health Organization (WHO) declared TB to be a global emergency. The 
development of multi-drug resistant (MDR) strains of M. tuberculosis and HIV co-infection are 
also responsible for the increase in the incidence of TB seen in developing countries 
(Kaufmann and McMichael, 2005). More recently, TB has re-emerged in the western societies 
that previously had lower incidence rates, because of its development as an opportunistic 
infection of individuals infected with HIV/AIDS (Hess et al., 2000). Co-infection of TB with 
HIV represents 12% of the total TB case load and dramatically increases the risk of developing 
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active TB owing to the immune-suppressive effect of HIV infection. TB accounted for 14% of 
all adult AIDS-related deaths from 1999 to 2002 (North and Jung, 2004).  
 While TB is an ancient disease, it is not a disease of the past. Genetic evidence of M. 
tuberculosis complex (MTBC) has been found in skeletal tissue of mummified remains from as 
early as 2050 BC (Zink et al., 2003). Identification of spinal TB lesions and M. tuberculosis 
DNA in lung lesions in a 1000 year old New World mummy is further evidence of human TB 
in the pre-Columbian era. Throughout history there were many names for TB, termed Phtisis 
during the ancient Greek period; Hippocrates identified it as the most widespread contagious 
disease. In the middle ages, the terminal stage of TB was termed “consumption” because 
infected individuals often had severe weight-loss and the appearance of being “wasted away”. 
It is also know as the “white plague” during the 19th century and was the leading cause of death 
in Europe and the United States of America. It was not until 1882 that Robert Koch identified 
M. tuberculosis as the causative organism for TB, providing the basis for microbiological 
approach to the disease. 
The current control measures against TB include chemotherapy, immunisation and 
reduction of transmission by improving public health standards. To combat TB, the WHO has 
recommended the adoption of a chemotherapeutic strategy called Directly Observed Therapy 
Short-course (DOTS) (Raviglione and Pio, 2002). This strategy has five essential components, 
namely, political commitment, high quality of diagnosis, high quality drugs, short-course 
chemotherapy given under direct observation, and systematic monitoring and accountability. 
The implementation of this strategy over the past few years has seen an increase in the cure 
rate of sputum smear positive pulmonary TB cases of up to 80% and a fall in TB mortality in 
many countries (Frieden and Driver, 2003). Although DOTS has demonstrated promising 
results for control of the disease, the necessity for closely monitored antibiotic treatment of 
each infected individual is often impractical or unaffordable in many of the affected developing 
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countries. The emergence of MDR and Extensively drug-resistant (XDR) TB has also 
threatened the success of the DOTS program. The only prophylactic vaccine against TB is 
Mycobacterium bovis Bacille Calmette- Guérin (BCG). BCG was first tested in humans in 
1921 and is the oldest vaccine in use. BCG is effective in preventing disseminated M. 
tuberculosis disease in young children, but it has been reported to have highly variable 
protective efficacies against pulmonary TB in adolescents and adults in different controlled 
studies. The protection ranges from 0 to 85% and although beneficial in children, BCG 
immunisation has not contributed to the control of the disease (Kaufmann, 2001, Boom, 2007). 
In recent decades, various efforts to understand the host response to M. tuberculosis and to 
develop novel, more effective vaccines have led to 11 vaccine candidates currently undergoing 
or entering clinical trials. Of the vaccine candidates, two are killed M. tuberculosis or semi-
purified bacterial components, a further two are forms of recombinant BCG and the remaining 
seven are subunit vaccines (Kaufmann, 2012).
 
1.2 Microbiology of the Mycobacterium  
M. tuberculosis, the causative infective agent of TB, belongs to the family Mycobacteriacea 
and the genus Mycobacterium. Mycobacterium is a genus of the phylum of Actinobacteria and 
owes its name to the unique way these bacteria grow as mould-like pellicles on liquid media, as 
first described by Koch in 1884 (Glickman et al., 2000). The genus Mycobacterium consists of 
approximately 115 defined species, most of which are commonly found in the environment 
(Cowan and Steel, 1974). The majority of these species are not associated with any human 
disease. Only a handful of mycobacterial species are implemented with human disease, such as 
M. tuberculosis and M. leprae, which cause TB and Leprosy respectively. M. marinum can 
cause swimming pool granuloma, an opportunistic infection of people often exposed to fish or 
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unclean waters and M. ulcerans is the cause of Buruli Ulcer, a tropical skin disease with 
chronic necrotic ulcers. Other mycobacterial species such as M. avium, M. haemophilum, M. 
kansaii, and M. simiae can cause opportunistic infections in immune-compromised individuals 
(Katoch, 2004). The M. tuberculosis complex (MTBC) consists of 8 genetically related but 
distinct mycobacterial species which are able to cause TB but differ in their epidemiological 
profiles, geographic distributions, host ranges, pathogenicity, and drug resistance (Yeboah-
Manu et al., 2011).  
M. tuberculosis, the a member of the MTBC which causes the majority of human TB, is 
a slow growing, aerobic, non-motile, non-encapsulated, non-spore forming bacillus. Owing to 
the thickness and hydrophobicity of the cell wall, mycobacterial cells are difficult to stain using 
the traditional Gram-staining method, they are not routinely classified neither as Gram negative 
or Gram positive, When stained with the Ziehl-Neelsen method, the bacterial cell wall retains 
carbol fuchsin dye after heating despite washing with acidified solutions. The mycobacterial 
cell wall comprises of more than 30% to 40% of the bacterium’s dry weight, and its unique 
ridged structure provides protection from the extracellular environment and accounts for its 
unusually low permeability, which inhibits entry of many antibiotics (Alderwick et al., 2007). 
The complex, mycolic acid-rich cell wall has been described as having a tripartite structure. 
The innermost peptidoglycan rich layer, followed by an intermediate layer containing 
covalently bound peptidoglycan, arabinogalactan, and mycolic acids, which form the insoluble 
cell wall skeleton. The mycolic acids extend out towards the outer matrix of the mycobacterial 
cell wall wall with includes a polysaccharide-rich layer and are responsible for this acid-fast 
property of the bacterium. The outer matrix included a polysaccharide-rich layer. There is 
controversy over the existence of an additional mycobacterial cell wall outer layer because of 
the inability to detect this outer layer using classical electron microscopy methods. In addition 
to these cell wall components, the outer layers also contain loosely bound biologically active 
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lipids that can form a ‘capsule’-like structure enveloping the bacteria (Guenin-Mace et al., 
2009). These loosely bound lipids include the phosphatidylinositol mannoside (PIM) and 
phtiocerol dimycocerosates (PDIM), important for the virulence of M. tuberculosis (Brennan, 
2003, Guenin-Mace et al., 2009). The mycobacterial cell wall also contains lipoarabinomannan 
(LAM), an immunogenic component of the cell wall that is anchored onto the plasma 
membrane and extends to the extracellular surface of the bacillus (Guenin-Mace et al., 2009). 
Arabinofuranosyl-terminated LAM (AraLAM) can activate macrophages in a toll-like receptor 
(TLR)-dependent manner and promote TNF-α release by macrophages (Guenin-Mace et al., 
2009, Underhill et al., 1999). The glycosylated phosphatidylinositol or mannosylated LAM 
(ManLAM) is an analogue of the macrophage cell membrane phospholipid, phosphotidyl-
inositol-3-phosphate, and has been implicated in blocking phagosome maturation (Fratti et al., 
2003).  
 
1.3 Pathogenesis of M. tuberculosis 
The progression of TB can be described as series of battles between the pathogen and the 
host’s immunes system. Each of the clinical signs and symptoms can be viewed as collateral 
damage caused by the well-armed arsenal of the immune system to clear the invading pathogen. 
The transmission of M. tuberculosis between humans is predominately through the respiratory 
route, the infectious dose is very low, aerosol droplets containing as little as 1-3 bacillus are 
sufficient to establish infection in the guinea pig model of TB (Lagranderie et al., 1993). Upon 
inhalation of the M. tuberculosis containing droplets, the bacilli reach the alveoli in the distal 
airways of the lung where they are engulfed by alveolar macrophages (Saunders and Cooper, 
2000). The aerobic nature of M. tuberculosis means it thrives in the oxygen-rich tissues of the 
lungs. Following the initial phagocytosis of M. tuberculosis by the alveolar macrophages, 
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bacterial factors can modify normal intracellular vacuole trafficking, phago-lysosomal fusion 
and acidification, allowing the bacteria to survive and continue to replicate slowly with a 
doubling time of approximately 12 hours. At this initial stage of infection, bacterial replication 
is either controlled by the infected host macrophage or allowed to continue until the infected 
macrophage is overwhelmed, resulting in necrotic death of the cell. The fate of the bacterial 
pathogen during this stage can have dramatic influence on the outcome of the disease. Rupture 
of the necrotic macrophage may result in further spread of the bacteria, both locally and 
haematogenously resulting in dissemination of the pathogen (Byrd et al., 1998). Dissemination 
of the bacteria to the draining lymph nodes triggers the onset of the potent acquired cell-
mediated immune response, which is sufficient to clear the infection in 90% of TB patients. In 
immunocompetent individuals, these replicating bacilli are contained at the site of infection 
within the infected macrophage, which secretes soluble factors that recruit immune cells to 
form granulomas. These granulomas are the cardinal pathological feature of TB disease. 
Structurally, granulomas are composed of the infected macrophages in the centre, surrounded 
by epithelioid cells, lymphocytes and other immune cells in a fibrotic capsule (Ulrichs and 
Kaufmann, 2006). However, in 5% to 10% of the infected individuals, the bacteria can survive 
the host’s initial immune response and enter a state, persisting either within an infected 
macrophage or in the extracellular environment encased within the granuloma (Ulrichs and 
Kaufmann, 2002). When the barrier of the granuloma weakens, the surviving bacilli are 
released into the surrounding tissue, reactivating the disease. Interestingly, the majority of the 
pulmonary tissue damage during infection is caused by the potent inflammatory response 
against M. tuberculosis and not by bacterial secreted factors (Mootoo et al., 2009).  
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1.4 Immune Responses to M. tuberculosis 
Following inhalation of M. tuberculosis, the infection is established in the distal alveolar 
compartment and the bacteria experience 2 to 6 weeks of exponential growth before reaching a 
plateau, following the development of the M. tuberculosis-specific cell mediated immunity 
(CMI) develops (North and Jung, 2004). During this time the mycobacterium interacts with the 
alveolar epithelium, disseminates and infects the surrounding alveolar macrophages 
contributing to the initial inflammatory response. Intracellular infection is established 
following the phagocytosis of the bacilli by tissue macrophages and dendritic cells. M. 
tuberculosis and BCG are able to persist and reside within the phagosome by blocking the 
natural process of phagosome maturation and thereby evading the antimicrobial effects of the 
lysosome (Vergne et al., 2005). Furthermore, selective inhibition of fusion with endosomes 
harbouring vacuolar ATPase prevents acidification of the phagosomal environment (Sturgill-
Koszycki et al., 1994). 
Binding and internalisation of M. tuberculosis occurs through a number of proposed 
receptor-mediated mechanisms; these include mannose-binding receptors (MR), complement 
receptors (CR1, CR2, CR3, and CR4), surfactant protein receptors, the CD14 receptor, and 
type A scavenger receptors on the surface of the mononuclear phagocytes (Cole, 2005). 
ManLAM, and trehalose 6,6’-dimycolate, which are present in the M. tuberculosis cell wall, 
are powerful inducers of pro-inflammatory cytokines and chemokines that initiate the local 
inflammatory responses and recruit circulating leukocytes to the site of infection (Geisel et al., 
2005). The first of the recruited leukocytes are monocytes, natural killer cells and neutrophils. 
Local dendritic cells (DC) that are also infected are activated to undergo both phenotypic and 
functional maturation. These activated DCs and macrophages migrate to the draining lymph 
nodes and present mycobacterial antigens to T cells through both major histocompatibility 
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complex (MHC) class I- and class II-dependent mechanisms, stimulating the development of 
the acquired immunity.  
Further spread and growth of the bacteria is limited by activation of the infected 
macrophages by primed antigen-specific CD4+ Th1 and cytotoxic CD8+ T cells which migrate 
back to the site of infection. Infected macrophages can fuse to form multinucleated giant cells 
or differentiate into epithelioid cells or foamy macrophages. This aggregation of lymphocytes, 
macrophages and epithelioid cells forms a granuloma, the pathological hallmark of M. 
tuberculosis infection. Chronic antigenic stimulation leads to caseous necrosis in the core of 
granulomas and the surviving bacilli are physically contained within a cellular zone of 
fibroblasts, lymphocytes, and blood-derived monocytes (Smith, 2003). Persisting bacilli within 
the granulomas are the potential foci of reactivation of infection and disease. 
Necrosis of the tissue surrounding a granuloma in TB infected lungs is generally caused 
by the host’s inflammatory response, which attempts to contain the infection. The 
inflammation and necrosis may erode onto airways, leading to the formation of cavities and the 
further spread of the infection into other areas of the lung (North and Jung, 2004). Long-term 
protection against TB will ultimately depend on the development of successful and durable 
adaptive immunity, as a decline of the CMI in infected individuals later in life often results in 
the re-activation disease (North and Jung, 2004). 
 
1.4.1 Role of Macrophages 
Macrophages play a crucial role during M. tuberculosis infection. Alveolar macrophages that 
reside in the lung are the first immune cells to come into contact and become infected with the 
invading pathogen. Although M. tuberculosis can attach and infect many cell types, acid-fast 
bacilli can be almost exclusively found to reside inside the aveolar macrophages in infected 
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lungs (Gaynor et al., 1995). Even though macrophages provide an ideal reservoir for the 
intracellular persistence of mycobacteria, such as providing protection from soluble immune 
effector molecules including circulating antibodies and complement proteins in the early stages 
of infection, they are also considered one of the first lines of defence again M. tuberculosis 
infection. Phagocytosis of the bacilli by an activated macrophage in most cases results in the 
death of the invading bacteria. The depletion of macrophages from the lungs before 
experimental infection with M. tuberculosis can dramatically alter the outcome of the disease 
(Leemans et al., 2005). The string of events following infection of an activated macrophage 
can be summarized by the following stages: surface binding of M. tuberculosis facilitated by 
multiple receptors, further activation of the macrophage and phagocytosis of the bacilli, 
mycobacterial growth inhibition/killing following phago-lysosomal fusion, recruitment of 
accessory immune cells and the initiation of inflammatory responses, and migration of DCs to 
the draining lymph nodes for antigen presentation and T cell priming, leading to the 
development of the adaptive immunity (Raja, 2004). 
Following priming in the draining lymph node, antigen-specific CD4+ T cells are 
recruited to the lung and activated through MHC-T cell receptor (TcR) complexes to secrete 
cytokines, such as interferon (IFN)-γ and tumour necrosis factor (TNF)-α, which in turn 
activate the surrounding macrophages. Stimulation of macrophages by M. tuberculosis also 
results in activation of the infected and neighbouring cells. Mycobacterial components act as 
pathogen-associated molecular patterns (PAMPs) and are recognised by the TLR-2, TLR-4 and 
TLR-9 pattern recognition receptors (PRR) (Bulut et al., 2001, Chambers et al., 2010b, 
Drennan et al., 2004, Quesniaux et al., 2004). These activated macrophages produce 
antimicrobial agents, such as cathelicidin, that inhibit growth and kill mycobacteria (Rivas-
Santiago et al., 2008). Although macrophage activation is essential for controlling bacterial 
infection, substantial collateral damage can be done to the surrounding tissues (Flynn and Chan, 
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2001). Thus, when designing vaccines against M. tuberculosis, the ability to reduce 
unnecessary immunopathology. An effective vaccine must be able to eliminate the pathogen 
while reducing any unnecessary tissue damage caused by the induced immune response. 
Activated macrophages destroy mycobacteria following phago-lysosomal fusion and 
acidification, whereby bacilli containing phagosomes fuse with lysosomes leading to a 
reduction in the pH of the local environment (Vergne et al., 2004). Acidification activates 
acidic hydrolases and the generation of reactive oxygen intermediates (ROI) via an oxidative 
burst. The production of nitric oxide (NO) and reactive nitrogen intermediates (RNI) is induced 
by nitric oxide synthase (NOS)-2, and this is dependant on levels of lL-arginine and the 
activation of iNOS by the cytokines, IFN-γ and TNF-α. This has been documented more 
clearly in murine models than in humans (MacMicking et al., 1997, Raja, 2004). In addition, 
up-regulation of chemokines and chemokine receptors, such as macrophage inflammatory 
protein (MIP)-1, monocyte chemotactic protein (MCP)-2, MCP-3, CCR2 and CCR5 
respectively allow recruitment of circulating leukocytes to the site of inflammation, and these 
act as the foci of granuloma formation (Flynn and Chan, 2001, Saunders and Cooper, 2000). 
 
1.4.2 Role of Dendritic Cells 
DCs are effective APCs in the anti-mycobacterial immune response and lead to more effective 
priming of naïve T cells than macrophages. Immature DCs are highly phagocytic and are 
characterised by their capacity to sample microbial components for processing at the site of 
infection, including mycobacterial cell wall components and secreted proteins, such as the 10 
kDa culture filtrate protein (CFP-10) (Kamath et al., 2004) and the Early secreted antigenic 
target 6 (ESAT-6). In DCs the initial phagocytosis of M. tuberculosis is facilitated by 
recognition of ManLAM by the cell surface molecule DC-associated ICAM-3 non-grabbing 
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integrin (DC-SIGN) (Tailleux et al., 2003). M. tuberculosis and its cell wall components, such 
as the 19 kDa lipoproteins and AraLAM, activate DCs via the TLR-2 and TLR-4 pathways 
(Quesniaux et al., 2004), leading to up-regulation of surface co-stimulatory molecules 
including CD80 (B7.1) and CD86 (B7.2), as well as the MHC class I and II molecules, 
essential for antigen presentation and priming of T cells.  
Mature DCs migrate to draining mediastinal lymph nodes where their phagocytic 
abilities are down-regulated, and they develop into potent APCs. Provided that both the MHC-
TcR and CD80-CD28 interactions of lymphocyte activation are present, a small pool of naïve 
T cells will develop into potent M. tuberculosis-specific CD4+ and CD8+ T cells (Saunders and 
Cooper, 2000).  
Following binding of M. tuberculosis, DCs produce and secrete an array of pro-
inflammatory cytokines, including interleukin (IL)-1, IL-6, TNF-α and the regulatory 
cytokines, IL-12 and IL-18, which are crucial for orchestration of CMI and the formation of 
granulomas (Demangel et al., 2001, Flynn and Chan, 2001). Cytokines produced following 
binding of ManLAM to DC-SIGN, such as IL-10, can also influence the quality of the adaptive 
immune response and limit the inflammatory response (Neyrolles et al., 2006). 
Both the protection and control of M. tuberculosis is dependant on the development of 
antigen-specific T cells. The destruction of bacteria in the phago-lysosome leads to the MHC 
class II dependent presentation of antigens to naïve CD4+ T cells. In addition, bacterial 
components and antigens, which have escaped the phagolysosome and are present in the 
cytosol, are processed and presented on MHC Class I molecules and interact with naïve CD8+ 
T cells. The CD1 family of cell surface proteins are non-polymorphic antigen-presenting 
molecules, that are able to present lipids and glycolipids to non-classically restricted T cells 
(Moody et al., 2000).  
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The control of M. tuberculosis infections is considered to rely primarily on the Th1-
type immune responses of both CD4+ and CD8+ T cells, which activate macrophages for 
bacterial killing through the production of IFN-γ as well as other cytokines, and the induction 
of apoptosis of infected cells, respectively (Molloy et al., 1994). 
 
1.4.3 CD4+ T cells   
Infection of macrophages with mycobacteria results in MHC class II presentation of 
mycobacterial peptides to CD4+ T cells and the secretion of IL-2 which drives differentiation 
and proliferation of the CD4+ T cells to the Th1 phenotype (Cooper et al., 2002). The primary 
function of Th1 cells is the production and secretion of potent pro-inflammatory cytokines, 
including IL-2, TNF-α and most importantly IFN-γ, which results in the activation of 
macrophages and inhibition of mycobacterial replication. CD8+ T cells also produce these 
stimulatory cytokines during intracellular bacterial infection; however, they are unable to 
compensate for the absence of functional Th1 responses (Caruso et al., 1999). This is 
demonstrated in CD4-depleted mice, which produce similar levels of IFN-γ but are unable to 
avoid rapid re-activation of the infection (Keane et al., 1997), and in human subjects with HIV 
co-infection, who are unable to effectively control TB infection owing to diminished CD4+ T 
cell responses (Kaufmann and McMichael, 2005). More recently, a role for CD4+ T cells which 
express IL-17 (Th17) in protective immunity against pulmonary TB has also been suggested 
(Wozniak et al., 2006b, Wozniak et al., 2010). 
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1.4.4 CD8+ T cells 
The role of CD8+ T cells in TB was initially considered less important as intracellular 
mycobacteria principally reside within the phagosomes and not within the cytosol of host 
macrophages. Experimental M. tuberculosis infection of CD4-/- and CD8-/- mice has revealed 
that while CD4 deficient mice die within a few weeks of infection, CD8 deficient mice have a 
less dramatic phenotype (Flynn and Chan, 2001, Keane et al., 1997, Turner et al., 2001). 
Nevertheless, presentation of mycobacterial antigens on MHC class I molecules to CD8+ T 
cells occurs during both M. tuberculosis and BCG infection (Ryan et al., 2009), and the 
increased efficiency of activation of CD8+ T cells by M. tuberculosis, is in part due to the 
secretion of ESAT-6 by the Esx1 secretion system encoded by the region of deletion (RD) 1 
deleted in BCG. Selective depletion of CD4+ and CD8+ T cells by neutralising antibodies has 
demonstrated that although CD8+ T cells are not required for the control of acute M. 
tuberculosis infection, they are essential for optimal control of chronic M. tuberculosis 
infection in mice (van Pinxteren et al., 2000). 
CD8+ T cells are also capable of secreting cytokines, such as IFN-γ and IL-4, and these 
are important at maintaining the balance of Th1 and Th2 phenotypes (Raja, 2004). Under the 
influence of this T cell help, CD8+ T cells differentiate into cytotoxic T Lymphocytes (CTL) 
and contribute to macrophage activation by secreting IFN-γ (Feng et al., 1999). Killing of 
intracellular M. tuberculosis via apoptosis of infected human macrophages is dependent on the 
production of CD8+ T cell associated granulysin and perforin (Stenger et al., 1998), as well as 
the triggering of apoptosis via the Fas-FasL pathway (Raja, 2004). Mice deficient in various 
genes involved in the processing and presentation of cytoplasmic antigens, such as TAP1 
(Behar et al., 1999), MHC class I molecules (Flynn and Chan, 2001) and surface CD8 
(D'Souza et al., 2000), show decreased resistance to tuberculosis infections. 
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1.5 Vaccines against Tuberculosis 
The only registered vaccine against TB currently available is BCG, which was attenuated by 
Calmette and Guérin in the 1920s by in vitro passaging of M. bovis for more than 200 passages 
over 13 years. At the time BCG was credited for the contributing to the control of the European 
TB epidemic, however its effectiveness has been less successful in developing countries (Fine, 
1995). Administration of the vaccine causes a mild localised mycobacterial infection at the site 
of inoculation, which lasts several weeks, however its efficacy against different forms of TB 
remains controversial. Meta-analysis of multiple BCG trials reveals while neonatal vaccination 
with BCG provides protective efficacy of approximately 80% against childhood forms of 
disseminated TB, its provides highly variable protective efficacy against adult pulmonary TB, 
the contagious form of the disease. The variability of the protective efficacy ranges from 0% to 
80%, with a median of 50% in different randomised control trials (Colditz et al., 1995). In the 
large BCG trial in adolescents in the United Kingdom, 80% protection was provided against 
pulmonary disease, but this protective efficacy waned from 10 years after immunisation 
(Sterne et al., 1998). By contrast, the long-term follow-up of BCG immunisation in Alaskan 
natives observed no significant waning of protective efficacy over 50 years (Aronson et al., 
2004).  
It is clear that BCG induces protective immunity in vaccinated children, but this 
protection quickly wanes as the individual reaches adolescence. It remains unknown why BCG 
confers such highly variable protective efficacy after this stage. Some suggest exposure to 
increased viral or helminth infections, as well as non-pathogenic environmental mycobacteria 
may all be contributing factors. A better understanding of mechanisms behind the variable 
BCG-induced protection may provide vital information for design of future vaccines against 
TB. One proposed mechanism is that BCG induces weaker CD8+ T cell responses compared to 
M. tuberculosis, so that reduced number of CD8+ T cells expand and migrate into site of 
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infection to limit the infection (Ryan et al., 2009). Another explanation may be that the 
memory responses induced by BCG vaccination wane as a result of the death of memory T 
cells over time (Fine, 1995). Another possibility is that the vaccine primed anti-TB memory 
response is ineffective because of pre-existing exposure to other environmental species of 
mycobacteria, which is more common in humid areas closer to the equator (Colditz et al., 
1995). The latitude at which BCG trials were conducted was associated with their reported 
efficacy. Prior sensitisation with other forms of mycobacteria renders BCG vaccination less 
effective against experimental mycobacterial infection (Brandt et al., 2002, Buddle et al., 2002). 
Understanding the mechanisms responsible for the expansion, maintenance, and boosting of 
these memory T cells is crucial for the development of more effective TB vaccines. 
 
1.5.1 The current state of anti-TB vaccines. 
Because of the impact of the HIV epidemic on increased rates of TB and the emergence of 
increasingly antibiotic resistant stains, the WHO declared TB as a global emergency in the 
early 1990s (Kaufmann and Parida, 2007). Since that time, research on all aspects of M. 
tuberculosis intensified because of both increased public interest and funding. To date, these 
increased efforts to eradicate the global TB problem resulted in at least 12 anti-TB vaccines in 
various stages of clinical trials. Of the vaccines in clinical trials, the two vaccine candidates in 
phase III are inactivated saprophytic mycobacterial strains, M. vaccae and M. indicus pranii 
(Lahey et al., 2010, Patel and Trapathi, 2003). Two of the three viral-vectored vaccine 
candidates are in phase IIb clinical trials, the modified vaccine Ankara (MVA)-based 
MVA85A/AERAS-485 and the replication-deficient adenovirus-based AERAS-405/Crucell 
Ad35 (Tameris et al., 2013, Ottenhoff and Kaufmann, 2012). The remaining vaccine 
candidates in phase I and II clinical trials are recombinant mycobacterial protein and adjuvant 
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formulations, with the exception of recombinant adenovirus-based AdAg85A in phase I and 
the fragmented M. tuberculosis cell-based RUTI® vaccine in phase II trials. The details for 
each of the vaccine candidates in clinical trials are summarised in Table 1.1. 
Table 1.1. Anti-TB vaccines in clinical trials. 
Clinical trial 
status 
Vaccine candidate Type Description References 
Phase III Mw (M. indicus pranii) 


Whole-cell preparation of 
non-TB mycobacterium 
(Patel and 
Trapathi, 
2003) 
 M. vaccae* 

 
Whole-cell preparation of 
non-TB mycobacterium 
(Lahey et al., 
2010) 
Phase IIb AERAS-485/MVA85A Viral-vector Modified vaccinia Ankara 
vector expressing Ag85A of 
M. tuberculosis 
(Tameris et 
al., 2013) 
 AERAS-402/Crucell 
Ad35 
Viral-vector Replication-deficient 
adenovirus 35 vector 
expressing Ag85A, Ag85B 
and TB10.4 of M. 
tuberculosis 
(Abel et al., 
2010) 
Phase IIa M72 + AS01 Recombinant protein 
in adjuvant 
Recombinant protein fusion 
of M. tuberculosis Rv1196 
and Rv0125 with the 
adjuvant, AS01. 
(Leroux-Roels 
et al., 2010) 
 VPM1002 Recombinant BCG rBCG with deleted Urease 
expressing listeriolysin 
(Grode et al., 
2005) 
 Hybrid 1 + IC31 Recombinant protein 
in adjuvant 
Recombinant protein fusion 
of Ag85B and ESAT-6 with 
the IC31 adjuvant 
(Langermans 
et al., 2005) 
 RUTI® 	
 
Fragmented M. tuberculosis (Vilaplana et 
al., 2010) 
Phase I AdAg85A Viral-vector Replication-deficient 
adenovirus 5 vector 
expressing Ag85A of M. 
tuberculosis 
(Santosuosso 
et al., 2006) 
 Hybrid 1 + CAF01 Recombinant protein 
in adjuvant 
Recombinant protein fusion 
of Ag85B and ESAT-6 with 
the CAF01 adjuvant 
(Christensen 
et al., 2010) 
 HyVac 4/AERAS-404 + 
IC31 
Recombinant protein 
in adjuvant 
Recombinant protein fusion 
of Ag85B and TB10.4 with 
the IC31 adjuvant 
(Aagaard et 
al., 2009b) 
 Hybrid 56 + IC31 Recombinant protein 
in adjuvant 
Recombinant protein fusion 
of Ag85B, ESAT-6 and 
Rv2660 with the IC31 
adjuvant 
(Aagaard et 
al., 2011) 
 ID93/GLA-SE Recombinant protein 
in adjuvant 
Recombinant protein 
formulation containing M. 
tuberculosis Rv2608, 
Rv3619, Rv3620 and the 
latent antigen Rv1813, and 
the GLA-SE adjuvant 
(Bertholet et 
al., 2008) 
 rBCG30* Recombinant BCG rBCG Tice strain modified 
to express the 30 kDa and 
Ag85B of M. tuberculosis 
(Ottenhoff 
and 
Kaufmann, 
2012) 
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Clinical trial 
status 
Vaccine candidate Type Description References 
Phase I cont’ AERAS-422* Recombinant BCG rBCG modified to express 
PfoA and overexpress 
Ag85A, Ag85B and 
Rv3407 
(Sun et al., 
2009) 
 M. smegmatis* Whole-cell extract Whole-cell preparation of 
non-TB mycobacterium 
(Decroix et 
al., 1984) 
 
Given the inconsistent protection protective efficacy of BCG and the growing incidence of TB, 
especially in developing countries, the development of more efficient and cost-effective 
vaccines are warranted. The availability of the M. tuberculosis and M. bovis genomes has 
allowed the comparative genome analysis, and this revealed that there are 16 regions of 
difference (RD) in M. bovis BCG, accounting for approximately 130 genes (Behr et al., 1999). 
A number of these genes encode for highly immunogenic secreted proteins of M. tuberculosis, 
such as the ESAT-6 and CFP-10 present in the RD1 of BCG (Gordon et al., 1999). The 
deletion of these RD-encoded genes was likely to have happened during the initial attenuation 
process. Other virulence factors, such as those promoting survival of intracellular mycobacteria, 
were also identified through the research into mycobacterial genetics (Triccas and Gicquel, 
2000). Antigens, such as those in the Ag85 complex, are shared between M. tuberculosis and 
M. bovis BCG (Huygen et al., 1996). Increased understanding of mycobacteria and its antigens, 
along with improvements in molecular biology has allowed continuing development of novel 
vaccines against TB, including those using rBCG or subunit vaccine strategies. More than two-
thirds of the vaccine candidates currently being tested in clinical trials have used components 
identified in the M. tuberculosis genome. The availability of the genome has also accelerated 
the identification and characterisation of potential T cell epitopes, which stimulate T cell 
responses in both humans and murine models of M. tuberculosis infection and are ideal for 
incorporation into subunit vaccines. Efforts to develop anti-TB vaccines can be broken down 
into three main strategies: the attenuation of M. tuberculosis or other mycobacterial species, 
modification of rBCG to improve the efficacy of the currently licensed BCG vaccines, and the 
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use of mycobacterial proteins or genes in subunit or viral-vectored vaccines. One major 
challenge for anti-TB vaccine development is the identification of appropriate correlates of 
protection to ensure vaccine candidates with the most potential are selected for clinical trials. 
 
1.5.1.1 Live Attenuated Vaccines 
Two main live vaccine approaches have been explored for the development of anti-TB 
vaccines. The first is the generation of live attenuated strains of M. tuberculosis. Auxotrophic 
knockout mutants, which are unable to synthesise essential amino acids, demonstrate marked 
reduction in bacterial growth in the lungs of infected mice in the absence of the required 
nutrients (Guleria et al., 1996, Smith et al., 2001). A second group of knockout mutants show 
reduced growth in lungs of experimentally infected mice, but are able to persist at a lower level 
than wild-type strains. These knockout mutations include deficiencies in regulatory proteins, 
such as the pho-P/pho-Q two-component regulatory system, or deficiencies in lipid metabolism 
and transport (Cox et al., 1999, Perez et al., 2001). Other knockout mutants, which are deficient 
in genes expressed during dormancy, replicate in an unrestrained manner in the lungs of 
experimental mice during early stages of infection, but cease replication once the dormancy 
stage is reached. A prime example of such a dormancy gene is the one encoding isocitrate lyase 
(McKinney et al., 2000). M. tuberculosis knockout mutants that lack other virulence factors are 
able to grow as well as wild-type strains. but induce weaker disease pathology. Other knockout 
mutants, such as that lacking the heparin-binding haemaglutinin adhesion molecule, behave 
like wild-type M. tuberculosis in the lung, but are unable to disseminate to other organs. 
Knockout of these genes associated with dissemination may be important to focus the vaccine 
responses in the draining lymph nodes. A recently defined group of M. tuberculosis counter-
immune mutants are able to grow in normal mice, but are unable to persist in mouse knockout 
strains with a defined immune defect, such as IFN-γ deficiency (Hisert et al., 2004). 
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Vaccine candidates based on attenuated M. tuberculosis are likely to face strong 
objections against their use in humans. This is because the genetic stability of the mutants is 
unknown, raising the possibility of a reversion to virulence and causing active disease, 
especially in immuno-compromised individuals, such as those with HIV infections. To 
overcome this problem, the introduction of two or more independent chromosomal gene 
deletions can greatly reduce the chance of reversions. On the other hand, one advantage of 
attenuated M. tuberculosis is their ability to replicate in the host and deliver a wide range of 
mycobacterial antigens. Many of the attenuated M. tuberculosis strains tested in vivo show 
stunted growth and relatively poor protected protective efficacy (Hondalus et al., 2000, Jackson 
et al., 1999). In order to achieve adequately attenuated strains of M. tuberculosis, mutations of 
genes other than those strictly related to virulence, may be required. 
 In recent years, the use of non-pathogenic mycobacterial species as vaccine candidates 
has also shown promising immunogenicity and protective efficacy. For example, immunisation 
with a recombinant M. smegmatis carrying the M. tuberculosiss esx-3 gene complex remains 
attenuated and is readily cleared by the host innate immune system, while provide lasting 
protection against subsequent M. tuberculosis infection (Sweeney et al., 2011).  
 
1.5.1.2 Recombinant BCG Vaccines 
Recombinant BCG vaccine candidates represent an important group in the current, live anti-TB 
vaccine candidates. One reason for this is because BCG is the most widely used and the only 
licensed anti-TB vaccine and provides good amount of immunogenicity (Abebe, 2012). 
Compared to M. tuberculosis, BCG lacks approximately 130 genes, many of which are 
involved in pathogenicity and persistence, clustered in 16 RDs (Behr et al., 1999). The re-
introduction of selected genes may increase immunogenicity, either individually or together 
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without causing reversion of BCG to a pathogen (Kaufmann and McMichael, 2005). Increasing 
the immunogenicity can result in the stimulation of the appropriate protective immune response, 
while an increase in antigenicity can be achieved by incorporation of antigens encoded in the 
RD regions or the over-expression of endogenous antigens. 
One strategy to generate rBCG strains is through the re-introduction of the entire RD1 
region from the M. tuberculosis genome (Pym et al., 2003). This region comprises of at least 
11 genes. Prior immunisation with rBCG expressing ESAT-6 provided reduced disease 
pathology and increased protection against M. tuberculosis, mice compared to the parental 
BCG strain (Pym et al., 2003). As a consequence, this rBCG vaccine candidate also displayed 
increased virulence in immuno-compromised mice. To avoid increasing the virulence of the 
vaccine strains, the use of M. tuberculosis genes not associated with virulence to develop 
rBCGs may prove to be a safer option. The over-expression of the immuno-dominant Ag85B 
in BCG induced an increased level of protective immunity in mice (Horwitz et al., 2000), and 
this rBCG30 has recently completed a phase 1 clinical study (Ottenhoff and Kaufmann, 2012). 
The expression of Ag85B fused to ESAT-6, which is lacking in BCG, also resulted in 
enhanced clearance of M. tuberculosis infections in mice (Palendira et al., 2005). The safety 
profiles of these rBCG vaccine candidates are considered to be at least equivalent to 
unmodified BCG (Ohara and Yamada, 2001). 
Other rBCG vaccine candidates capable of producing strong IFN-γ-secreting T cell 
responses include those expressing murine cytokine genes, such as IFN-γ, IFN-α, IL-2, 
granulocyte macrophage colony stimulating factor (GM-CSF) (Murray et al., 1996), IL-18 
(Luo et al., 2004) and monocyte chemotactic protein (MCP)-3 (Ryan et al., 2007). Of these 
rBCG-GM-CSF is the most promising as it stimulates enhanced antigen-specific IFN-γ 
responses and increased protection against M. tuberculosis in mice when delivered by the 
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subcutaneous and intra-nasal routes, as well as increased safety in immuno-deficient mice 
(Nambiar et al., 2010, Ryan et al., 2007). This strain is yet to be studied in humans. 
A different approach to enhance the CD8+ T cells responses induced by BCG 
immunisation is the incorporation of the gene encoding listeriolysin O (Hly) from Listeria 
monocytogenes. This cytolysin creates pores in the phago-lysosome and so allows increased 
escape of mycobacterial antigens into the cytosol, resulting in increased processing and 
presentation of these antigens on MHC class 1 molecules to the CD8+ T cells. The rBCG-Hly 
(VPM 1002), which expresses Hly in a urease-deficient strain of BCG, induced enhanced 
levels of protection compared to unmodified BCG in mice (Grode et al., 2005) and is currently 
in phase 1 clinical trials (Kaufmann et al., 2006). The AREAS 422 BCG vaccine strain utilised 
expression of perfringolysin to provide a similar endosome escape along with overexpression 
of the antigens Ag85A, Ag85B and Rv3407 in BCG (Tice). Although immunogenic in mice, 
this vaccine was withdrawn recently after two of 10 subjects in a Phase 1 Clinical study 
developed herpes zoster (Sun et al., 2009). 
 
1.5.1.3 Subunit Vaccines  
New subunit vaccine strategies against M. tuberculosis currently in development include 
protein antigen-adjuvant protein formulations, naked or packaged plasmid DNA and virally 
vectored vaccines. Most vaccine antigens tested are secreted proteins, such as ESAT-6 of the 
RD1 and Ag85B. There are over 400 culture filtrate proteins, but some components are more 
immuno-dominant in humans and mice than others, and the best studied of these is the Ag85 
complex (Huygen et al., 1996). For individuals with latent M. tuberculosis infections, a post-
exposure vaccine using dormancy-related antigens, such as Hsp-X has also been studied (Boon 
and Dick, 2002). 
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Although purified proteins and peptides are the only commonly types of antigens used 
in subunit vaccines, glycolipid antigens may also be included in these vaccine formulations. 
These glycolipids could serve both as antigen for the presentation by CD1 molecules and as 
ligands for TLRs, promoting an adjuvant effect (Dascher et al., 2003). Subunit vaccines alone 
may be poor immuno-stimulants so they require appropriate adjuvants to stimulate the desired 
Th1 immune responses essential for protection against TB (Cole, 2005). Mice immunised with 
Ag85A, Ag85B, and ESAT-6 in a variety of adjuvant formulations has shown promise in 
inhibiting M. tuberculosis growth following aerosol challenged mice. The Hybrid 1 vaccine 
comprising of a protein fusion of ESAT-6 and Ag85A in a mixture of oligodeoxynucleotides 
(ODN) and the polycationic peptide, IC31 adjuvant has shown promising results in 
experimental animals and is currently in phase I trials (Langermans et al., 2005, Olsen et al., 
2004). 
Plasmid DNA constructs expressing pathogen proteins can stimulate both CD4+ and 
CD8+ T cells. Although proven to have high immunogenicity in small-rodent animal models, 
naked DNA constructs have been less successful in human trials (Mwau et al., 2004). 
Recombinant bacterial such as recombinant Salmonella typhimurium expressing Ag85B (Hess 
et al., 2000) and other recombinant viral vectors expressing mycobacterial antigens have been 
constructed, and their vaccine efficacy against M. tuberculosis established in experimental 
animal models suggesting they induce potent CD8+ and CD4+ Th1 responses.  
Mtb-72F is a recombinant fusion protein composed of Rv0125 and Rv1196 with a 
predicted size of 70 kDa. The adjuvant AS02A is composed of a non-toxic lipopolysaccharide 
derivative and QS21 from Quillaja saponaria (a triterpene glycoside) in an oil-in-water 
emulsion. Immunisation with Mtb-72F protein with the AS02A adjuvant or in the form of 
plasmid DNA induces protective immunity in both mice and guinea pigs models (Skeiky et al., 
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2004). The Mtb-72F/AS02A formulation has now entered a phase 1 clinical trial in healthy M. 
tuberculosis-uninfected humans (Kaufmann and McMichael, 2005). 
Prime-boost schemes for subunit vaccines against pathogens consist of an initial DNA 
component to prime a focused immune response, followed by a boosting with a different vector 
expressing the same antigen to amplify the antigen-specific response. In the case of TB, prime-
boost vaccination schemes utilise priming with BCG followed by boosting with a subunit 
vaccine. This inverted strategy of prime-boost vaccination against TB was adopted with the 
aim of correcting the waning protective immunity of BCG-vaccinated individuals (Kaufmann 
and McMichael, 2005). One example of the prime-boost approach, which improved protection, 
utilised the recently discovered hypothetical protein Rv3407. Mice primed with BCG then 
boosted with plasmid DNA encoding Rv3407 achieved increased protection against TB, 
indicating that this protein is an important antigen of M. tuberculosis (Mollenkopf et al., 2004). 
Boosting with Mtb-72F/AS02A also increased the protection induced by BCG priming 
(Brandt et al., 2004). The rMVA expressing Ag85A can be used as a priming vaccine alone or 
as a booster vaccination following BCG priming. A slight increase in protection was observed 
when MVA-85A was used to boost the BCG-primed response (Brandt et al., 2004). 
 
1.6 DNA Vaccines 
Gene-based vaccinations using DNA is a promising strategy for developing an effective 
vaccine against TB as it efficiently induces a Th1 response essential for clearing the infection 
and protection against subsequent infections. Wolff et al. initially observed intramuscular 
inoculation of plasmid DNA led to the production of the encoded gene in the inoculated muscle 
cells (Wolff et al., 1991). Subsequently, many studies using animal models have confirmed that 
DNA vaccines induce both humoral and cellular responses, stimulating CD4+ and CD8+ T cells. 
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The ability to induce protective immunity against many pathogens has also been observed 
(Kamath et al., 1999b, Wang et al., 1998). An important advantage of stimulating both CD4+ 
and CD8+ T cells is that it mimics the long-term antigen delivery of live attenuated vaccines. 
DNA vaccines are able to induce cellular responses against intracellular pathogens, as well as 
the antibody responses. Therefore this is promising approach for immunisation against M. 
tuberculosis infection (Kamath et al., 1999b).  
Although there is no published evidence, one possible concern with the use of DNA 
vaccines is the potential for DNA integration through homologous recombination with host 
DNA or random insertions into the host genome is serious. This may cause disruption in gene 
regulation with the potential for inducing malignant transformation. Another concern is the 
development of anti-DNA antibodies in response to the plasmid DNA immunisation with the 
potential for causing autoimmune disease (Parker et al., 1999). Finally DNA vaccines may 
induce tolerance to the encoded antigens because of the extended period of expression of 
antigens in non-immune cells, which lack the appropriate co-stimulatory signals required for 
immune activation. In practice, none of these problems have risen in experimental use of DNA 
vaccines. The efficiency of DNA vaccines still needs to be greatly improved for application in 
larger animal models as well as in humans. 
There are three possible ways that antigens encoded in a DNA vaccine can be presented 
to the immune system. The first is via the direct priming of T cells by the transfected somatic 
cells, such as keratinocytes and myocytes. From our current immunological understanding this 
model is inconsistent with the paradigm of T cell activation, since these somatic cells lack co-
stimulatory molecules required for T cell activation. Second, antigen presentation is established 
through cross-priming. This occurs when the transfected somatic cells produce and secrete the 
encoded antigen, which is phagocytosed by professional APCs, processed and presented to T 
cells on MHC class II molecules. T cell activation is facilitated because the APCs express the 
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necessary co-stimulatory molecules required. There is also evidence indicating that these 
exogenous antigens are presented on MHC class I molecules (Harding, 1996). This  cross-
priming may also occur after DCs take up transfected cells which have undergone apoptosis. 
The third method is the direct transfection of the DNA vaccine into the APCs, although the 
frequency of this type of transfection is predicted to be very low (0.4%). A number of studies 
suggest that bone marrow-derived DCs are responsible for the initiation of immune responses 
to DNA vaccines, rather than the somatic cells, although the somatic cells may have a role as 
antigen reservoirs (Doe et al., 1996, Porgador et al., 1998). Intramuscular immunisation of 
DNA elicits generally a Th1 response and immunisation using the gene gun produces Th2 type 
responses. 
 
1.6.1 Improving DNA vaccines 
Although DNA vaccines can efficiently prime the immune system to induce transgene-
specific immune responses, the resulting responses following administering plasmid DNA 
alone are often relatively weak owing to the lack of immune activating signals (Dubensky et al., 
2000). One strategy to induce a stronger immune response is prime-boosting with DNA 
immunisations followed by recombinant protein vaccines or recombinant viral vectors (Kent et 
al., 1998, Wang et al., 2004). A number of strategies have been explored to enhance the 
efficacy of DNA immunisation by increasing the level of expression of the encoded antigen or 
the use of alternative vectors for genetic delivery. The administration of self-replicating viral 
replicon DNA expressing HIV-1 proteins produced replicating viral vaccines, and these 
stimulated vaccine-specific immune responses (Leitner et al., 2000). Another example of 
recombinant viral vectors is modified vaccinia virus Ankara (MVA) expressing Ag85A, which 
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utilises a non-replicating form of vaccinia virus obtained by serial passage through avian cells. 
This MVA-85A vaccine has already entered phase IIb clinical trials (Beveridge et al., 2007). 
Recombinant bacterial vectors, such as Salmonella sp., have also been used to target 
gene delivery to the mucosal tissues (Woo et al., 2001), however the danger may arise from the 
use of actively replicating vaccines in immuno-compromised individuals, such as HIV-infected 
subjects. Alternatively, tissue-targeted gene delivery can be enhanced with the use of non-
replicating viral construct, such has adeno-associated virus (AAV) engineered to express 
antigen (Kuck et al., 2006).  
Other methods, such as in vivo electroporation following intramuscular immunisation 
and the use of gene gun delivery, also increased the delivery of the plasmid DNA into cells 
(Widera et al., 2000). Modification of the DNA sequences can also enhance the efficacy of 
DNA vaccines. Codon optimisation of DNA vaccines for HIV increased the expression of HIV 
structural proteins and the subsequent antigen-specific responses (Gao et al., 2003). The 
construction of DNA vaccines encoding a string of multiple immunogenic epitopes elicited 
specific T cell responses to multiple antigens (Shinoda et al., 2004, West et al., 2011). 
Targeting of the expressed antigen to the endocytic or the ubiquitin protein degradation 
pathway resulted in the processing and presentation of peptides by either MHC class II and 
MHC class I, respectively (Thomson et al., 1998). The incorporation of additional CpG motifs 
into the DNA vaccine may also increase the immune response by inducing IL-12 and 
chemokines via the TLR-9 pathway (Pinxteren et al., 2000). As the immune responses to the 
plasmid-encoded genes are primarily due to processing and presentation by bone marrow 
derived APCs, the incorporation of cytokines, chemokines, and co-stimulatory molecules as 
adjuvants that enhance this process has been found to be beneficial to DNA vaccines 
(Scheerlinck et al., 2001). These immuno-stimulatory proteins may be co-immunised on a 
separate plasmid with the DNA vaccine, co-expressed by the one DNA vaccine, or fused with 
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the antigen expressed by the DNA vaccine. Examples include the cytokines, GM-CSF, IL-12, 
IL-23, flt-3-ligand and IL-15, chemokines, such as MCP-3 and MIP-1α, and co-stimulatory 
molecules such as CD40L (CD154), CD80, and CD86 (as reviewed in (Berzofsky et al., 2001) 
and (Britton and Palendira, 2003)). 
Enhancing the delivery and antigen expression of gene-based vaccines and constructing 
more potent DNA vaccines by either codon optimisation, incorporation of additional CpG 
motifs, or co-delivery with immuno-stimulating components, may result in a new generation of 
DNA vaccines capable of efficiently eliciting the desired protective immunes responses. 
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Table 1.2. DNA vaccines that have stimulated protection in animal models of M. 
tuberculosis infection. 
Antigen Route of 
infection 
Animal 
model 
Time 
before 
challenge 
(weeks) 
Protection in the 
lung (log10)* 
    
   DNA       BCG 
Protection in the 
spleen (log10)* 
 
   DNA         BCG 
Reference 
Ag85A aerosol C57Bl/6 
mice 
3-10 1.2 ND ND ND (Huygen et al., 
1996) 
 i.v. C57Bl/6 
mice 
8 0.4 1.2 ND ND (Tanghe et al., 
2001) 
Ag85B aerosol C57Bl/6 
mice 
4 0.5 0.9 ND ND (Kamath et al., 
1999b) 
ESAT-6 aerosol C57Bl/6 
mice 
4 0.45 1.0 0.25 1.2 (Morris et al., 
2000) 
 i.p BALB/c 
mice 
3 < 0.5 > 1.0 1.4 1.5 (Lowrie et al., 
1997) 
 aerosol C57Bl/6 
mice 
4 0.65 1.0 ND ND (Kamath et al., 
1999c) 
PstS-1 i.v C57Bl/6 
mice 
4-12 0# 1.4# 0# 2.0# (Tanghe et al., 
1999) 
PstS-2 i.v C57Bl/6 
mice 
4-12 0# 2# 0.5# 
 
2.0# 
 
(Tanghe et al., 
1999) 
PstS-3 i.v C57Bl/6 
mice 
4-12 1# 1.5# >1.5# 2# (Tanghe et al., 
1999) 
MPT64 aerosol C57Bl/6 
mice 
4 0.25 1.0 <0.2 1.2 (Kamath et al., 
1999c) 
Ag85B-ESAT6  i.t macaque 8-12 1.5 ND ND ND (Langermans et 
al., 2005) 
Mtb32-Mtb39 aerosol C57Bl/6 
mice 
4 0.7 1 ND ND (Skeiky et al., 
2004) 
 aerosol Guinea 
pigs 
13-70 Increase 
survival  
   (Skeiky et al., 
2004) 
i.v; intravenous     ND; not done 
i.p; intraperitoneal    ** DDL/MPL adjuvant 
i.t; intratracheal 
* relative protective response normalised to vector controls 
# 4 weeks post-infection, similar degree of protection through to 12 weeks. 
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1.7 Immuno-stimulatory Adjuvants 
Adjuvants are substances or immunological agents administered together with antigens during 
immunisation to aid, enhance or modify the immune response to the vaccine antigen (Barr et 
al., 2006). In the case of DNA vaccines, the incorporation of appropriate adjuvants can increase 
the subsequent immune responses (Petrovsky and Aguilar, 2004, Wozniak et al., 2006b). The 
mechanism for the generation of immune responses to DNA vaccines is believed to be through 
the uptake, expression and presentation of the plasmid-encoded antigen by bone marrow 
derived APCs. The co-administration of plasmid DNA encoding immune-modulating 
cytokines, chemokines or co-stimulatory molecules can provide additional immunological 
stimulation, both spacially and temporally close to the expressed antigens, and thus enhancing 
the desired vaccine-specific immune responses. The mechanisms of such adjuvants include 
increased activation of APCs, resulting in upregulation of co-stimulatory molecules and surface 
MHC molecules, leading to more effective antigen presentation and priming of T cells 
following antigen capture. 
DNA vaccines used in the mouse model of M. tuberculosis infection have generally 
produced levels of protection weaker than those induced by s.c. BCG immunisation. Therefore 
improving anti-TB DNA vaccine by providing exogenous cytokines and co-stimulatory 
molecules to increase the expansion and activation of CD4+ and CD8+ T cells may potentially 
improve the level of protection provided by the DNA vaccine. Plasmid encoding the IL-12 
family of cytokines (Palendira et al., 2002, Wozniak et al., 2006a) and members of the TNF 
super family of molecules, such as CD40L and Glucocorticoid induced TNF receptor family 
related protein ligand (GITRL), (Stone et al., 2006a) have shown promise as adjuvants for 
DNA vaccines. 
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1.7.1 Interleukin-12 
Successful immunity to intracellular pathogens, such as M. tuberculosis, depends of the 
development of an effective CMI response. During M. tuberculosis infection, production of IL-
12 by subsets of dendritic cells drives the activation, differentiation and expansion of antigen-
specific Th1 cells (Cooper et al., 2007). IL-12 exists as a heterodimer (IL-12p70) consisting of 
a p35 and a p40 subunit. The p35 is structurally related to type 1 cytokines, while p40 is 
homologous to the α-chain of the soluble IL-6 receptor. IL-12 binds to the IL-12 receptor 
(IL12R) complex composed of IL12Rβ1 signalling chain and IL12Rβ2 binding chain on the 
surface of CD4+ T cells and NK cells. The p40 subunit predominantly interacts with IL12Rβ1, 
while p35 binds IL12Rβ2. 
The primary action if IL-12 is the expansion of CD4+ T cells and the production of 
IFN-γ by those cells, thus producing a Th1 type response crucial for the control of intracellular 
pathogens. Production of IFN-γ following IL-12 signalling is mediated through the signal 
transducer and activation of transcription 4 (STAT4) and the major Tbx21-encoded 
transcription factor, T-bet. IFN-γ production in CD8+ T cells, on the other hand, can develop in 
an IL-12/STAT4 independent manner (Szabo et al., 2002). Deficiencies in IL-12 resulted in 
increased susceptibility to M. tuberculosis infection in experimental mice (Cooper et al., 2002). 
Interestingly mice that are deficient in the p40 subunit show increased susceptibility to M. 
tuberculosis and lower levels of IFN-γ production than those deficient in the p35 subunit 
(Cooper et al., 2002). The administration of recombinant IL-12 at the time of M. tuberculosis 
infection resulted in increased CD4+ T cell responses and improved resistance to infection and 
increased survival (Feng et al., 2005a). Co-immunisation of plasmids encoding IL-12 with 
DNA vaccines encoding M. tuberculosis and M. avium protein antigens increased the antigen-
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specific IFN-γ production and protection against M. tuberculosis (Palendira et al., 2002) and M. 
avium (Martin et al., 2003).  
There are two other members of the IL-12 family of cytokines IL-23 and IL-27, both of 
which are produced by APCs (Wozniak et al., 2006b), and IL-18, which is a homologue of IL-
1b also induces the differentiation of naïve CD4 T cells into Th1-like T cells. IL-23 is of 
particular interest because it shares the same p40 subunit as IL-12. The other component of the 
IL-23 heterodimer is p19, which shares homology with IL-6 and IL-12p35. p19 signals through 
a novel receptor chain, IL-23R (Parham et al., 2002). IL-23 and IL-12 have some similar 
functions, including the induction of IFN-γ production by CD4+ T cells. In vitro IL-12 is 
important for the differentiation of naïve CD4+ T cells into Th1 T cells, while IL-23 causes the 
expansion of differentiated Th1 cells. Both IL12Rβ1-/- and IL-12p40-/- deficient mice 
respectively are highly susceptibility to M. tuberculosis infections (Cooper et al., 2007). 
Polymorphisms in the human IL-12RB1 and IL-12p40 are associated with low IFN-γ T cell 
responses to mycobacteria and increased susceptibility to infections with non-tuberculosis 
mycobacteria and M. tuberculosis (Akahoshi et al., 2003). 
In summary, these studies have established that IL-12 is important for the initiation and 
development of a Th1 type response, while IL-23 acts at a later stage of T cell differentiation 
and aids the expansion of the effector T cells. Nevertheless, plasmid encoding IL-23 when give 
as an adjuvant with DNA vaccine expressing M. tuberculosis Ag85B stimulated increased 
levels of antigen-specific IFN-γ secreting T cells and increased protection against M. 
tuberculosis infection (Wozniak et al., 2006b). 
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Table 1.3. Examples of the use of IL-12 as an adjuvant for vaccine studies. 
Vaccine candidate Adjuvant type 
(amount) 
Pathogen Model/route Immunological 
Outcomes 
Protective 
efficacy 
References 
Pneumonococcal 
WCA/ 
rhIL-12 (2 ng) S. pneumonia Human BAL 
cells 
↑TNF-α, IFN-γ ND (Wright et 
al., 2011) 
Inactivated Yersinia 
pestis CO92 
mIL-12 Y. pestis Mice i.n. ↑Y. pestis 
specific IgGs, 
↓proinflammat-
ory cytokines 
100% 
protection 
(Kumar et 
al., 2011) 
rBCG expressing 
ESAT-6-hIL-12 
fusion 
 M. tuberculosis BALB/c ↑IFN-γ No increase (Deng et 
al., 2011) 
rFPV/HN and rHN chIL-12 Newcastle 
disease virus 
chickens i.m. ↓HI antibody 
titre, ↑ IFN-γ 
↑ Protection (Su et al., 
2011) 
DC vaccination AdΔB7/IL12/G
MCSF 
 B16-F10 
melanoma 
tumours 
C57BL/6 
↑DC to lymph 
nodes, ↑CCL21, 
↓CD4+CD25+ 
T-cells 
↑Antitumor 
effect 
(Zhang et 
al., 2011) 
OVA Chitosan/IL-12  Mice ↑CD4+ T-cell 
proliferation, 
↑Th1 cytokines, 
↑IFN-γ 
 (Heffernan 
et al., 
2011) 
HIV Gag 
(pGag4Y), HIV Pol 
(pMPol) 
 
macaque IL-12 
(0.3 mg) 
 
HIV Rhesus 
macaques i.m. 
 
↑IFN-γ, 
Th1>Th2 
 (Morrow et 
al., 2010) 
SWAP rmIL-12 in F2 
gel matrix 
Schistosoma 
mansoni 
C57BL/6 ↑TNF-α, ↑IFN-
γ 
↓Eggs in 
liver 
(Salem et 
al., 2010) 
BCG DNA mIL-12 M. tuberculosis BALB/c ↓esinophils, 
↓IL-4, ↑IFN-γ 
in BAL fluid 
 (Ke et al., 
2010) 
SFVeE6.7 SFV-IL12 HPV C57BL/6 ↑CTL at lower 
doses 
 
 (Riezebos-
Brilman et 
al., 2009) 
F1-V-Ag fusion DNA mIL-12 Y. pestis BALB/c ↑IFN-γ, ↑IL-6, 
↑IL-17, ↑IL-10, 
↑IgG 
↑Protection (Yamanaka 
et al., 
2009) 
SAG1-ROP2 DNA mIL-12 Toxoplasma BALB/c ↑IgG2a, 
↑Splenocyte 
proliferation, 
↑IFN-γ 
↑Survival (Xue et al., 
2008) 
pGag4Y and 
pEY2E1-B 
DNA macaque 
IL-12 
electroporated 
HIV Rhesus 
macaques i.m. 
↑IFN-γ, ↑IgG, 
↑polyfunctional 
T cells, ↑CD4+ 
and CD8+ T cell 
proliferation 
 (Hirao et 
al., 2008) 
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Vaccine candidate Adjuvant type 
(amount) 
Pathogen Model/route Immunological 
Outcomes 
Protective 
efficacy 
References 
Plasmid Ag85B, 
MPT64, BCSP31, 
SOD, L7/L12 
DNA mIL-12 M. tuberculosis, 
Brucekka 
abortus 
C57BL/6 ↑IFN-γ, ↑IgG, 
↑Lysis ↑GrB, 
↑Protection (Yu et al., 
2007) 
SIGgag pDNA DNA macaque 
IL-12 
SIV Rhesus 
macaques i.m. 
↑IFN-γ, ↑IL-2, 
↑IgG 
ND (Chong et 
al., 2007) 
DNA 
Mtb8.4/human IL-
12 fusion 
 M. tuberculosis C57BL/6N ↑IFN-γ, ↑IL-2, 
↓IL-4, ↑CTL 
 (Li et al., 
2006) 
Cytomegalovirus, 
Town strain 
 
Recombinant 
human IL-12 
Human cytomeg
alovirus 
 
Human 
subjects 
↑IgG titre, 
↑CD4+ T cells, 
↑IFN-γ from 
CD8+ 
 (Jacobson 
et al., 
2006) 
DNA Hsp65/HVJ 
liposome 
DNA, mouse 
IL-12 
M. tuberculosis BALB/c  ↑IFN-γ, ↑IL-2, 
↑T cell 
proliferation, 
↑CTL 
↑Protection (Yoshida et 
al., 2006) 
pVIVO2-IL12-Sj23 
and vegetal 
polysaccharides 
 Schistosoma 
japoncium 
BALB/c ↑IgG ↑Worm 
reduction 
rate 
(Feng et 
al., 2005b) 
DNA SIVmac239 
gag p55, rVSV  
HIV-1 env 89.6P 
gp160 
DNA, macaque 
IL-12 
SIV Rhesus 
macaques i.m. 
  (Winstone 
et al., 
2011) 
DNA Hepatitis  B 
pan-S gene 
DNA, IL-12 Hepatitis B BALB/c ↑IFN-γ, ↑IL-12, 
↑Splenocyte 
proliferation, 
↑IgG titre 
 (Tan et al., 
2004) 
DNA TSSA gene DNA, mouse 
IL-12 
Trypanosoma 
cruzi 
C57BL/6, 
BALB/c 
C3H/Hej 
↑IFN-γ, ↑CD8+ 
T cells 
↑Protection, 
↑Survival 
(Katae et 
al., 2002) 
DNA Ag85B DNA, mouse 
IL-12 
M. tuberculosis C57BL/6 ↑IFN-γ, 
↑Splenocyte 
proliferation,  
↑Protection (Triccas et 
al., 2002) 
Antigen 2 cDNA DNA, mouse 
IL-12 
Coccidioides 
immitis 
BALB/c ↑IFN-γ, ↑IgG2a 
and 2b 
↑Protection 
in spleen 
and live 
(Jiang et 
al., 1999) 
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1.7.2 CD40-Ligand 
The importance of co-stimulatory molecules for the development of effective immune 
responses against the infections is increasingly apparent. CD40L a member of the tumour 
necrosis factor superfamily (TNFSF5) and is primarily expressed on activated T cells. 
Interaction between CD40L on T cells and CD40 on B cells is essential for germinal centre 
formation, isotype switching and memory B cell development (Banchereau et al., 1994). 
Activation of CD40 on APCs by CD40L on T cells is crucial for the optimal priming and 
expansion of antigen-specific CD4+ T cells and the up-regulation of other co-stimulatory 
molecules on the APC (Grewal and Flavell, 1996). A mutation in the human CD40L gene 
results in the failure to produce IgG and IgA in response to antigen in the primary immuno-
deficiency, X-linked hyper IgM syndrome (Allen et al., 1993). Mutations in the CD40L gene in 
both mice and humans results in impaired T cell-mediated immunity and increased 
susceptibility to infections (Grewal et al., 1995, Levy et al., 1997). The CD40-CD40L 
interaction plays an important role in the development of cell-mediated immunity against 
intracellular pathogens, such as Trypanosoma cruzi (Chaussabel et al., 1999). Soluble forms of 
recombinant CD40L are immuno-stimulatory in mice, macaques, and humans both in vitro and 
in vivo (Stone et al., 2006a, Stone et al., 2006b). The use of soluble CD40L as molecular 
adjuvants with an HIV DNA vaccine resulted in increased vaccine-induced CD8+ T cell 
responses (Stone et al., 2006a). 
 
1.7.3 Glucocorticoid-induced TNF receptor family related protein ligand 
(GITRL) 
GITRL (TNFSF18) is expressed on macrophages, dendritic cells, endothelial cells and B cells 
and is the natural ligand and activator of GITR in vivo. GITR is constitutively expressed at 
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high levels on CD4+ CD25+ T regulatory (Treg) cells, but is also found on activated CD4+ 
CD25- cells. The GITR-GITRL interaction acts as a co-stimulatory signal for T cell activation 
and also reverses the inhibitory effects of Treg cells (Shevach and Stephens, 2006). 
 The co-stimulatory effect of GITRL ligation has been increasingly studied, in keeping 
with other members of the TNFSF. Signalling through GITR after GITRL ligation is mediated 
by recruitment of either Siva or TRAF2, depending on the biological environment, and this 
recruitment results in apoptosis or cell proliferation, respectively (Gurney et al., 1999). In one 
study, the addition of soluble GITRL to H-Y antigen-specific TcR-transgenic T cells increased 
proliferation following antigen challenge with H-Y peptide (Tone et al., 2003). Co-culture of T 
cells with anti-GITR monoclonal antibodies or GITRL-transfected cells increased T cell 
proliferation, activation and cytokine production following anti-CD3 triggering (Ronchetti et 
al., 2004). The effects of co-stimulation by GITRL on T cell activation are less than that 
induced by CD28 triggering, however, triggering through both GITR and CD28 produced a 
synergistic co-stimulatory effect (Kanamaru et al., 2004). Soluble GITRL also had a strong 
adjuvant effect when co-administered with an HIV DNA vaccine in mice (Stone et al., 2006a).  
The GITR ligation by GITRL on Treg cells inhibits the suppressive effects of Treg cells 
in mouse experimental models, however, anti-human GITR monoclonal antibodies and soluble 
human GITRL did not block the same suppressive effect of Treg cells in humans (Levings et 
al., 2002). This suggests that GITRL may have slightly different roles in mice and in humans.  
 
1.8 Adeno-associated Virus 
Recombinant AAVs (rAAV) can effectively transduce dividing and non-dividing cells and use 
the host cell machinery to express the virus-encoded genes (Grieger et al., 2006). For that 
reason, rAAVs have attracted interest as both delivery agents for gene therapy and vaccine 
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vectors. The first AAV was cloned in 1982 following its identification in adenovirus cultures. 
Since then, there has been a steady increase in studies on AAV and those utilising rAAV 
vectors. Most of these reports examine AAV vectors in the context of gene therapy 
applications (Coura and Nardi, 2007). In addition to efficient cellular transduction, the virus 
also possesses desirable features, such as limited reproduction in vivo, and the ability to 
achieve long-term persistent transgene expression in the mammalian host (Halbert et al., 2007, 
Coura and Nardi, 2007). 
Table 1.4. Summary of AAV serotypes and their preferential cell type for transduction in 
vivo. 
AAV serotype Cell types most efficiently 
transduced in vivo 
References 
AAV1 Vascular endothelium 
Muscle 
(Chambers et al., 2010a) 
(Chao et al., 2001) 
AAV2 Brain 
Liver 
Muscle 
(Fu et al., 2003) 
(McCarty et al., 2003) 
(Wang et al., 2003) 
AAV3 Cochlear inner hair cells (Liu et al., 2005b) 
AAV4 Ependyma and astrocytes (Liu et al., 2005a) 
AAV5 Lung epithelial cells 
Retina 
Brain 
Arthritic joint tissue 
(Zabner et al., 2000) 
(Lotery et al., 2003) 
(Burger et al., 2004) 
(Apparailly et al., 2005) 
AAV6 Muscle 
Lung 
(Blankinship et al., 2004) 
(Halbert et al., 2007) 
AAV7 Muscle (Louboutin et al., 2005) 
AAB8 Liver 
Heart 
Pancreas 
(Gao et al., 2004) 
(Wang et al., 2005) 
(Wang et al., 2006) 
AAV9 Heart (Pacak et al., 2006) 
AAV10 N/A N/A 
AAV11 N/A N/A 
 
AAVs are helper-dependent parvoviruses belonging to the genus Dependovirus in the 
subfamily Parvovirinae. AAVs are one of the smallest viruses identified to date; the virion is 
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approximately 25 nm in diameter and is comprised entirely of proteins and DNA. Currently 
there are 11 serotypes of AAVs characterised, each with different patterns of tropism for in 
vivo infection (Table 1.4). AAV serotype 2 (AAV2) is the most extensively studied for gene 
therapy and vaccines (Table 1.5) (Sun et al., 2003). The genome of AAV is composed a 4.7 KB 
single stranded DNA in both positive and negative senses. The defining characteristic feature 
of the AAV genome is the cis-active, GC-rich inverted terminal repeats (ITRs) on either end of 
the genome, and are required for the encapsulation and self-primed DNA replication (McCarty 
et al., 2003). The wild-type (WT) AAV genomes encode 2 overlapping open reading frames 
(ORFs). The first, termed rep, encodes for the protein required for the AAV2 ori-dependent 
DNA replication and site specific integration into the AAVS1 site located on chromosome 19 
in humans (Kotin et al., 1990). The second ORF, termed cap, encodes for the 3 main structural 
proteins VP1, VP2, and VP3 by alternative splicing or transcriptional initiation (Sun et al., 
2003). These structural proteins assemble to form the AAV virion, the naked icosahedral 
particle. rAAVs are generally constructed by replacing these two ORFs from the AAV genome 
and replacing these with the transgene of interest. Essential elements, such as the rep and cap 
ORFs and the “helper” elements from adenovirus, are provided in trans either through stably 
transfected host cell lines or as co-transfected plasmids (Grieger et al., 2006). Following 
receptor mediated attachment of AAV to the cell membrane, the viral particles are endocytosed 
and traffic through the endosomal system. The viral particles eventually escape from the 
endosome/lysosome and translocate into the nucleus where DNA synthesis of the second strand 
and expression of the transgene occurs (Sun et al., 2003).  
In the context of genetic transfer and viral vaccines, rAAVs have many advantages over 
other recombinant viral systems such as retro/lentiviruses and adenovirus. These include low 
pathogenicity and low immunogenicity of the virion itself and chemical and physical stability 
in conditions of different temperatures, solvents and pHs (Wright et al., 2003). rAAVs are 
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highly attenuated because in addition to WT AAV’s dependence on helper viruses for 
productive replication, rAAVs only retain around 300 base pairs of the non-translated ITRs, 
and are devoid of all genes required for structural and replication associated genes. This 
minimises the risk of reversion to WT virus so that they can be used in immuno-compromised 
individuals (Coura and Nardi, 2007). 
Table 1.5. rAAV-based vaccine studies. 
Pathogen Antigen AAV 
serotype 
Adjuvant Rou
te 
Dose Model Responses References 
HPV16 L1 Protein AAV5 and 9  i.n 1×1013 rhesus 
macaques 
Ab (Nieto et 
al., 2012) 
HIV Gag AAVrh32.33  i.m.i 3×1010 rhesus 
macaques 
CD8+ T 
cells, Ab 
(Lin et al., 
2007a) 
CMV pp65mll, IE-1 AAV2  i.m.i 1.5×108 
 
HLA-A2 
transgenic 
C57BL/6 
CD8+ T 
cells, Ab 
(Gallez-
Hawkins et 
al., 2004) 
HIV-1 env, tat, rev, 
HA 
AAV2 AAV-IL2 i.n, 
i.m.i 
109-1011 BALB/c 
 
Ab (IgG, 
IgA), CMI 
(Xin et al., 
2001) 
EBV LMP2 AAV1  i.m.i 1×1011 BALB/c CTL assay, 
Ab 
(Wang et 
al., 2011c) 
SOIV HA, NP, M1 AAV9  i.m.i 2×1011 C57BL/6 IFN-γ, Ab (Sipo et al., 
2011) 
 Merozoite 
surface 
protein 4/5 
AAV C3d 
fusion 
i.m.i 1×1012 BALB/c Ab (Logan et 
al., 2010) 
HPV16/18 E7 onco-
protein, 
Hsp70 fusion 
 AAV1 and 2  i.m.i 2×1011 C57BL/6 CTL assay, 
IFN-γ 
(Zhou et al., 
2010) 
 
Some drawbacks of using rAAVs as vectors include the limited capacity available for the 
insertion of the transgene expression cassette (4.7 kb) and the relatively slow gene expression 
with the rate-determining step being the DNA synthesis of the second strand. Strategies to 
overcome this slow expression by encapsulating double stranded DNA have been developed, 
however this further decreases the capacity for transgene insertion (McCarty et al., 2001). The 
development of neutralising anti-AAV antibodies by the host following AAV administration 
has been reported, and this means that AAV-based vaccines of the same serotype cannot be 
repeatedly administered, however this problem is now overcome by the use of chimeric rAAVs 
packaged using viral structural proteins from other serotypes in combination with the ITRs of 
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another AAV serotype (Sun et al., 2003). Even though rAAV have very low integration rate 
into the host genome, tumorogenesis following AAV2 application was reported in preclinical 
model of mucopolysachharidosis VII (Donsante et al., 2001). This observation, however, has 
not been reproduced and the cause still remains unclear. 
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1.9 Aims of the current study 
The specific aim of the current study is to identify and develop methods to improve the 
efficiency of genetic subunit vaccines against TB and to assess whether rAAV is a viable 
vector for the delivery of genetic vaccines and immuno-stimulatory cytokines. 
 
Hypothesis 1. That co-administration of plasmid DNA encoding the co-stimulatory molecules 
CD40L or GITRL with DNA vaccines encoding M. tuberculosis antigens will increase antigen-
specific T cell responses and enhance protection against aerosol M. tuberculosis infection 
(Chapter 3). 
Aim 1. To evaluate the adjuvant effect of plasmid DNA encoding two trimers (pACRP30-
CD40L) and four trimers (pSP-D-CD40L) of mouse CD40L, as well as plasmid encoding four 
trimers of GITRL (pSP-D-GITRL), when co-administered with anti-TB DNA vaccines. 
 
Hypothesis 2. That immunisation with rAAV expressing M. tuberculosis antigens will lead to 
increased T cell responses to the vaccine antigens and improved protection against aerosol 
challenge of M. tuberculosis when compared to plasmid DNA immunisation (Chapter 4). 
Aim 2. To construct and purify rAAV serotype 2 vector encoding a fusion construct of the M. 
tuberculosis antigens, Ag85B, MPT64190-198, and ESAT-6, and to evaluate whether 
intramuscular immunisation with this rAAV vector stimulates antigen-specific T cell responses 
and protective immunity comparable to their plasmid DNA vaccine counterparts. 
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Hypothesis 3. That local and sustained delivery of the immuno-stimulatory cytokine, IL-12, by 
co-administration of rAAV encoding IL-12 with rAAV encoding the M. tuberculosis antigen 
fusion will increase the development of antigen-specific T cell responses leading to enhanced 
protection against aerosol challenge with M. tuberculosis (Chapter 5). 
Aim 3. To construct and purify rAAV serotype 2 encoding mouse IL-12 and evaluate this 
rAAV-IL-12 as an adjuvant for intramuscular and intranasal immunisation with rAAVs. 
Aim 4. To evaluate whether administration of rAAV-IL-12 as immuno-therapy following 
aerosol infection with M. tuberculosis will result in increased clearance of M. tuberculosis. 
 
Hypothesis 4. That the mycobacterial lipoprotein, MPT83, is recognised by T cell responses 
during M. tuberculosis infection and that delivery of MPT83 as a DNA vaccine or protein 
subunit vaccine will lead to the induction of protective immunity against M. tuberculosis 
(Chapter 6). 
Aim 5. To characterise the T cell response to MPT83 in human and murine M. tuberculosis 
infection and map the H-2b- and H-2d-restricted CD4+ and CD8+ T cell epitopes in MPT83 
following immunisation with DNA-MPT83. 
Aim 6. To test MPT83 as a DNA and recombinant protein vaccine and evaluate the resulting 
immune responses and protective efficacy against aerosol challenge with M. tuberculosis. 
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2.1 Chemicals and Reagents 
All reagents used were at analytical and reagent grades. Unless stated, chemicals were stored as 
specified on the technical data sheets and according to the safety manuals. Water used in this 
study was either reverse osmosis (RO) water or triple distilled water (TDW) obtained by 
passing deionised water through a Milli-Q system (Millipore, Billerica, MA). DNase and 
RNase free Ultrapure™ water (Life Technologies, Calsbad, CA) was used for polymerase 
chain reactions (PCR) and molecular manipulation of DNA. Buffers and solution were 
reconstituted in water to pH adjusted with 1 or 10 M hydrochloric acid (HCl) or sodium 
hydroxide (NaOH) at room temperature and measured using a pH meter (Hanna Instruments, 
Australia). The components of buffers and solutions used in this study are either described in 
the text or listed in the appendix. 
 The protein antigens, Antigen 85B (M. tuberculosis Rv2660c) (Ag85B) and MPT64 
(Rv1980c) were either expressed from recombinant E. coli or derived from M. tuberculosis and 
were obtained from The Tuberculosis Research Material and Vaccine Testing Contract at 
Colorado State University (NIAD AI-75320). Antigens were reconstituted in phosphate 
buffered saline pH 7.4 (PBS) or as directed by the supplier. Recombinant MPT83 was 
expressed and purified as described in section 2.9.1. All proteins and antigens were stored at -
30˚C until use. 
 The synthetic peptides used in this study (Table 2.1) were purchased from Genescript 
(Piscataway, NJ). The purities of the peptides were confirmed by HPLC and reconstituted 
following the supplier’s instructions. The dissolved peptide stocks were stored at -30˚C in 
aliquots until use. 
  
Chapter 2. Materials and Methods 
 
45 
Table 2.1. The synthetic peptides used in the study. 
Peptides Sequence Reference 
Peptide 25 (Ag85B240-254) FQDAYNAAGGHNAVF (Yanagisawa et al., 1997) 
MPT64190-194 FAVTNDGVI (Feng et al., 2001a) 
TB10.44-11 IMYNYPAM (Billeskov et al., 2007) 
MPT83 peptides   
MPT831-15 MINVQAKPAAAASLA This study 
MPT8311-25 AASLAAIAIAFLAGC This study 
MPT8321-35 FLAGCSSTKPVSQDT This study 
MPT8331-45 VSQDTSPKPATSPAA This study 
MPT8341-55 TSPAAPVTTAAMADP This study 
MPT8351-65 AMADPAADLIGRGCA This study 
MPT8361-75 GRGCAQYAAQNPTGP This study 
MPT8371-85 NPTGPGSVAGMAQDP This study 
MPT8381-95 MAQDPVATAASNNPM This study 
MPT8391-105 SNNPMLSTLTSALSG This study 
MPT83101-115 SALSGKLNPDVNLVD This study 
MPT83111-125 VNLVDTLNGGEYTVF This study 
MPT83121-135 EYTVFAPTNAAFDKL This study 
MPT83131-145 AFDKLPAATIDQLKT This study 
MPT83141-155 DQLKTDAKLLSSILT This study 
MPT83151-165 SSILTYHVIAGQASP This study 
MPT83161-175 GQASPSRIDGTHQTL This study 
MPT83171-185 THQTLQGADLTVIGA This study 
MPT83181-195 TVIGARDDLMVNNAG This study 
MPT83191-205 VNNAGLVCGGVHTAN This study 
MPT83201-215 VHTANATVYMIDTVL This study 
MPT83211-225 ATVYMIDTVLMPPAQ This study 
Fine-mapping peptides   
MPT83121-129 EYTVFAPTN This study 
MPT83122-130 YTVFAPTNA This study 
MPT83123-131 TVFAPTNAA This study 
MPT83124-132 VFAPTNAAF This study 
MPT83125-133 FAPTNAAFD This study 
MPT83126-134 APTNAAFDK This study 
MPT83127-135 PTNAAFDKL This study 
MPT83128-136 TNAAFDKLA This study 
MPT83128-135 TNAAFDKL This study 
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2.2 Mice 
Six to eight week old female C57BL/6 and Balb/c mice were obtained from the Animal 
Resources Centre (Perth, WA, Australia). The C57BL/6 IL-12p40 knock-out (IL-12p40–/–) 
mice were originally obtained from the Jackson Laboratory (Bar Harbor, ME), and maintained 
in-house at the Centenary Institute animal facility. The P25 TCR transgenic mice express the 
Ag85B P25 epitope-specific H-2 IAb-restricted TCR from CD4+ T cell clone BP1 under the 
C57BL/6 background (Tamura et al., 2004). All mice were maintained under specific 
pathogen-free conditions with unrestricted access to food and acidified water. Mice infected 
with M. tuberculosis were housed in a Physical Containment Level 3 (PC3) rated animal 
facility, and mice infected with M. bovis BCG were housed in a PC2 quarantined animal 
facility. Unless otherwise stated, anaesthesia of mice was induce by the delivery of 4% 
isoflurane with O2 at a flow rate of 1 L/min and maintained at 2% isoflurane with O2 at a flow 
rate of 0.1 L/min. All DNA vaccines and rAAV vectors animal experiments were approved by 
the Animal Care and Ethics Committee of the University of Sydney, under the protocol number 
K75/3-2004/3878. 
 
2.3 Bacterial Strains and Growth Conditions 
Escherichia coli DH5α and SURE® (Agilent Technologies, VIC, Australia) strains were 
cultured in Luria-Bertani (LB) broth (10 g/L peptone, 5 g/L yeast extract, 10 g/L NaCl) (Difco 
laboratories, Franklin Lakes, NJ) and cultured on LB supplemented with 15 g/L of 
bacteriological agar (Amyl Media) when solid medium was required. Ampicillin (100 µg/ml) 
and kanamycin (25 µg/ml) were used for selective growth media where required. 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-gal, 0.004%, w/v) was used where appropriate. All 
bacterial cultures were incubated at 37˚C unless otherwise stated, and liquid broth cultures 
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were agitated during incubation in an orbital shaking incubator at 200 rpm when required. All 
E. coli stocks were prepared as 15% v/v glycerol in LB from fresh overnight cultures and 
stored at -70˚C. M. tuberculosis H37Rv was obtained from American Type Culture Collection 
(ATCC, Manassas, VA). Working cultures were incubated from glycerol stocks stored at -80˚C 
to the log phase of growth in Middlebrook 7H9 liquid media supplemented with 0.2% v/v 
tyloxapol (Sigma-Aldrich, St Louis, MO), 10% ADC (Becton-Dickinson (BD), Franklin Lakes, 
NJ) and 1% v/v Glycerol. M. tuberculosis cultures for enumerating bacterial load were grown 
on Middlebrook 7H11 agar supplemented with 10% v/v OADC (BD) and 1% v/v glycerol. All 
M. tuberculosis cultures were incubated at 37˚C. 
 M. bovis BCG for protection experiments was obtained from The Pasteur Institute 
(Paris, France) and cultured in the same fashion as stated above. 
 
2.4 Plasmids 
The plasmids used in this study are outlined in Table 2.2. 
Table 2.2. Description of plasmid vectors used in this study. 
 
Plasmid Features Source 
pcDNA3 The vector contains the ColE1 ori, CMV EI promoter and intron A, 
BGH polyadenylation sequence, tPA signal sequence and the T7 and 
Sp6 RNA promoters flanking the multiple cloning site. 
Neomycin/Kanamycin and Ampicillin resistance for eukaryotic and 
bacterial selection respectively. 
Life 
Technologies 
pCR2.1 This vector contains the lac promoter/operator region; M13 forward 
and reverse priming site; LacZ and T7 promoter priming sites, 
Kanamycin and Ampicillin resistance cassette and a pUC origin of 
replication. 
Life 
Technologies 
pIRES2-DsRed2 The vector harbours the CMV EI promoter, the internal ribosome 
entry site (IRES) from the encephalomucarditis virus (ECMV) and a 
red fluorescent protein (DsRed2) from Discosoma sp. 
Neomycin/Kanamycin resistance and has a pUC origin of 
replication. 
BD 
Bioscineces 
Clonetech 
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Plasmid Features Source 
DNA3-Ag85B-64 The vector is based on pcDNA3 and harbouring the entire ORF for 
Ag85b with the sequence for MPT64190-198 epitope fused to the 3’ 
end of the Ag85b gene. The fusion gene is under the control of 
CMV EI promoter. 
Current 
study 
DNA3-Ag85B-64-ESAT This vector is based on pcDNA3, harbouring the entire ORFs of 
Ag85b (5’) and ESAT-6 (3’) with the sequence for MPT64190-198 
epitope inserted between the two genes. The fusion is under the 
control of CMV EI promoter. 
Current 
study 
DNA3-Ag85B-ESAT-64 This vector based on pcDNA3, harbouring the entire ORF for 
Ag85b followed by the entire ORF for ESAT-6 with the sequence 
for MPT64190-198 epitope fused to the 3’ end of the Ag85b-ESAT-6 
fusion. The fusion gene is under the control of CMV EI promoter. 
Current 
study 
pAAV-Ag85B-64 This vector is based on the pAAV-ARAP4 plasmid with the entire 
ORF for AP removed and the ORF for AG85b-MPT64190-198 fusion 
was inserted using HindIII RE sites. This is expressed from a RSV 
promoter and enhancer sequences, and contains the simian virus-40 
(SV40) early polyadenylation signal. 
Current 
study 
pAAV-Ag85B-64-ESAT This vector is based on the AAV-ARAP4 plasmid with the entire 
ORF for AP removed and the ORF of 85b64ESAT was inserted 
using HindIII RE sites. This is expressed from a RSV promoter and 
enhancer sequences, and contains the SV40 early polyadenylation 
signal. 
Current 
study 
pAAV-Ag85B-ESAT-64 This vector is based on the AAV-ARAP4 plasmid with the entire 
ORF for AP removed and the ORF for Ag85b-ESAT-6-MPT64190-
198 fusion was inserted using HindIII RE sites. This is expressed 
from a RSV promoter and enhancer sequences, and contains the 
SV40 early polyadenylation signal. 
Current 
study 
pCl-mIL-12 This plasmid is based on the pCl eukaryotic expression vector. The 
murine IL-12p40-2A-p30 gene is expressed under the control of the 
CMV EI promoter. The plasmid harbours Ampicillin resistance and 
SV40 late polyadenylation signal. 
 
pAAV-IL-12 This vector is based on the AAV-ARAP4 plasmid with the entire 
ORF for AP removed and the gene for mouse IL-12p40-2A-p30 was 
inserted using HindIII RE sites. This is expressed from a RSV 
promoter and enhancer sequences, and contains the SV40 early 
polyadenylation signal. 
Current 
study 
pAAV-IL-23 This vector is based on the AAV-ARAP4 plasmid with the entire 
ORF for AP removed and gene for mouse IL-23p40-2A-p19 cloned 
in using HindIII RE sites. This is expressed from a RSV promoter 
and enhancer sequences, and contains the SV40 early 
polyadenylation signal. 
Current 
study 
pACRP30-CD40L This plasmid is based on pcDNA3.1 and contains the gene for 
murine CD40L fused to adiponectin (ACRP30) to produce the two-
trimer for of soluble CD40L. 
Kornbluth, 
R. S. 
pSP-D-CD40L This plasmid is based on pcDNA3.1 and contains the gene for 
murine CD40L fused to surfactant protein D (SP-D) to produce the 
four-trimer for of soluble CD40L. 
Kornbluth, 
R. S. 
pSP-D-GITRL This plasmid is based on pcDNA3.1 contain the gene for murine 
GITRL fused to surfactant protein D (SP-D) to produce the two-
trimer of soluble GITRL. 
Kornbluth, 
R. S. 
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Plasmid Features Source 
pAAV-ARAP4 The AAV2-based vector ARAP4 contains the human placental 
alkaline phosphatase (AP) cDNA expressed from a RSV promoter 
and enhancer sequences, and contains the simian virus-40 (SV40) 
early polyadenylation signal. 
Miller, A. D. 
pCMV-cap2 This plasmid expresses the AAV serotype 2 structural proteins from 
the cap ORF under the control of the CMV promoter. 
Miller, A. D. 
pCMV-cap6 This plasmid expresses the AAV serotype 6 structural proteins from 
the cap ORF under the control of the CMV promoter. 
Miller, A. D. 
pMT-rep2 This plasmid expresses the AAV serotype 2 non-structural proteins 
and contains the AAV2 rep coding region downstream of a 
metallothionine (MT) promoter. 
Miller, A. D. 
pDGM6 This plasmid harbours the AAV6 cap genes, AAV2 rep genes, and 
also adenovirus helper genes. 
Gregorevic, 
P. 
pMT-E4orf6 This plasmid contains the adenovirus type 5 E4orf6 coding region 
downstream of the CMV immediate early promoter. This gene 
product allows production of high titre AAV without helper 
adenovirus. 
Miller, A. D. 
pSM2 This plasmid is based on the pET19b expression vector and contains 
mpt83 (Rv2873). The entire ORF for MPT83 was blunt ligated into 
a BamHI digested vector. Expression of MPT83 was driven by the 
T7 promoter. 
Mahmuda, S. 
pSM7 This vector is based on pcDNA3, harbouring the entire ORF for 
MPT83. The expression of MPT83 is under the control of CMV EI 
promoter. 
Mahmuda, S. 
 
2.5 DNA Manipulation  
2.5.1 Small scale plasmid Isolation 
Plasmid DNA was extracted by the alkaline lysis method followed by precipitation of DNA. 
Liquid E. coli cultures were grown overnight at 37˚C in 10 ml of LB broth with appropriate 
antibiotic selection. Up to 5 ml of culture was centrifuged at 18,000 g for 1 min, and the pellet 
was thoroughly resuspended in 200 µl of Solution I (50 mM glucose, 25 mM Tris-HCl, 10 mM 
EDTA, pH 8.0). Then 200 µl of Solution II (0.2 M NaOH, 1% SDS) was added to the samples 
and mixed immediately by inverting the tube 8-10 times, thereby lysing the cells. The alkaline 
solution was then neutralised by the addition of 200 µl of Solution III (3 M potassium, 5 M 
acetate) and mixed by inverting the tube 8-10 times. Samples were then centrifuged at 18,000 g 
for 5 min at room temperature. The clear supernatant containing the plasmid DNA was 
carefully transferred to a new tube. DNA in the supernatant was precipitated by the addition of 
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70% supernatant volume of isopropanol and left standing for 2 min at room temperature 
followed by centrifugation at 18,000 × g for 5 min. The resulting pellets were washed with 
70% ethanol, air dried and resuspended in 50 µl of TE buffer (10 mM Tris, 1 mM EDTA, pH 
8.0) containing ribonuclease (40 µg/ml). Alternatively, the Wizard® Plus Minipreps DNA 
Purification System (Promega, Fitchburg, WI) was used according to the manufacturer’s 
instructions. 
 
2.5.2 Large Scale Plasmid Isolation 
Plasmid DNA for large-scale transfections and DNA immunisation was prepared using the 
PureLink™ HiPure Plasmid DNA Megaprep and Gigaprep Kits (Life Technologies) following 
the manufacturer’s protocols. Briefly, E.coli cells were cultured overnight in 2.4 L or 500 ml of 
LB for Gigaprep and Megaprep samples respectively. The cells were pelleted by using the 
Beckman J2-MC centrifuge at 4000 g for 15 min at 4˚C, and the pellet was thoroughly 
resuspended in the resuspension buffer (R3). The cells were lysed by the addition of lysis 
buffer (L7), mixed by inversion and incubated at 23˚C for 5 min. Cellular proteins and 
genomic DNA were precipitated by the addition of the precipitation buffer (N3) and mixed 
gently. The precipitated lysate was filtered with the lysate filtration cartridge, and the flow-
through containing the plasmid DNA was loaded onto the DNA Binding Cartridge. The bound 
plasmid DNA was washed with washing buffer (W8) twice and eluted by the application of 
elution buffer (E4). Following elution the eluted DNA was precipitated by the addition of 0.7 
volume of isopropanol per volume of eluate and pelleted by centrifugation with the Sorvall 
Evolution™ RC Superspeed Refrigerated Centrifuge DNA at 13,000 g for 30 min at 4˚C. DNA 
pellets were washed using 70% ethanol, air-dried and resuspended in an appropriate volume of 
sterile TE buffer and stored at -30˚C until use. 
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2.5.3 Digestion by Restriction Endonuclease 
Restriction endonucleases used in this study and their respective buffers were either obtained 
from Roche Applied Science (Indianapolis, IN) or New England Biolabs (Ipswich, MA). 
Typically, restriction endonuclease digests were performed on 0.5 to 5 µg of plasmid DNA 
with 1 to 10 U of enzyme per 1 µg of plasmid DNA. Reactions were performed under the 
conditions specified on the technical data sheets provided, and the reactions requiring multiple 
enzymes were performed in buffers optimal for the particular combination. Restriction digests 
reactions were generally incubated at 37˚C for at least 1 h, unless otherwise stated. If required, 
enzymes were heat-inactivated at 65˚C for at least 20 min.  
 
2.5.4 Agarose Gel Electrophoresis 
DNA fragments were routinely separated according to size in 0.85% agarose gel in TAE buffer 
(40 mM Tris-HCI, 10 mM EDTA, 20 mM acetic acid, pH 8.4) using a Hoeffer Agarose Gel 
Unit (Hoeffer Scientific Instruments, Holliston, MA) at 110 v for 1 h. Fragment size and 
quantity were estimated using a quantitative 1 kb molecular weight marker Hyperladder I 
(Bioline, UK) following the manufacturer’s instructions. Visualisation of the DNA fragments 
was achieved by either inclusion of 10 µg/ml ethidium bromide in the agarose gel or by 
staining the agarose gel in 0.75 µg/ml ethidium bromide solution following electrophoresis. 
 
2.5.5 Ligation of DNA Fragments 
Prior to ligation, DNA fragments were digested with appropriate enzymes and separated by 
electrophoresis in 0.85% agarose. The required fragment was then excised from the gel and 
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purified using the Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI) 
according to the manufacturer’s instructions. When required, cohesive overhangs were blunt-
ended using either the T4 polymerase or the Klenow enzyme to fill the 3’ end and remove the 5’ 
overhang. The concentration of insert and vector were determined either by absorbance at 
optical density (OD) at 260 nm using the Nanodrop 2000 Spectrophotometer (Thermo 
Scientific, Waltham, MA) or by using quantitative molecular weight markers on the agarose 
gels. Ligation of DNA was achieved by the preparation of a 20 µl reaction mix containing 100 
ng of vector DNA, and the amount of insert DNA required to achieve approximately a 3:1 
molar ratio of insert to vector DNA. Ten units of T4 ligase (Bioline, UK) were added to the 
reaction mix and incubated at 16˚C overnight. 
 
2.5.6 Transformation  
E. coli strains were made chemically competent to facilitate the uptake of recombinant plasmid 
DNA. Cells were cultured in 100 ml of LB broth to an OD of 0.6 at 600 nm. Following 
centrifugation, the cell pellets were resuspended in 5 ml of chilled and filter sterilised TSS 
buffer (PEG 0.2%, DMSO 0.01%, and MgCl2 10mM, in LB) and then stored at -80˚C. 
 One to five µl of the DNA samples were mixed with 100 µl of competent cells and 
incubated on ice for 30 min. To facilitate uptake of plasmid DNA, the reaction mixtures were 
heat-shocked at 42°C for 30 sec and then returned onto ice for a further 1-2 min. Following 
heat shock treatment, cells were allowed to recover by the addition of 400 ml of LB or super-
optimal media (2% w/v tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 mM KCl) and 
incubated at 37˚C for 60 min. This recovery stage is necessary to allow for expression of the 
plasmid-encoded antibiotic resistance markers. The cells are then plated onto appropriate 
selective solid growth media. 
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2.5.7 Polymerase Chain Reaction 
2.5.7.1 PCR procedure 
The polymerase chain reaction (PCR) was utilised to amplify the genes of interest from 
plasmid DNA, bacterial genomic DNA or mammalian cDNA. The reactions were carried out in 
0.2 ml thin-walled tubes containing 50 µl of reaction mix. Examples of the reaction 
components are described in Table 2.3. 
 
Table 2.3. General components of the PCR reaction mix. 
Component Volume / Amount 
Template  1-2 µl 
Primer Mix 2 µl 
dNTP Mix 1 µl 
10X PCR buffer 5 µl 
Hi-Spec Enhancer 10 µl 
Bio-X-act Long Polymerase 0.8 µl 
MgSO4 2 µl 
dH2O 27.2 µl 
Total 50 µ l 
 
The primers used in the study are summarised in Table 2.4, Primers were designed with the aid 
of the Primer3 algorithm in the Macvector 12 software (Macvector Inc., Cary, NC) and the 
reactions were performed using a Mastercycler ep System (Eppendorf, Germany). 
Amplification was done using 3 U of Biotaq DNA polymerase (Bioline). After the initial 
denaturation cycle of 94˚C for 4 min, the reaction proceeded for 35 cycles, each consisting of 
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denaturation for 1 min at 94˚C, annealing and elongation at 72˚C. The temperature and time for 
primer annealing and elongation time is optimised for each primer set. The presence of 
amplified DNA was determined by gel electrophoresis as described earlier. 
Table 2.4. Primers used in this study. 
Name Primer sequence Purpose 
wpr102 AAAGGATCCATGACAGACGTGAGCCGAAAG Forward primer for Ag85b  
85b64R AAATCTAGAAATCACCCCGTCGTTCGTGACTGCGAAG
GCGCCTAACGAAC 
Rerverse primer for Ag85b containing 
the Mpt64 CD8 with no stop codon 
wpr121 TCTAGATTAAATCACCCCGTCGTTCGTGACTGCGAAT
GCGAACATCCCAGTGAC 
Reverse primer for Ag85b-ESAT-64 
with stop (Mpt64 CD8 epitope) 
wpr122 TCTAGATTAAATCACCCCGTCGTTCGTGACTGCGAAG
GCGCCTAACGAACTCTG 
Reverse primer for Ag85b64 with 
stop (Mpt64 CD8 epitope) 
wpr123 AACGACCCTACGCAGCAG Internal Forward for 3' end of Ag85b 
wpr138 AGCTTATGACAGACGTGAGCCGAAAG Ag85b forward primer 1 for Sticky-
end PCR 
wpr139 TATGACAGACGTGAGCCGAAAG Ag85b forward primer 2 for Sticky-
end PCR  
wpr140 AGCTTTTAAATCACCCCGTCGTTCG MPT64 reverse primer 1 for Sticky-
end PCR 
wpr141 TTTAAATCACCCCGTCGTTCG MPT64 reverse primer 2 for Sticky-
end PCR  
wpr142 AGCTTCTATGCGAACATCCCAGTGAC ESAT-6 reverse primer 1 for Sticky-
end PCR  
wpr143 TCTATGCGAACATCCCAGTGAC ESAT-6 reverse primer 2 for Sticky-
end PCR  
wpr144 AGCTTACCATGTGTCAATCACGC IL-12 p35 forward primer 1 for 
Sticky-end PCR  
wpr145 TACCATGTGTCAATCACGC IL-12 p35 forward primer 2 for 
Sticky-end PCR  
wpr146 AGCTTCTAGGATCGGACCCTGCA p40 reverse primer 1 for Sticky-end 
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Name Primer sequence Purpose 
PCR  
wpr147 TCTAGGATCGGACCCTGCA p40 reverse primer 2 for Sticky-end 
PCR  
wpr148 AGCTTACCATGCTGGATTGCAGA IL-23 p19 forward primer 1 for 
Sticky-end PCR  
wpr149 TACCATGCTGGATTGCAGA IL-23 p19 forward primer 2 for 
Sticky-end PCR  
wpr161 CCACATTGGTGTGCACCTCCAAGCTACCATGTGTCAA
TCACGC 
AAV upstream primer IL-12 p35 
forward 
wpr162 AGTTAGATCTCGACGGTATCGATAAGCTCTAGGATCG
GACCCTGCA 
AAV downstream primer p40 reverse 
fkp1 TCGCTGGTCAGGAAGGTTTC Ag85B (431-412) 
fkp2 TCAAGAGCAGTAGCAGTTCC mIL-12 p40 (492-511) 
fkp3 TCCTTGAGAGTTTTCGCCCC 
beta lactamase (161-180) pAAV 
vector bb for 
fkp4 CGTTGTTGCCATTGCTACAGG 
pAAV (pMV) internal (b-lac side) 
vector bb rev 
fkp5 TGTGTTGGAGGTCGCTGAGTAGTG AAV qPCR forward (RSV) 
fkp6 AAACGCCTAACCCTAAGCAGATTC AAV qPCR reverse (RSV) 
fkp7 CAATGGGTGGAGTATTTACG 
AAV CMV promoter internal forward 
1 (qPCR) 
fkp8 AACGTCAATAGGGACTTTCC 
AAV CMV promoter internal forward 
2 (qPCR) 
fkp9 GGTCATGTACTGGGCATAAT 
AAV CMV promoter internal reverse 
(qPCR) 
 
2.5.7.2 Cloning of PCR Products 
Additional deoxyadenosine bases generated by Taq based polymerases at the 3’ end of the PCR 
product can be utilised for the cloning of the fragment. The TA Cloning Kit (Life Technologies) 
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utilises these single base overhangs for the direct cloning into vector pCR2.1 (Table 2.2). The 
linear vector supplied processes single deoxythymidine overhangs, which enable ligation of the 
PCR product. Standard ligation procedures were utilised to generate recombinant plasmids 
harbouring the PCR product, which were then transformed into chemically competent DH5α 
cells. Selection of positive clones was done using both kanamycin resistance and blue/white 
selection on X-gal containing agar, made possible by the disruption of the β-galactosidase gene 
upon fragment insertion. 
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2.5.8 DNA Sequencing 
The sequencing of plasmid DNA were carried out either at the Sydney University Prince 
Alfred Macromolecular Analysis Centre (SUPAMAC, Sydney, Australia) on an ABI PRISM® 
3700 Capillary DNA Sequencer, or at the Australian Genomic Research Facility (AGRF, 
Brisbane, Australia) on an ABI 3730xl 96-capillary automated DNA sequencer. Reaction 
mixtures were made up according to the specifications of each sequencing facility. 
 
2.6 Cell Culturing Conditions and Growth Media. 
Human Embryonic Kidney cell line (HEK 293T) and human epithelial cell line, HT1080 were 
cultured in complete Dubecco Modified Eagle Media (DMEM) (Life Technologies) (DMEM, 
1.5g/L Na2HCO3, 10% v/v foetal calf serum (FCS)). When required, the culture media was 
supplemented with penicillin/streptomycin (Life Technologies). All cell cultures were 
incubated in a humidified 37˚C incubator with 5% CO2 and were passaged when cells reach 
60-80% confluent. 
 
2.7 Transfections 
2.7.1 Small Scale Transfection  
HEK 293 cells cultures at 70-80% confluence in 6-well plates were used for transfection with 
FuGENE 6 transfection reagent (Roche). Before transfection, the culture media was replaced 
with 2 ml of serum-free and antibiotic-free OptiMEM media (Life Technologies) for at least 1 
h. Transfection procedures and the transfection mixtures were prepared according to the 
manufacturer’s instructions. Typically 5 µl of FuGENE 6 and 0.5-1 µg of plasmid DNA were 
used in each transfection. Transfection was performed at 37˚C in 5% CO2 for 8 h, after which 
time the FuGENE 6 containing media was removed and replaced with complete DMEM. 
Chapter 2. Materials and Methods 
 
58 
2.7.2 Large scale Transfection 
Large-scale transfection of HEK293T cells was required for the production of rAAV vectors 
for immunisation. The calcium phosphate transfection method is based on the formation of a 
calcium phosphate-DNA precipitate. These calcium phosphate nano-particles facilitate the 
binding of the DNA molecules to the cell surface, which subsequently enter the cell by 
endocytosis. The transfections done in this study were based on methods established in this 
laboratory. Briefly, HEK293T cells were plated one day before transfection at a density of 3.5 
× 106 per 10 cm tissue culture plate, and the medium was changed 4 h before transfection. In 
one 15 ml conical tube, solution A was prepared containing 250 mM CaCl2 and 25 µg of the 
total plasmid DNA mix (pAAV, pHLP19 and pAdeno5 at a 1:1:1 molar ratio), and the final 
volume was adjusted to 2 ml with 1/10 TE buffer (1 mM Tris-HCI pH 8.0, 100 µM EDTA). 
The formation of the DNA-CaCl2 precipitant was achieved by adding solution A drop-wise to 
solution B consisting of 2x HEPES buffer solution (50 mM HEPES, pH 7.05, 10 mM KCl, 12 
mM dextrose, 280 mM NaCl) and 1.5 mM Na2PO4 prepared in another tube while mixing by 
vortex on high. The resulting solution was mixed by vortex for a further 1 min to ensure the 
adequate agitation and the formation of a fine precipitant. 
 One ml of the milky solution containing the fine DNA-CaCl2 precipitate was applied to 
the each plate containing the HEK293T monolayer in a drop-wise fashion evenly across the 
tissue culture plate, and then mixed by rocking the plates back and forth gently. The cells were 
incubated for 16 h at 37˚C in a CO2 incubator before the media was replaced with DMEM 
containing 2% FCS. The transfected cells were incubated for a total of 72 h before harvest for 
rAAV vector purification. 
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2.8 Packaging of recombinant AAV virus 
2.8.1 Small scale packaging of rAAV 
Seventy-two h following the triple transfection of HEK-293T cells with pAAV-based plasmids, 
pDGM6 (rAAV6) or pHLP19 and pAdeno5 (rAAV2) in 6-well tissue culture plates (BD 
Falcon), the cells were resuspended in the spent media and transferred to 2 ml microcentrifuge 
tubes. The samples were centrifuged at 12,000 × g for 2 min to pellet the cells. The media were 
transferred to new tubes. The cell pellet was resuspended in 0.3 ml TE buffer and subjected to 
three freeze-thaw cycles to release the viral particles from the cells. The samples were 
centrifuged again at 12,000 × g for 2 min, and the supernatant containing the cell lysate was 
transferred to new tubes and stored at 4˚C. For the purpose of titration by PCR, un-capsulated 
DNA was digested using DNase I treatment of the cell lysate. Samples were diluted 1/100 in 
Tris pH 8 (22 mM) and MgCl2 (2.2 mM). Thirty µl of the diluted sample was treated with 10 U 
of DNase I (Sigma-Aldrich) and incubated overnight at 37˚C. The samples were further diluted 
by adding 360 µl of H2O, and the DNase I was inactivated by the addition of 30 µl of NaOH 
(400 mM) and incubated at 65˚C for 45 min. Finally the NaOH was neutralised with 30 µl of 
HCl (400 mM), resulting in a final concentration of NaCl of 26.7 mM. Two µl of the final 
DNase I treated samples were used as template for PCR reactions. 
 
2.8.2 rAAV packaging and purification 
rAAV vectors were packaged into AAV capsids using a helper virus-free system with the 
packaging plasmids, pHLP19, pAdeno5 and pAAV encoding AAV inverted terminal repeats 
(ITR). Briefly, HEK-293 cells were seeded into 100 mm diameter petri dishes at 3.5 × 106 
cells/plate and incubated overnight. The medium was replaced with fresh complete DMEM, 
and a transfection mix was prepared containing plasmids encoding adenovirus helper functions 
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(pEorf6), a plasmid encoding either rAAV capsid serotype 2 (pHLP19) or rAAV capsid 
serotype (pRepCap6) and a plasmid encoding the transgene flanked by AAV serotype 2 ITRs 
(pAAV). The transfection mix was dispensed to plates, which were then incubated overnight. 
After a medium change with fresh complete DMEM at 16 h post-transfection, cells were 
harvested 72 h following transfection and pelleted at 400 × g for 10 min. Cells were 
resuspended in buffer (100 mM NaCl, 2 mM MgCl2, 10 mM Tris–HCl (pH 8)) at 1 ml per 10 
cm plate and subjected to three freeze-thaw cycles. Cellular debris was pelleted by 
centrifugation at 3000 × g for 10 min. The supernatant was treated with Benzonase (Sigma-
Aldrich) at 50 U/ml and subjected to two precipitation steps using saturated (NH4)2SO4 in PBS 
(pH 7.0). Cellular contaminants were precipitated on ice for 10 min in 35% ammonium 
sulphate and removed by centrifugation at 5000 g for 15 min, The viral particles in the 
supernatant were precipitated for 20 min on ice in 55% ammonium sulphate. The viral vectors 
in the resultant pellet were resuspended in a CsCl solution at a density of 1.37 g/ml and 
transferred into a ultracentrifuge tube (#344059, Beckman Coulter, Indianapolis IN) cushioned 
with 1 ml of CsCl solution at 1.5 g/ml. The tubes were centrifuged for 48 h at 330,000 g in a 
SW41Ti rotor (Beckman Coulter) with a Beckman Optima XL-90 ultracentrifuge (Beckman 
Coulter). One ml fractions were collected using a 21 G needle and assayed for the presence of 
rAAV by PCR, and the positive fractions were pooled and dialysed overnight against PBS 
(with Ca2+ and Mg2+) using a 7K MWCO Slide-A-Lyzer dialysis cassette (Thermo Scientific) 
in 1000-fold volume. The titre of rAAV vectors were determined using quantitative PCR 
(qPCR), and the characterised rAAV stocks were stored at −80˚C before immunisation. 
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2.8.3 Quantification of viral titres 
qPCR was performed to determine the genomic titre of rAAV vector stocks. Absolute 
standards were prepared from pAAV plasmids for the corresponding rAAV construct and 
included in the qPCR reaction. Briefly, samples of purified and dialysed rAAV stocks were 
diluted serially from 10-3 to 10-5 in 1/10 TE buffer. Oligonucleotide primers specific for the 3’ 
region of the RSV promoter and an internal site of either Ag85B or mIL-12 (Table 2.4) were 
used to amplify the respective recombinant viral genomes on the Strategene Mx3000P real-
time PCR platform (Aligent Technologies, Santa Clara, CA). EXPRESS SYBR® GreenER™ 
qPCR supermix (Life Technologies) was used to make each qPCR reaction according to the 
manufacturer’s recommendation.  
 
2.8.4 In vitro virus transduction and gene expression 
Purified vector stocks were transduced into HT1080 or HEK-293 cells at an MOI of 1000 in 6-
well plates. Briefly, 80% confluent cell monolayers were treated with 4.8 µM of camptothecin 
(Sigma-Aldrich) in complete DMEM for 4 h. The camptothecin containing media was replaced 
with 1 ml of DMEM with 2% FCS containing the rAAV vectors. The plates were swirled 
gently at 30 min intervals for up to 2 h, and then a further 1 ml of DMEM with 18% FCS was 
added to each well and incubated for at least 48 h before detection of transgene expression. 
 
2.9 Protein studies 
2.9.1 Expression of recombinant protein 
The expression of recombinant MPT83 was driven by the T7 promoter after transformation of 
E. coli BL21 strain with the plasmid, pSM2. Positive transformants were obtained by culturing 
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on LB agar (Difco laboratories) supplemented with ampicillin. For large-scale production of 
recombinant protein, an overnight starter culture was used to seed 3 L of LB broth and 
incubated at 37˚C for 16 h with agitation. This resulted in the over-expression of the N-
terminal histidine-tagged cytoplasmic protein, which aggregated as insoluble inclusion bodies. 
The inclusion bodies containing the recombinant proteins were purified by resuspending the 
cell pellet recovered from an overnight, E. coli BL21 (DE3) expression culture in 100 ml of 8 
M urea buffer (8 M urea, 0.3 M NaCl, Sodium Phosphate buffer pH 7.6) per litre of culture and 
slowly agitating at 4˚C.  
 
2.9.2 Protein purification 
To obtain purified protein species for use for immunisation and immunological assays, an E. 
coli expression system was used to produce the histidine-tagged recombinant proteins. 
Solubilised recombinant proteins from the inclusion bodies were purified by TALON 
(Clonotech, Mountain View, CA), Co2+ charged immobilised metal affinity chromatography 
(IMAC), according to the manufacturer’s instructions. Briefly, a batch/gravity purification 
format was conducted where histidine-tagged proteins were bound to resin in batches using 50 
ml conical tubes and gentle agitated for 30 minutes on the RSM6 rotary mixer (Ratek, 
Australia). The protein-bound resin was washed twice with the 8 M urea buffer by 
centrifugation at 3267 × g and resuspended in fresh urea buffer. A final stringency wash was 
performed with 8 M urea buffer containing 10 mM imidazole. Following this, the resin was 
transferred to a 20 ml disposable column and washed with 8 M urea buffer by gravity-flow. 
The histidine-tagged protein was eluted by the addition of 150 mM imidazole containing buffer 
and 1 ml fractions were collected by gravity-flow. Eluted proteins in fractions were visualised 
on sodium dodecyl sulphate poly-acylamide gel electrophoresis (SDS-PAGE) gel. The 
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fractions containing the purified protein of interest were pooled and then dialysed against Tris 
buffer (500 mM, pH 7.5) at a 1:1000 ratio using a T4 CelluSep tubular cellulose membrane 
(Fisher Biotec, WA, Australia) overnight at 4˚C. The purified protein was stored at -30˚C until 
required. 
 
2.9.3 Quantification of protein 
To quantify total protein concentration in a sample, either the Bicinchoninic acid (BCA) assay 
(Thermo Scientific, Rockford, IL) or the Bradford assay was performed using bovine serum 
albumin (BSA) as concentration standards. The BCA assay was performed in 96-well plates by 
mixing 10 to 25 µl of standard or sample solutions with 200 µl of working reagent (mixture of 
Reagent A and B at a 50:1 ratio). The reaction was incubated at 37˚C in the dark for 30 minutes 
resulting in a green to purple colour change, and the absorbance was read at 550 nm. The 
Bradford assay was performed when reducing agents are present in the sample diluents. The 
assay was performed by mixing 5 µl of protein concentration standards or sample solutions 
with 250 µl Bradford reagent (Sigma-Aldrich) and then incubation at 23˚C for 5 to 40 min, The 
colour change was measured by reading the absorbance at 620 nm. For both assays, protein 
concentration was determined by interpolating values in an equation obtained from the 
concentration standard curve. 
 
2.9.4 Visualisation of proteins 
Proteins were separated by SDS-PAGE. The SDS-PAGE gel was made by layering the 4% 
polyacrylamide stacking gel (pH 6.8) on top of the 12% resolving gel (pH 8.0). Samples were 
prepared by adding equal volumes of the sample and 2× reducing sample buffer (250 mM Tris 
pH 6.8, 20% v/v Glycerol, 2% w/v SDS, 10% v/v 2-ME, 0.1% w/v Bromophenol Blue) and 
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denaturing at 100ºC for 15 min. The samples were loaded into the wells of the gel immersed in 
SDS-PAGE running buffer (250 nM Tris, 192 mM Glycine, 0.1% w/v SDS) and 
electrophoresed in a mini-PROTEAN® 3 cell apparatus (BioRad, Hercules, CA) alongside 
unstained protein markers (BioRad) at 140-160 V for approximately 90 min until the dye-front 
reached the bottom of the gel. For visualisation of separated protein, SDS-PAGE gel was 
stained with Coomassie Blue staining solution (0.1% w/v Coomassie Brilliant Blue R-250, 
20% v/v methanol, 10% v/v acetic acid). The gel was destained with solution of 50% v/v 
methanol and 10% v/v acetic acid. 
 
2.9.5 Immunoblotting 
For the immunoblotting and detection of specific proteins the samples, separated protein bands 
were transferred onto nitrocellulose or polyvinylidene difluoride (PVDF) membrane (Pall 
Corporation, Port Washington, NY) by electrophoresis in cold Western blot transfer buffer (25 
mM Tris, 192 mM glycine, 10% v/v methanol) at 30 V overnight or at 150 V for 45 minutes 
using a Mini Trans-blot® Electrophoretic Cell at 4˚C (BioRad). Prestained All-blue protein 
markers (BioRad) were used during electrophoresis on a SDS-PAGE. The M. tuberculosis 
extracts and culture filtrate proteins were provided by the NIH contract NIAD AI-75320. A 
successful protein transfer was determined by visualising the stained protein ladder on the 
membrane. Following protein transfer, the membrane was blocked in a 1% w/v solution of 
skim milk in PBS for 2 h or overnight at 4˚C. Blocked membrane was then incubated with a 
primary antibody diluted in PBS with 3% w/v BSA for 1-2 h at 23˚C with gentle agitation. The 
membrane was then washed in PBS-T (PBS, 0.05% v/v Tween-20) for 15 min for at least 3 
times, and then incubated with the secondary antibody diluted in PBS with 3% w/v BSA for 1 
h at 23˚C with gentle agitation. Histidine-tagged proteins were detected using a nickel-chelated 
horseradish peroxidase (HRP) (Thermo Scientific) at a dilution of 1:10,000. For identification 
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of MPT83, anti-sera raised in mice immunised with rMPT83 were used at a dilution of 1:500. 
A secondary HRP-conjugated goat anti-mouse IgG mAb (GE healthcare, Piscataway, NJ) was 
used at a dilution of 1:10,000. After washing with PBS-T, SuperSignal West Pico 
Chemiluminescent Substrate solution (Thermo Scientific) was added. Bands bound by the 
specific immunoglobulins were detected by luminescence on the membrane, and these were 
visualised using the Kodak Image Station 2000MM (Kodak, Rochester, NY). 
 
2.10 Immunisations 
2.10.1 Intramuscular immunisation 
Mice were immunised three times at two weekly intervals with 100 µg of plasmid DNA or 1012 
vg of rAAV vectors in a volume of 100 µl. When a mixture of DNA vectors were used, 200 µg 
of total plasmid DNA mixture was delivered, consisting of the vaccine construct at 100 µg/ml 
and the control vector pcDNA3 at 100 µg/ml. DNA vaccines at either 1 mg/ml or 2 mg/ml and 
rAAV vectors at 1013 vg/ml were administered by intramuscular injection (i.m.i), with 50 µl of 
the mix being injected into each tibialis anterior muscle of an anesthetised mouse. Negative 
control mice were immunised in the same fashion with 100 µg or 200 µg control vector 
pcDNA3 or the equivalent amount of control rAAV vector. 
 
2.10.2 Subcutaneous Immunisation 
Recombinant protein vaccines and BCG were administered by subcutaneous immunisation 
(s.c.). Frozen stocks of BCG were diluted to 2.5 x 106 cfu/ml in sterile PBS. rMPT83 was 
mixed with a dimethyl-dioctadecyl ammonium bromide (DDA) and monophosphoryl lipid A 
(MPLA) (Sigma-Aldrich) to form a protein/adjuvant emulsion. Two hundred µl of the either 
BCG or the rMPT83/DDA/MPLA mixtures were administered by s.c. at the base of tail of 
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anesthetised mice to deliver either 5 x 105 cfu of BCG or 10 µg of MPT83 with 500 µg of 
DDA and 25µg of MPLA. For immunogenicity and protective efficacy experiments, mice were 
given three immunisations at two weekly intervals and rested for at least four weeks following 
the final immunisation. 
 
2.10.3 Intranasal delivery of rAAV vectors 
Mice were lightly anesthetised with isoflurane and positioned in a 60º inclined supine position. 
Mice were briefly exposed to isoflurane to maintain a level of light anaesthesia before an 
intranasal administration with a single dose of 12.5 µl of rAAV vector (4 x 1013 vg/ml) was 
delivered slowly into each of the nares to deliver 1011 vg of rAAV vector in a volume of 25 µl 
to the mouse.  
 
2.11 Protection studies 
For protection studies, mice were challenged with approximately 100 CFU of M. tuberculosis 
H37Rv strain by the aerosol route, using the Inhalation Exposure system nebuliser apparatus 
(Glas-Col, Terre Haute, IN). M. tuberculosis-infected mice were rested for 4 to 6 weeks, at 
which time M. tuberculosis reaches the peak of infection, and then sacrificed. The mice were 
perfused with PBS and the right lobes from the mice lungs were collected and fixed in 10% 
neutral buffered formalin (Thermo Fisher Scientific, Australia) to examine the lung histology, 
while the left lobes and the spleens were homogenised, serially diluted and plated onto 7H11 
agar plates to enumerate the bacterial load in the lungs and spleen. The CFU were counted after 
21 days of incubation at 37˚C. 
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2.12 Immunological assays 
2.12.1 Preparation of single cell suspension of splenocytes 
Spleens harvested from sacrificed mice were placed on ice in 2 ml of RPMI media (Life 
Technologies) supplemented with 10% FCS, 50 µM 2-ME (Sigma-Aldrich), and Penicillin-
Streptomycin (Life Technologies). Single-cell suspensions of the spleen were prepared by 
passing the organ and media through a 70 µm cell strainer (BD). Red blood cells (RBC) were 
lysed by the addition of ACK lysis buffer (0.15 M NH2Cl, 1 mM KHCO3, 0.1 mM Na2EDTA, 
pH 7.2) and incubated at 23˚C for 2 mins, and the RBC lysis reaction was neutralised by the 
addition of 9 ml of RPMI containing FCS. Splenocytes were centrifuged and resuspended in 5 
ml of complete RPMI. Viable cells were enumerated using a hemocytometer following Trypan 
Blue exclusion with a 0.4% w/v Trypan Blue solution. 
 
2.12.2 ELIspot 
The anti-murine IFN-γ monoclonal antibody (clone AN18, DNAX, Palo Alto, CA) at 10 µg/ml 
was coated onto the nitrocellulose membranes of 96 well plates, which had been pre-wet with 
20 µl of 35% ethanol. Splenocyte suspensions prepared from immunised and control mice were 
added to the wells at 2 x 105 cells per well and incubated with Ag85B at final concentrations of 
3 µg/ml, 1 µg/ml and 0.3 µg/ml, peptide 25 at 3 µg/ml and 1 µg/ml, MPT64 at 3 µg/ml and 1 
µg/ml and MPT64190-198 at 3 µg/ml, 1 µg/ml and 0.3 µg/ml, or with concanavalin A (Con A) at 
3 µg/ml as the positive control and media alone as the negative control. Each treatment 
condition was replicated at least in duplicate. Following 16 h of incubation at 37˚C, the cells 
were removed, and the plates were washed six times with PBS 0.1% v/v TWEEN-20, followed 
by incubation for 1 h with biotinylated anti-murine IFN-γ monoclonal antibody (clone XMG1.2, 
ATCC) at 10 µg/ml. The membrane was washed a further six times followed by labelling with 
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Avidin-Alkaline Phosphatase (Sigma-Aldrich) at the recommended dilution for 
immunoblotting and the. IFN-γ producing cells were visualised using the AP Substrate Kit 
(BioRad), spots were enumerated with an automated spot counter (Autoimmun Diagnostika, 
Straßberg, Germany).  
 
2.12.3 ELISA 
Single-cell suspensions prepared as previously described were added to the wells of 96-well 
round bottom plates at 4 × 105 cells per well and cultured for 72 h at 37˚C with either Ag85B at 
a final concentrations of 3 µg/ml, 1 µg/ml and 0.3 µg/ml, peptide 25 at 3 µg/ml and 1 µg/ml, 
MPT64 at 3 µg/ml and 1 µg/ml and MPT64190-198 at 3 µg/ml, 1 µg/ml and 0.3 µg/ml or Con A 
at 3 µg/ml as the positive control and media alone as the negative control. Culture supernatants 
were collected after 72 h, and the cytokine production was measured by capture ELISA. 96-
well round-bottom ELISA plates (Biofusion Dyntech) were coated with 100 µl of capture 
antibody, α-IFN-γ (AN18) at 10 µg/ml diluted in Bicarbonate/carbonate coating buffer (100 
mM Na2CO3, 100 mM NaHCO3 pH 9.6) overnight at 4˚C. The plates were washed 3 times 
with PBST (0.05% v/v TWEEN-20, PBS) followed by blocking with 200 µl of blocking buffer 
(3% w/v BSA, PBST) for 1 h at 23˚C. The blocking buffer was washed off six-times with 
PBST and 100 µl of the culture supernatant, cytokine standards (BD Pharmingen) and controls 
were added to the plates and incubated at 23˚C for 2 h. The samples were decanted, and the 
plate was washed six-times with PBST, 100 µl of biotinylated secondary antibody, α-IFN-γ-
biotin (XMG1.2) diluted in secondary antibody buffer (1% w/v BSA, PBST) at 10 µg/ml were 
added to the plate and incubated for 1 h at 23˚C. The secondary antibody was washed off six-
time and 100 µl of strepavidin-Horseradish Peroxidase diluted 1 in 10,000 in secondary 
antibody buffer was add to each well and incubated for 1 h at 23˚C. The plate was washed six-
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times with PBS, and 100 µl of ABTS substrate solution were added to each well, and the plate 
was incubated in the dark for 15-20 min to allow for colour development. The absorbances for 
each of the wells were measured using the Multiskan EX Microplate reader (Thermo Scientific) 
at a wavelength of 405 nm and corrected with the absorbance at 492 nm. 
 
2.12.4 Antibody titre determination 
Antigen-specific antibodies in the sera of immunised mice were determined by antibody 
ELISA. Following coating of Ag85B protein (2 µg/ml) onto 96-well round-bottom ELISA 
plates (Biofusion Dyntech), five-fold serial dilutions of the collected mouse anti-sera starting 
from 1/100 were added. Sera from an unimmunised, uninfected C57Bl/6 mouse were included 
as control anti-sera. Alkaline phosphatase-conjugated goat anti-mouse total IgG, IgG1, and 
IgG2a were used at recommended dilutions to bind the antigen-specific antibodies. Antibodies 
were detected chromatically by the addition of the substrate n-nitro-phenyl-phosphate. To 
determine the titre of the antigen-specific antibody, the mean plus three standard deviations of 
control anti-sera was used as the cut-off absorbance. 
 
2.12.5 T cell Proliferation assay 
Splenocytes were enriched for T cells by passage through nylon wool columns. Six g of nylon 
wool fibres (PerkinElmer) were soaked overnight in 0.2 M HCl. The nylon wool was washed 
thoroughly with distilled water to remove any HCl before packing into 20 ml syringes to form 
the nylon wool columns. The moist columns were covered with foil and sterilised in the 
autoclave on a wet cycle. On the day of use, the nylon wool columns were pre-washed twice 
with pre-warmed complete RPMI media (Life Technologies). At least 1 x 108 pooled 
splenocytes from each experimental group were loaded onto the column and incubated at 37˚C 
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for 60 min. Non-adherent cells eluted by irradiating single-cell suspension of the splenocytes 
with 2500 rads using the Gammacell 40 Extractor (Nordion International, ON, Canada). The T 
cell enriched splenocytes and the syngenic APCs at a 1:1 ratio were added to a 96-well round-
bottom tissue culture plate in a total cell density of 2.5 x 105 per well in triplicates. The mixed 
cultures were cultured at 37˚C and stimulated for 72 h with Ag85B at 3 µg/ml, 1 µg/ml and 0.3 
µg/ml, peptide 25 at 3 µg/ml and 1 µg/ml, MPT64 at 3 µg/ml and 1 µg/ml, and MPT64190-198 at 
3 µg/ml, 1 µg/ml and 0.3 µg/ml, with ConA at 3 µg/ml and media alone as the positive and 
negative controls, respectively. 
 After 72 h, the cultures were pulsed with 1 µCi of [3H]-Thymidine per well and 
harvested onto glass fibre filters (PerkinElmer, Waltham, MA) 24 h later using an automated 
cell harvester (PerkinElmer). Scintillation fluid was used to saturate the filter membrane, and 
the [3H]-Thymidine incorporation was measured with a MicroBeta2 Beta-counter 
(PerkinElmer). The results were calculated by subtracting the mean counts per minute (CPM) 
of the negative control wells from the mean CPM of the sample wells. 
  
2.13 Cell staining for flow cytometry 
2.13.1 Antibody staining 
To determine the phenotype of T cells following immunisation, single-cell suspensions of the 
lymph node, spleen and lung from experimental animals were prepared. All surface antigen 
staining were performed with fluorophore-conjugated mAb diluted in FACSwash (PBS 2% v/v 
FCS, 2 mM EDTA, 0.02% NaN3). Non-specific binding was blocked using Fc blocking 
antibody (BD), and surface staining was performed using the mAb detailed in Table 2.5. The 
optimal dilution of mAb was determined by titration. Typically, cells were washed three times 
after each layer of antibody stain by centrifuging at 500 × g for 5 min with the Beckman 
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Coulter Allegra X-15R bench top centrifuge (Thermo Scientific), and the pellets were 
thoroughly resuspended in 200 µl of FACSwash. Cells were washed twice before staining with 
the antibody mix in a volume of 50 µl in a 96-well round-bottom tissue culture plates (BD) and 
incubated for 30 min on ice. The stained cells were washed a further two times with 
FACSwash before acquisition with the flow cytometer. Stained cells were fixed by 
resuspending in 200 µl of 10% neutral buffered formalin (Fronine) when required. 
 
2.13.2 Intracellular cytokine staining 
Splenocytes prepared as previously described were cultured at 5 x 106 cells per well in the 
wells of a 24-well, flat-bottom tissue culture plate (BD). Cells were either stimulated overnight 
with Ag85B and MPT64190-198 at 3 µg/ml, or PMA (50 ng/ml) and Ionomycin (1 µg/ml) as a 
positive control and unstimulated cells were used as the negative control. Six h before cell 
surface staining, Brefeldin A (10 µg/ml) was added to each well to inhibit cellular protein 
export from the Golgi and retaining any cytokines produced within the cells. Washing and 
staining of the cells were performed in a 96-well round-bottom tissue culture plate (BD). 
FACSwash was used for both washing buffer and surface staining antibody diluent. Following 
staining for surface markers, the cells were washed with FACSwash, then transiently 
permeabilised by treatment with 100 µl of 1x Cytofix/Cytoperm solution (BD) per well for 20 
min at 4˚C. Following permeabilisation, washing and intracellular staining steps were done 
using Cytowash (BD). Intracellular IFN-γ and TNF-α were stained with FITC conjugated anti-
IFN-γ antibody (Caltag Laboratories) and APC conjugated anti- TNF-α (BD), respectively.  
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2.14 Flow cytometry 
After antibody staining of the single-cell suspensions, the samples were passed through a 70 
µm filter to exclude clumps before data acquisition with the flow cytometer. For analysis, all 
events were collected using the BD LSR II flow cytometer (BD) at the optimal PMT voltages 
adjusted at the time of acquisition, and the data were acquired using the Diva 6.1 software 
(BD). 
 Data acquired from flow cytometry were analysed using Flowjo 9.6 (Tree Star, Inc., 
Oregon, USA). Cell populations are either plotted as histograms or density plots (red being the 
most dense to blue dots representing individual cells). The numbers within each figure indicate 
percentage of cell population within the gated area. Events representing doublet cells were 
excluded on the basis of forward scatter (FSC) height versus FSC area and side scatter (SSC) 
height versus SSC area plot as shown on Figure 2.1. Events that represented cell debris or dead 
cells were identified by their position on the FSC area versus SSC area plot, and live/dead 
discrimination was performed using the LIVE/DEAD fixable violet dead cell stain (Life 
Technologies).
 
2.14.1 Gating strategy for the evaluation of cytokine cells 
A general gating strategy was employed for the analysis of cytokine secreting cells (Figure 2.1). 
Cells of interest were gated based on size and granularity determined by the forward (FCS-A) 
and side scatter area (SSC-A) profiles, respectively. To exclude cellular debris and doublet 
cells, both forward and side scatter area versus height (FSC-A vs FSC-H and SSC-A vs SSC-H, 
respectively) were used. Lymphocytes were identified by the expression of surface CD3, and 
then further discriminated by the surface expression of either CD4 or CD8. The secretion of 
cytokines and activation states of these T cell subsets were then analysed. Single-stained cells 
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or BD CompBeads (BD) were used to determine spectral overlap for each of the utilised 
fluorochromes, and unstained negative controls were included in all experiments. 
Table 2.5. Antibodies used in this study. 
Name Species Clone Source 
IFN-γ Rat α-Mouse AN18 In house purified 
IFN-γ-biotin Rat α-Mouse XMG 1.2 In house purified 
IFN-γ-FITC Rat α-Mouse XMG 1.2 BD Pharmingen 
IL-12p40 Rat α-Mouse C15.6 In house purified 
IL-12p40-biotin Goat α-Mouse AKD11 R&D Systems 
Strepavidin-HRP - - BD Pharmingen 
CD32/CD16 Rat α-Mouse 2.4G2 BD Pharmingen 
CD3-PE.Cy7 Rat α-Mouse 145-2C11 BD Pharmingen 
CD4-APC Rat α-Mouse GK1.5 BD Pharmingen 
CD8-APC.Cy7 Rat α-Mouse 53-6.7 BD Pharmingen 
CD62L-PE Rat α-Mouse MEL14 BD Pharmingen 
CD44-biotin Rat α-Mouse IM7.8.1 In house purified 
Strepavidin-Qdot655 - - Invitogen 
 
FITC - fluorescein isothiocyanate 
APC - allochycocyanin 
PE - R-phycoerythin 
Cy7 - cyanine 7 
HRP - horse radish peroxidase  
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Figure 2.1. Gating strategy for the evaluation of cytokine producing cells. 
Small cells and debris were excluded by size and granularity, doublets were excluded, and the 
T lymphocytes were gated based on surface expression of CD3+. The production of IFN-γ was 
analysed for CD4+ and CD8+ T lymphocyte subsets. The proportions of cells in each quadrant 
are displayed. 
  
Doublet exclusion Cell size 
CD3+ cells CD4+ and CD8+ Cells 
IFN-γ producing CD4+ 
Cells 
IFN-γ producing CD8+ 
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2.15 Statistical analysis 
The significance of the differences in human T lymphocyte responses were analysed by the 
Mann-Whitney U test, and the differences in murine T lymphocytes responses between two 
groups of immunised and non-immunised mice were analysed using an unpaired Student’s t-
test. The differences in immune responses and bacterial load between multiple groups of mice 
were assessed using the one-way analysis of variance (ANOVA) with the Turkey’s post-hoc 
test to correct for multiple comparisons. Statistical analysis was performed using the GraphPad 
Prism 5 software (GraphPad Software, La Jolla, CA). The differences between groups were 
considered significant when the P values were ≤0.05. 
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3.1 Introduction 
A major aim in the development of more effective anti-TB vaccines is to induce long-lasting 
memory T cell responses, sufficient for the attenuation or clearance of infection following 
exposure to M. tuberculosis. Many types of vaccines, including live attenuated M. tuberculosis 
(Pinto et al., 2004, Sampson et al., 2011), modified BCG vaccines (Nambiar et al., 2010, Grode 
et al., 2005, Sun et al., 2009), and subunit protein and viral vectored vaccines (McShane et al., 
2004, Santosuosso et al., 2006) are in development for this purpose. DNA vaccines present a 
potentially safe and simple method for the induction of CD4+ and CD8+ T cell responses 
(Perreau et al., 2011) and have been demonstrated to deliver bacterial and viral antigens 
efficiently and induce protection against subsequent infections (Barouch et al., 2000, Kao et al., 
2012). In addition to displaying promising results in small animal and preclinical studies, DNA 
vaccines have the potential to induce immunological effects cheaply whilst being safe for use 
in immuno-compromised patients. In TB vaccine research, DNA vaccines have not achieved 
the same levels of protective efficacy as other types of vaccine candidates (Baldwin et al., 1998) 
or BCG, the currently only licenced anti-TB vaccine (Gupta et al., 2007). Therefore, various 
approaches have been studied to enhance the responses induced by DNA vaccines. These 
include the incorporation of multiple immunogenic antigens (West et al., 2011, Yuan et al., 
2012), exploring appropriate adjuvants or formulations (Triccas et al., 2007, Wang et al., 2012a) 
and using different routes or methods of vaccine delivery (Lin et al., 2012) to enhance the 
induction of Th1 type T cell responses essential for the control of M. tuberculosis infections 
(Redford et al., 2010, Salgame, 2005, Wangoo et al., 2001). 
The clonal expansion of T cells requires both activation of the TCR by antigen-MHC 
complexes and the activation of a second ligand-receptor interaction, the co-stimulatory signal. 
The presence of this second signal dictates the outcome of the interacting T cells, activation 
and expansion or clonal anergy (Schwartz, 2003). Co-stimulatory molecules are categorised 
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into two main types according to their molecular structures, the immunoglobulin (Ig) or the 
TNF superfamily. Members of the TNF superfamily that lack the cytoplasmic death domains 
are involved in gene activation and anti-apoptotic signalling. CD40L (CD154), which activates 
CD40 on B cells and APCs, is a member of the TNF superfamily of co-stimulatory molecules 
and is predominately expressed on activated CD4+ T cells (Banchereau et al., 1994), although 
it is also expressed on activated human and murine B cells and DCs (Grammer et al., 1999, 
Johnson et al., 2009). The CD40-CD40L interaction is important for B cell licensing (Lipsky et 
al., 1997) as well as playing an integral part in the regulation of DC-T cell crosstalk. Upon 
CD40 activation, DCs are activated to become more effective APCs, upregulating MHC class 
II molecules as well as other co-stimulatory molecules, such as CD80 and CD86 (Kobayashi et 
al., 2004). Cytokines, such as IL-12, are also secreted, aiding the development of a Th1-
polarised T cell response (Cella et al., 1996). 
GITRL on the other hand, is expressed mainly by professional and non-professional 
APCs, as well as some endothelial cells (Tone et al., 2003, Gurney et al., 1999), and interacts 
with the important co-stimulatory molecule GITR, expressed on all T cell subsets (Nocentini et 
al., 1997, Ronchetti et al., 2004). The GITR-GITRL interaction has been demonstrated to be a 
critical mediator of the inflammatory response, as well as autoimmune diseases (Santucci et al., 
2007). In addition, ligation of GITR enhances the expansion of CD4+ and CD8+ T cells 
(Ronchetti et al., 2004, Kanamaru et al., 2004), while also rendering the effector T cells 
resistant to Treg-mediated suppression (Shimizu et al., 2002). 
The extracellular domains of the TNF superfamily members are usually configured as 
homo-trimers in vivo, and CD40L and GITRL are no exception (Matsuura et al., 2001, 
Chattopadhyay et al., 2007). While some TNF superfamily receptors such as TNFR-I and 
TWEAK are capable of inducing full signalling in the homo-trimeric form, other receptor and 
ligands, including CD40L, requires the formation of higher-order oligomers for optimal 
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signalling (Haswell et al., 2001). The enforced trimerisation of GITRL led to a 100-fold 
increase in the receptor binding affinity (Chattopadhyay et al., 2007). The plasmid construct 
used in this study encodes the extracellular domain of CD40L fused to adiponectin (ACRP30) 
or surfactant protein D (SP-D) both of which form homo-trimers following translation. Trimers 
of the ACRP30 fused proteins further dimerise to form hexamers, while the SP-D-fused trimers 
form tetramers resulting in an effective dodecameric protein (Stone et al., 2006a, Zhang et al., 
2001). 
In this chapter, a DNA vaccine construct expressing the immunogenic antigens, Ag85B 
(Rv1886c) and MPT64190-198 (Rv1980c) as a single protein fusion was constructed and utilised 
in combination with plasmids that express the soluble co-stimulatory molecules, CD40L or 
GITRL in different multimeric configurations. The ability of this immunisation strategy to 
enhance the induction of a Th1-type T cell responses to the vaccine-encoded antigens and 
improved protective efficacy of the DNA vaccine was assessed. 
 
3.2 Results 
3.2.1 Construction of DNA vaccine encoding the Ag85B and MPT64190-198 
fusion. 
To examine the specific T cell responses to IM immunisation of plasmid DNA, a DNA vaccine 
was constructed expressing the fusion protein of Ag85B and the H2-Db-restricted CD8+ T cell 
epitope of MPT64, MPT64190-198. The sequence of MPT64190-198 was incorporated into the 
reverse primer, wpr122 (Table 2.2), and using this together with primer wpr102, the full-length 
Ag85B was amplified resulting in a 971 bp sized amplicon. Following cloning into the 
intermediate cloning vector pCR2.1 the full ORF of the Ag85B64 fusion was cloned into 
pcDNA3 using BamHI and XbaI restriction sites. The resulting plasmid (DNA3-Ag85B64) was 
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6.4 kb in size (Figure 3.1A) and the presence of the insert was confirmed by PCR (Figure 3.1B), 
as well as DNA sequencing. All large-scaled preparations of plasmid vectors for use in in vivo 
immunisations were prepared using commercial giga-prep plasmid purification kits, as 
described in Section 2.5.2. 
 
3.2.2 Recombinant multimeric forms of CD40L are biologically active 
Primary B and T cells require activation signals for cell survival and proliferation. These 
activation signals include antigenic stimulation, cytokine stimulation and engagement of co-
stimulatory molecules. To test whether the multimeric forms of the co-stimulatory molecule, 
CD40L, expressed following transfection were biologically active on murine lymphocytes, 
splenic lymphocytes were transduced with the MSCV-EGFP retrovirus in the presence of 
culture supernatants from HEK293T cells transfected with either pACRP30-CD40L, pSP-D-
CD40L or pcDNA3. Recombinant CD40L aggregated with anti-FLAG® mAb, as well as LPS, 
were used as positive controls for the assay. Following 48 h, treatment with supernatant from 
pACRP30-CD40L-transfected cells resulted in 14.2% of lymphocytes expressing EGFP, and 
treatment with supernatant from pSP-D-CD40L-transfected cells resulted in 13.8% of 
lymphocytes producing EGFP. The transduction rates of lymphocytes treated with multimeric 
CD40L expressed from pACRP30-CD40L or pSP-D-CD40L were not different from those of 
cells treated with anti-FLAG® aggregated CD40L (Figure 3.2A). Lymphocytes transduced in 
the presence of LPS resulted in 58% EGFP expression, while no EGFP expression was 
detected in the cells treated with pcDNA3-transfected cellular supernatant (Figure 3.2A). 
Therefore both the ACRP30-CD40L and SP-D-CD40L multimeric forms of CD40L are 
biologically active.  
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Figure 3.1. Construction of the DNA vaccine encoding Ag85B and MPT64190-198. 
(A) The DNA vaccine, DNA3-Ag85B64 utilised the pcDNA3 vector backbone. The expression of the antigen 
fusion was under the control of the CMV IE promoter and harbours the bovine growth hormone polyadenyation 
(bGH polyA) terminator. The fusion antigen, Ag85B-MPT64190-198, was cloned into the pcDNA3 vector using the 
BamHI and XbaI restriction enzymes. (B) Amplification of the Ag85B-MPT64190-198 antigen fusion. Lane M, 10 
kb DNA marker; lane 1, negative control; lane 2, DNA3-Ag85B64; and lane 3, pCR2.1-Ag85B64.  
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Figure 3.2. The biological activities of recombinant CD40L encoded by the pACRP30-
CD40L and pSP-D-CD40L plasmids.  
Culture supernatants of HEK293T cells transfected for 48 h with pACRP30-CD40L, pSP-D-CD40L or pcDNA3 
were collected and assayed for biological activity. (A) B cell survival and retrovirus transduction assay. Briefly, 
lymphocytes purified using Histopaque-1077 were transduced with the MSCV-EGFP retrovirus in the presence of 
the culture supernatants from pACRP30-CD40L, pSP-D-CD40L transfected cells, soluble FLAG-tagged CD40L 
or LPS. The expression of EGFP was measured 48 h later by flow cytometery. (B) Nylon wool-enriched 
splenocytes from the p25-transgenic mice were labelled with CFSE then applied to irradiated syngenic APCs 
pulsed with peptide-25 or no antigens and then cultured in the presence of culture supernatant from pcDNA3 or 
pSP-D-CD40L transfected cells, LPS or anti-CD3/CD28. The antigen-specific proliferation was determined by the 
measurement of the CFSE dilution profile by flow cytometery. The data represent the mean + S.E.M of two 
independent experiments, and the statistical significances were determined by one-way ANOVA (*, p≤0.05;&**, 
p≤0.01).  
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 To test the effects of the recombinant CD40L molecules on T cell proliferation, 
transgenic T cells were activated with antigen in the presence of culture supernatant from pSP-
D-CD40L-transfected cells. When syngeneic APCs pulsed with 1 µg/ml of the dominant H2b-
restricted CD4+ T cell epitope, Ag85B240-254 (peptide 25) and CFSE-labelled T cells from 
peptide 25-specific TCR transgenic mice enriched by nylon wool purification were cultured in 
the presence of supernatant from CD40L-transfected cells, the proportion of proliferating 
CFSElow CD4+ T cells was 56%. This was significantly higher than when the transgenic T cells 
were exposed to pcDNA3-transfected cellular supernatant (Figure 3.2B). Peptide 25-specific T 
cells, which were activated by peptide in the presence of LPS or anti-CD3/CD28 stimulation, 
demonstrated 60% and 87% of T cell proliferation, respectively. No proliferation was detected 
in the T cells co-cultured without antigen-pulsed APCs. These results indicate that co-
stimulation with expressed recombinant forms of CD40L increases the degree of T cell 
activation (Figure 3.2B). 
 
3.2.3 The effects of co-immunisation with plasmids encoding co-stimulatory 
molecules CD40L and GITRL on DNA vaccine induced T-cell 
proliferation 
To examine the adjuvant effects of co-immunisation with plasmids encoding different 
multimeric configurations of CD40L and GITRL on the antigen-specific T cell proliferation 
following DNA3-Ag85B-64 immunisation, C57BL/6 mice were co-immunised three times 
with DNA3-Ag85B-64 and pACRP30-CD40L, pSP-D-CD40L or pSP-D-GITRL plasmids at 
two-weekly intervals. Mice were immunised with DNA3-Ag85B-64 or pcDNA3 alone as 
controls. Four weeks after the final immunisation, the antigen-specific T cell proliferative 
responses were measured by [3H]-thymidine incorporation in the splenocytes following 72 h of 
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antigen stimulation. When the splenocytes were stimulated with Ag85B at 10 µg/ml, mice co-
immunised with DNA3-Ag85B-64 and pSP-D-CD40L encoding the dodecameric (4-trimers) 
form of CD40L demonstrated the strongest T cell proliferation 12200 ± 2223 ∆CPM, which 
was double that of the mice co-immunised with DNA3-Ag85B-64 and pcDNA3 (p≤0.05, 
Figure 3.3A). Co-immunisation with pACRP30-CD40L, the hexameric CD40L (2-trimers) and 
pSP-D-GITRL, dodecameric GITRL resulted in similar levels of Ag85B-specific T cell 
proliferation, as mice co-immunised with DNA3-Ag85B-64 alone (Figure 3.3A). The control 
plasmid, pcDNA3 induced no antigen-specific T cell responses. A similar pattern of 
proliferation was observed when splenocytes were stimulated with the dominant H2b-restricted 
CD4+ T cell epitope, peptide 25 at 3 µg/ml (Figure 3.3B).  
Immunisation with DNA3-Ag85B-64 also induced T cell responses to whole MPT64 
protein, as well as the H2-Db-restricted CD8+ T cell epitope, MPT64190-198 (Figure 3.3C and D). 
Co-immunisation with pACRP30-CD40L, pSP-D-CD40L or pSP-D-GITRL resulted similar 
levels of increase in the antigen-specific T cell proliferation following stimulation, however, 
these increases were not statistically significant when compared to mice immunised with 
DNA3-Ag85B-64 alone (Figure 3.3C and D). 
 
3.2.4 Effects of co-immunisation with plasmids encoding CD40L and GITRL on 
DNA vaccine-induced T cell IFN-responses 
To evaluate whether the co-delivery of plasmids encoding CD40L or GITRL influenced the 
IFN--secreting T cell responses induced by DNA immunisation, C57BL/6 mice were 
immunised as described above. The antigen-specific IFN-γ responses were measured by IFN-γ 
ELISpot following 16 h of stimulation with 10 µg/ml of MPT64 protein or 3 µg/ml of 
MPT64190-198, and the levels of IFN-γ secretion were measured following 72 h of antigen 
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stimulation by IFN-γ ELISA. Following stimulation with Ag85B at 10 µg/ml, mice co-
immunised with pSP-D-CD40L or pSP-D-GITRL displayed significantly increased frequencies 
of IFN-secreting T cells compared to mice immunised with DNA3-Ag85B-64 alone 
(p≤0.05). Co-immunisation with pACRP30-CD40L did not enhance the frequency of Ag85B-
specific IFN- secreting T cells. No Ag85B-specific IFN- production was detected in mice 
immunised with pcDNA3 control alone (Figure 3.4A). Mice immunised with DNA3-Ag85B-
64 resulted in statistically significant antigen-specific responses under all stimulation 
conditions compared to pcDNA3 control (Figure 3.4). 
This pattern of increased frequency of IFN-γ T cell responses was also evident 
following antigen stimulation with the CD4+ T cell epitope of Ag85B, peptide 25, for both 
pSP-D-CD40L and pSP-D-GITRL co-immunised mice. Mice co-immunised with pSP-D-
CD40L also resulted in significantly increased levels of IFN-γ release following 72 h of 
stimulation with Ag85B and peptide 25 (p≤0.05, Figure 3.3C and D). Mice co-immunised with 
pACRP30-CD40L and pSP-D-CD40L showed a trend for increased IFN- secretion, but this 
did not reach statistical significance (Figure 3.4D). 
The impact of co-stimulation on the IFN-γ T cell response was further investigated by 
intracellular cytokine staining (ICS) for IFN-γ. Splenocytes pooled from mice in each of the 
immunisation groups were stimulated with the recall antigen overnight. Four hours after the 
addition of Brefeldin A, the cells were stained for the surface T cell markers, CD3, CD4, and 
CD8, followed by staining for intracellular IFN-γ. Splenocytes from the DNA3-Ag85B-64 
immunised mice displayed significantly higher percentages of IFN-γ producing CD4+ T cells 
compared to those immunised with control DNA (Figure 3.6). Co-immunisation with the DNA 
adjuvants pACRP30-CD40L, pSP-D-CD40L and pSP-D-GITRL resulted in trends for 
increased percentages of IFN-γ producing CD4+ T cells, with the greatest increase produced by 
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co-immunisation with pSP-D-CD40L (Figure 3.6B). There were lower numbers of IFN-γ 
producing CD8+ T cells following stimulation with the Ag85B (Figure 3.6B). 
 
3.2.5 Effects of co-immunisation with plasmid CD40L and GITRL on DNA 
vaccine induced CD8+ T cell antigen-specific IFN-responses 
To assess the effects of plasmid DNA adjuvants encoding co-stimulatory molecules CD40L or 
GITRL during DNA immunisation on the induction of antigen-specific CD8+ T cells, mice 
were immunised as described above. The antigen-specific IFN- responses were measured by 
IFN- ELISpot following 16 h of stimulation with 10 µg/ml of MPT64 protein or 3 µg/ml of 
MPT64190-198, and the levels of IFN- secretion were measured following 72 h of antigen 
stimulation by IFN-γ ELISA. When the splenocytes of immunised mice were stimulated with 
the whole protein, no differences were observed between mice co-immunised with the plasmid 
adjuvants compared to those immunised with DNA3-Ag85B-64 alone (Figure 3.5A). By 
contrast, significantly increased levels of IFN-γ release were observed in the pSP-D-CD40L 
(p≤0.05) or pSP-D-GITRL (p≤0.01) co-immunised mice following 72 h of antigen stimulation 
(Figure 3.5C). When splenocytes were stimulated with MPT64190-198, both mice co-immunised 
with pACRP30-CD40L and pSP-D-CD40L showed significantly increased frequencies of T 
cells producing IFN-(Figure 3.5B). Co-immunisation with pSP-D-GITRL did not result in 
increased frequencies of IFN- secreting T cells compared to mice immunised with the DNA 
vaccine alone. When the levels of IFN- secretion were measured following 72 h of 
stimulation with MPT64190-198, mice co-immunised with pSP-D-CD40L or pSP-D-GITRL 
showed increased levels of IFN-release compared to those immunized with DNA vaccine 
alone, however this was only significant for the pSP-D-GITRL co-immunised mice (p≤0.05, 
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Figure 3.5D). Mice immunised with DNA3-Ag85B-64 resulted in statistically significant 
antigen-specific responses following stimulation with MPT64 protein and MPT64190-198 
compared to pcDNA3 control (Figure 3.5).  
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Figure 3.3. The effects of co-immunisation of plasmids encoding CD40L on the antigen-
specific T cell proliferation following DNA immunisation.  
C57BL/6 mice were co-immunised three times at two weekly intervals with DNA3-Ag85B-64 and either 
pACRP30-CD40L, pSP-D-CD40L, pSP-D-GITRL or the negative control plasmid. Four weeks following the final 
immunisation, the antigen-specific T cell proliferation was measured by [3H]-thymidine incorporation in a 
lymphocyte proliferation assay following stimulation with (A) Ag85B at 10 µg/ml, (B) peptide 25 at 3 µg/ml, (C) 
MPT64 at 10 µg/ml, (D) MPT64190-198 peptide at 3 µg/ml. The data shown are the means + SEM for 4 mice, and 
are representative of least two independent experiments. The statistical significances of differences between 
groups was determined by one-way ANOVA (*, p≤0.05;&**, p≤0.01). 
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Figure 3.4. The effects of co-immunisation of plasmids encoding CD40L on the CD4+ T 
cell antigen-specific IFN-  responses induced by DNA immunisation.  
C57BL/6 mice were co-immunised three times at two weekly intervals with DNA3-Ag85B-64 and either 
pACRP30-CD40L, pSP-D-CD40L, pSP-D-GITRL or with the negative control plasmid. Immunisation with 
pcDNA3 alone served as negative control. Four weeks following the final immunisation, the number IFN-γ 
secreting cells were enumerated by the ELIspot assay following ex vivo stimulation with (A) Ag85B at 10 µg/ml, 
(B) peptide 25 at 3 µg/ml. Following 72 h stimulation with Ag85B at 10 µg/ml or peptide 25 at 3 µg/ml, the levels 
of IFN-γ in the culture supernatants were measured with an IFN-γ ELISA (C and D, respectively). The data shown 
are the means + SEM for at least 3 mice, and are representative of two independent experiments. The statistical 
significance of the differences between groups was analysed by one-way ANOVA (*, p≤0.05;&***, p≤0.005). 
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Figure 3.5. The effects of co-immunisation of plasmids encoding CD40L on the CD8+ T 
cell antigen-specific IFN-  responses induced by DNA immunisation.  
C57BL/6 mice were co-immunised three times at two weekly intervals with DNA3-Ag85B-64 and either 
pACRP30-CD40L, pSP-D-CD40L, pSP-D-GITRL or with the negative control plasmid. Immunisation with 
pcDNA3 alone served as negative control. Four weeks following the final immunisation, the number IFN-γ 
secreting cells were enumerated by the ELIspot assay following ex vivo stimulation with (A) MPT64 at 10 µg/ml, 
(B) MPT64190-198 peptide at 3 µg/ml. Following 72 h stimulation with MPT64 at 10 µg/ml or MPT64190-198 at 0.3 
µg/ml, the levels of IFN-γ in the culture supernatants were measure with an IFN-γ ELISA (C and D, respectively). 
The data shown are the means + SEM for at least 3 mice, and are representative of two independent experiments. 
The statistical significance of the differences between groups was analysed by one-way ANOVA (*, p≤0.05;&**, 
p≤0.01). 
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Figure 3.6. CD4+ T cells responses following co-immunisation with plasmid DNA 
encoding CD40L or GITRL.  
C57BL/6 were co-immunised three times at two-weekly intervals with DNA3-Ag85B-64 and either pcDNA3, 
pACRP3-CD40L, pSP-D-CD40L or pSP-D-GITRL. Four weeks after the final immunisation, single-cell 
suspensions of the splencocytes from each group were pooled and then stimulated for 16 h with 3 µg/ml of Ag85B. 
Cellular secretion was stopped with the addition of brefeldin A, and intracytoplasmic IFN-γ was stained using a 
FITC-conjugated anti-IFN-γ mAb. (A) The numbers of IFN-γ secreting cells were determined by gating on the 
surface expression of CD3+ and CD4+ cellular markers. (B) The mean percentage of IFN-γ secreting CD4+ and 
CD8+ T cells in response to Ag85B stimulation. Data represent the means + SEM of triplicate samples. Statistical 
significance of differences between groups was determined by one-way ANOVA followed by the Turkey’s post-
hoc test (* p<0.05).  
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Figure 3.7. CD8+ T cells responses following co-immunisation with plasmid DNA 
encoding CD40L or GITRL.  
C57BL/6 were co-immunised three times at two-weekly intervals with DNA3-Ag85B-64 and either pcDNA3, 
pACRP3-CD40L, pSP-D-CD40L or pSP-D-GITRL. Four weeks after the final immunisation, single-cell 
suspensions of the splenocytes from each group were pooled and then stimulated for 16 h with 3 µg/ml of 
MPT64190-198. Cellular export was stopped with the addition of brefeldin A, and intracytoplasmic IFN-γ was 
stained using a FITC-conjugated anti-IFN-γ mAb. (A) The numbers of IFN-γ secreting cells were determined by 
gating on the surface expression of CD3+ and CD8+ cellular markers. (B) The mean percentage of IFN-γ secreting 
CD4+ and CD8+ T cells in response to MPT64190-198 stimulation. Data represent the mean of duplicate samples. 
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The MPT64-specific CD8+ T cell responses induced by the DNA vaccines were also 
investigated by ICS. Following stimulation MPT64190-198, the percentage of CD8+ MPT64190-
198-specific IFN-γ producing T cells was increased by 3-fold in the DNA3-Ag85B-64 
immunised group compared to those immunised with pcDNA3 (Figure 3.7B). Co-
immunisation with pSP-D-GITRL increased the percentage of IFN-γ producing CD8+ T cells 
4-fold compared to the DNA3-Ag85B-64 immunised mice and was higher than pcDNA3 
control. A 3-fold increase was seen when co-immunised with pSP-D-CD40L (Figure 3.7B). 
Therefore both pSP-D-CD40L and pSP-D-GITRL increased the MPT64190-198-specific IFN- 
secreting CD8+ T cell responses to the vaccine-encoded antigen. 
 
3.2.6 The effects of co-immunisation with CD40L or GITRL on the IgG 
antibody responses to DNA vaccine. 
To determine the effects of co-immunisation with plasmids encoding the co-stimulatory 
molecules CD40L or GITRL on the levels of antigen-specific antibodies, C56BL/6 mice were 
immunised as described above, and serum samples were collected four weeks following the 
final immunisation. The titres of Ag85B-specific IgG antibodies were determined by IgG 
ELISA as described in Section 2.12.3. 
Mice co-immunised with pSP-D-CD40L displayed the highest titre of Ag85B-specific 
IgG antibodies, and this titre was significantly higher than for mice immunised with DNA3-
Ag85B-64 alone (p≤0.05). Co-immunisation with pACRP30-CD40L or pSP-D-GITRL also 
resulted in modestly elevated titres of Ag85B-specific IgG antibodies, but these increases were 
not statistically significant (Figure 3.8). 
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Figure 3.8. The effects of CD40L co-immunisation of the antigen-specific humoural 
response induced by DNA immunisation.  
C57BL/6 mice were co-immunised three times at two weekly intervals with DNA3-Ag85B-64 and either 
pACRP30-CD40L, pSP-D-CD40L, pSP-D-GITRL or with the negative control plasmid. Immunisation with 
pcDNA3 alone served as negative control. Four weeks following the final immunisation, blood was collected by 
cardiac puncture, and the Ag85B-specific antibody titre in the serum was analysed by an IgG ELISA. The data 
represent sera pooled from 4 mice tested in triplicate and are the means + SEM of log10 IgG titres and are 
representative of two independent experiments. The statistical significance of the differences between groups was 
analysed by one-way ANOVA followed by the Turkey’s post-hoc test (*, p≤0.05).  
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3.2.7 Effects of co-immunisation with plasmid CD40L or GITRL on DNA 
vaccine-induced protective efficacy against M. tuberculosis.  
To investigate whether the increased immunogenicity provided by co-immunisation with 
DNA3-Ag85B-64 and plasmids encoding CD40L or GITRL influenced protective efficacy of 
DNA immunisation, C57BL/6 mice were immunised as described above, rested for six weeks 
following the final immunisation and then infected aerogenically with 100 cfu of M. 
tuberculosis H37Rv. Immunisation with DNA3-Ag85B-64 alone provided significant 
protection with 0.6 and 0.65 log10 cfu reductions in the bacterial load in the lungs and spleen, 
respectively (Figure 3.9). Co-immunisation with the plasmids encoding the multimeric forms 
of CD40L did not increase the level of protection compared to immunisation with the DNA3-
Ag85B-64 alone. Co-immunisation with pSP-D-GITRL provided no further reduction in the 
bacterial load compared to mice that had received the DNA vaccine alone. Mice immunised 
with BCG displayed markedly reduced bacterial numbers compared to control mice in both the 
lungs and the spleen, with 1.5 and 1.9 log10 cfu reductions respectively, and this was 
significantly greater than the protection afforded by the DNA3-Ag85B-64 vaccine (Figure 3.9). 
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Figure 3.9. The effects of co-immunisation with plasmid encoding CD40L and GITRL on 
the protective efficacy of DNA immunisation against M. tuberculosis.  
C57BL/6 mice were co-immunised three times at two weekly intervals with DNA3-Ag85B-64 and either 
pACRP30-CD40L, pSP-D-CD40L, pSP-D-GITRL or with the negative control plasmid.  Immunisation with BCG 
served as positive control, while immunisation pcDNA3 plasmid alone served as negative control. Mice were 
rested for six weeks following the final immunisation and then challenged with 100 cfu of aerogenic M. 
tuberculosis H37Rv. Four weeks later the bacterial loads in (A) the lungs and (B) the spleen were enumerated. 
The data shown are the means + SEM for 5 mice, and are representative of two independent experiments. The 
statistical significance of the differences between groups was analysed by one-way ANOVA (***, p≤0.005). 
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3.3 Discussion 
Effective vaccines against intracellular pathogens depend on the development of an effective 
long-lasting memory T cell response. DNA immunisation with plasmid vectors encoding 
mycobacterial antigens has previously been demonstrated to elicit relevant Th1 type antigen-
specific CD4+ and CD8+ T cell responses, as well as protective efficacy (Triccas et al., 2002, 
Franco et al., 2008, Kamath et al., 1999a). Nevertheless, the protective efficacy against 
tuberculosis induced by DNA vaccines alone seldom outperforms BCG in animal models of M. 
tuberculosis infection (Romano et al., 2006, Kao et al., 2012). Consequently, numerous 
approaches to improve the outcome of DNA immunisation have been examined, such as the 
inclusion of multiple immunogenic antigens, improved adjuvant formulations and the 
modifications to the vaccine delivery system (Wang et al., 2011a). 
In this chapter, a DNA vaccine expressing components of two mycobacterial genes 
from a single plasmid was developed to test the impact of co-delivery of the co-stimulatory 
molecules CD40L and GITRL encoding plasmids as molecular adjuvants. This was achieved 
by cloning the entire sequence of the immunogenic mycobacterial antigen, Ag85B (Rv1886c), 
and the sequence encoding the H2b-restricted epitope of MPT64 (Rv1980c), MPT64190-198 into 
the pcDNA3 plasmid backbone, so that the antigens were expressed as a single fusion protein 
(Figure 3.1). 
The transfection of the plasmids pACRP30-CD40L and pSP-D-CD40L into eukaryotic 
cells confirmed that they expressed biologically active CD40L molecules (Figure 3.2). Co-
immunisation of these plasmids with DNA3-Ag85B-64 resulted in significant increases in the 
vaccine-induced T cell responses to Ag85B, CD4+ T cell responses to peptide 25 and CD8+ T 
cell responses to MPT64190-198 (Figures 3.3-7) and IgG antibody responses to Ag85B (Figure 
3.8).  The dodecameric configuration of CD40L was more efficient than the hexameric version 
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leading to approximately twice the frequency of IFN-γ secreting CD4+ and CD8+ T cells to 
each of the defined epitopes. The specificity of these CD4+ and CD8+ T cell responses were 
detected by ICS (Figure 3.6-7) but these require further confirmation. The co-delivery of 
GITRL with DNA3-Ag85B-64 also significantly increased the CD4+ and CD8+ T cell 
responses. Nevertheless, despite this increased immunogenicity, there were no increases in 
antigen-specific T cell proliferation (Figure 3.3) and in the protective efficacy after M. 
tuberculosis challenge following co-immunisation with each of the co-stimulatory molecules as 
adjuvants (Figure 3.9). One possible explanation for the lack of impact on protective efficacy 
by the plasmids encoded CD40L is the levels of basal expression of CD40 on the surrounding 
immune cells at the site of immunisation. It is well documented that B cells constitutively 
express high levels of surface CD40 (Ledbetter et al., 1987), while the levels of CD40 on DCs 
and macrophages remains less clear (Ma and Clark, 2009). CD40 is an NF-κB-regulated gene, 
and not surprisingly the level of CD40 expression on DCs are unregulated upon exposure to 
microbial products so that CD40 expression can be used as a marker to distinguish between 
inactivated and activated DCs (Kawai and Akira, 2007). While there is also evidence that 
exposure to naked DNA can also up-regulate CD40 expression (Jaen et al., 2009), the 
conditions created by DNA immunisation may not have provided adequate pro-inflammatory 
stimuli for the induction of surface CD40 to sufficient levels for the cross-linking with 
multimeric CD40L constructs. If this is indeed the case, the inclusion of an adjuvant that 
activates DCs to up-regulate the surface expression of CD40 may further enhance the 
effectiveness of the soluble CD40L adjuvants. Enhancing co-stimulation through CD40L or 
GITRL alone was insufficient to increase the complex cellular immune responses that are 
required for protective immunity against M. tuberculosis. 
Another factor that may contribute to the lack of increased protective efficacy induced 
by the DNA immunisation is the heterogeneity of functional outcomes following exposure of 
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monocytes and macrophages to CD40L. These functional outcomes are dictated by other 
cytokines and chemokines present within the antigen-presentation microenvironment. As IL-12 
is the most important factor in driving T cells towards Th1 type response, factors that influence 
the CD40-induced production of IL-12 will determine the effectiveness of the CD40L 
adjuvants. The induction of IL-10 has been associated with DNA immunisation (Franco et al., 
2008), and this can have major negative consequences on CD40-induced activation of iNOS 
and dramatically downregulates the production of IL-12p40 (Bullens et al., 2001). On the other 
hand, chemokines, such as CCL2, have been demonstrated to enhance signalling by CD40 
activation (Futagami et al., 2008). The magnitude of the CD40L stimulation can also influence 
the outcome of the immune response (Mathur et al., 2004). This may explain why the extent of 
the multimerisation of the CD40L influenced the resulting adjuvant activity as demonstrated in 
IFN-γ ELISpot, ELISA, as well as ICS analysis, of the adjuvant co-immunised mice (Figures 
3.4-7). Although repeated experiments are needed to confirm this effect. Interestingly, this 
difference was not seen in lymphocytes treated with supernatants from pACRO30-CD40L and 
pSP-D-CD40L transfected cells (Figure 3.2). Differences between the various multimeric 
versions of the CD40L have also been reported in previous studies (Stone et al., 2006a). The 
degree of multimerisation may influence the potency of the signaling through CD40L, where 
strong CD40 signals resulted in p38 activation and the production of IL-12p40, while a weak 
signal resulted in ERK1/2 induction leading the production of the anti-inflammatory cytokine 
IL-10, which could be detrimental for the development of M. tuberculosis-specific T cell 
responses (Mathur et al., 2004, Roach et al., 2001). 
An additional limitation of the exogenous delivery of multimeric soluble CD40L co-
stimulatory molecules is that these soluble molecules only provide one-half of the signalling 
pathways that are activated through CD40-CD40L interactions in vivo. While the downstream 
effects of CD40 activation by CD40L have been well characterised (Pullen et al., 1999, 
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Vidalain et al., 2000, Zhu et al., 2002), the consequences of CD40L activation by CD40 are 
less understood. Recent studies have indicated that the activation of CD40L on T cells alone by 
anti-CD40L mAb triggers the activation of MAP kinases, protein kinase C as well as Src 
family of kinases leading to increased cytokine production (Mackey et al., 1998), CD3-
dependent proliferation (Blair et al., 2000) and apoptosis (Ronchetti et al., 2004). In the 
original study characterising the plasmids pACRP30-CD40L and pSP-D-CD40L, the 
dodecameric soluble form of CD40L was more effective than membrane-bound CD40L in 
generating antigen-specific, IFN--producing CD62Llow T cells and increasing their cytolytic 
potential (Stone et al., 2006a). The increased accessibility of the soluble multimeric CD40L 
molecules to various cell types may account for the increased adjuvant activity compared to 
membrane-bound CD40L. Nevertheless, the increased immunogenicity following co-delivery 
of pSP-D-CD40L did not increase the protective efficacy of the DNA-Ag85B-MPT64 vaccine 
(Figure 3.9). Adjuvants based on CD40-CD40L interactions may provide more effective co-
stimulation if downstream signaling through both CD40 and CD40L is enhanced in DC, B cells 
and T cells. 
Co-delivery of the plasmid encoding soluble multimeric GITRL (pSP-D-GITRL) with 
the DNA vaccine also increased the antigen-specific IFN-γ responses to Ag85B and the CD4+ 
T cell epitope, peptide 25 (Figure 3.4), as well as to the CD8+ T cell epitope, MPT64190-198. 
One difference between the co-stimulation with GITRL and CD40L is that the receptor, GITR 
is expressed on Treg cells and NK cells, as well as naïve T cells. Minimal levels are also 
present on B cells, DCs, or macrophages (Ronchetti et al., 2011, Nocentini and Riccardi, 2009). 
From the effects observed in Figures 3.3, 3.5 and 3.7 and the reported expression profile of 
GITR we can postulate that the delivery of recombinant GITRL may be exerting a direct effect 
on the CD4+ and CD8+ T cells, as compared to acting through DC activation and cytokine 
production as is considered for CD40L. The antigen-specific cytokine responses are consistent 
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with previous studies, which reported that co-stimulation with GITRL or GITR-specific 
antibodies (DTA-1) enhanced both T cell expansion and cytokine production (Tone et al., 2003, 
Esparza and Arch, 2005). This adjuvant effect, however, is insufficient to increase the level of 
protection provided by the DNA vaccine against M. tuberculosis (Figure 3.9). Interestingly, in 
our hands, the co-immunisation with plasmid encoding GITRL did not enhance T cell 
proliferation (Figure 3.3). This discrepancy may be explained by different levels of interaction 
between GITR and the DTA-1 mAb compared to the expressed recombinant GIRL. One aspect 
of the exogenous GITRL stimulation not addressed in this study is whether the pro-
inflammatory conditions created by the elevated co-stimulation increases the development of 
self-reactive T cells, in addition to those induced by the DNA vaccine. GITR is expressed on 
the surface of Treg cells, and its engagement can render effector T cells resistant to Treg-
mediated suppression (McHugh et al., 2002, Mahesh et al., 2006). This effect, however, is less 
clear in the murine model than in humans (Carrier et al., 2012).  
In this study, the adjuvant effects of co-delivering plasmids encoding co-stimulatory 
molecules CD40L and GITRL were examined in the context of DNA immunization against M. 
tuberculosis infection. The failure of co-delivery of multimeric CD40L to increase protective 
efficacy, despite increasing the frequency of antigen-specific IFN-γ T cells responses to the 
vaccine-encoded antigens, exemplifies our lack of understanding of the correlates of protective 
immunity against M. tuberculosis. While IFN-γ is essential for the protection against M. 
tuberculosis in both humans and mice (Cooper et al., 1993), increasing IFN-γ production alone 
may not be sufficient to improve vaccine-induced protective immunity. This is a major issue 
facing TB vaccine research, as there are no clear correlates of protective immunity against M. 
tuberculosis infection (Ottenhoff et al., 2012). It is obvious from this and other studies that 
additional indicators of protective immunity is required (Kagina et al., 2010). Other attempts to 
improve the protective efficacy of DNA vaccines through manipulating the immune system 
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have had a similar effect. The co-delivery of the cytokines GM-CSF, IL-18 and IL-27-
expressing constructs with anti-TB DNA vaccines also stimulated increased IFN-γ T cell 
responses to the vaccine antigen, but no improvement in protective efficacy (Kamath et al., 
1999c, Triccas et al., 2002, Wozniak et al., 2006b). 
The effectiveness of CD40L-based adjuvants has also been studied in both cancer and 
other infectious disease vaccine models (Auten et al., 2012, Gao et al., 2012, Wu et al., 2011). 
A number of studies have suggested the activation of other TNFSF receptors, such as 4-IBB, 
LIGHT, OX40 and BAFF in addition to CD40L activation is required for optimal enhancement 
to the T cell responses (Gray et al., 2008, Kanagavelu et al., 2012). The combination of CD40L 
with TLR-2 ligands such as HSP70 from M. tuberculosis, has also been reported to work in 
synergy to increase the T cell response to the hepatoma antigen, H22 (Gao et al., 2012). An 
alternative approach of targeting both the vaccine antigen and CD40L to the DCs using DEC-
205 also resulted in enhanced antigen-specific T cell proliferation, IFN-γ secretion and 
antibody responses (Njongmeta et al., 2012). Similarly, vaccine vectors engineered to express 
antigen-CD40L fusions also resulted in significantly increased numbers of antigen-specific T 
cells with ability to produce polyfunctional cytokines. Interestingly, the effect was only 
observed in animals with intact CD4+ T cell populations or partially depleted CD4+ T cells 
(Auten et al., 2012). The transfection of a DNA construct encoding the hepatitis B virus S-
antigen fused CD40L resulted in increased DC activation and production of IL-12 (Wu et al., 
2011). These experiments confirm the importance of CD40L expression at the site of antigen 
presentation. The delivery of CD40L using alternative vectors, such as rAAV or adenovirus, 
has also resulted in increased IL-12 and T cell responses, respectively (Auten et al., 2012, Wu 
et al., 2007). Similarly, the co-delivery of GITRL in anti-cancer vaccines led to increased 
CD8+ T cell activation and CD8+ T cell-dependent tumour inhibition (Dittmer et al., 2008, 
Nishikawa et al., 2008). 
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The mechanism of co-stimulation with multimeric GITRL while distinct from CD40L, 
produced similar increases in antigen-specific IFN- T cell responses, particularly in the 
CD8+ T cell compartment. Although these increased responses did not translate into protection 
against M. tuberculosis, the pathogen, M. tuberculosis, has developed complex and varied 
strategies to evade the immune response mounted by the infected host. While DNA vaccines 
are capable of inducing M. tuberculosis-specific CD4+ and CD8+ T cell responses, the 
enhanced T cell responses afforded by augmenting one or two of the co-stimulation signals 
may not be sufficient to overcome the virulence strategies of the pathogen. While further 
studies are required to define DNA vaccine-induced T cell responses as correlates of protection, 
ultimately, the ability of the adjuvants to increase protection against bacterial challenge 
remains the only valid test of their potential to improve vaccines against TB. 
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4.1 Introduction 
In recent years, the continued efforts to develop a more effective vaccine for the prevention of 
TB have utilised a number of different vaccine development strategies. Although a handful of 
these vaccines have reached phases I and II clinical trials, the aim for a vaccine which is more 
more protective than BCG, has yet to be achieved. The development of anti-TB vaccines can 
be divided into three main strategies. The first is modification of the only currently licenced 
vaccine, BCG, through genetic modification to overexpress antigens, such as Ag85B, or 
immuno-modulatory cytokines, or to add components that promote its immunogenicity. The 
second strategy is to attenuate the causative agent itself, M. tuberculosis. While M. tuberculosis 
is potently immunogenic, one obvious concern is the degree of attenuation achieved. A fine 
balance needs to be struck between being adequately immunogenic yet sufficiently attenuated 
for use in immune-compromised individuals, such as those infected with HIV/AIDS. One 
method of attenuating M. tuberculosis is through the generation of auxotrophic mutants or 
mutants that modify cell surface proteins or disrupt regulatory genes (Gonzalo Asensio et al., 
2006, Santosuosso et al., 2006). The third strategy is the development of subunit anti-TB 
vaccines. Advances in the understanding of molecular immunology in recent decades have led 
to the minimalistic approaches of using purified mycobacterial protein with potent adjuvants or 
mycobacterial genes expressed in DNA vaccines. The identification of immunogenic proteins, 
which are secreted into the culture filtrate, such as ESAT-6, or are non-secreted and retained in 
the cytoplasm, has led to the evaluation of these antigens in subunit vaccines. The 
immunogenic and protective responses elicited by these subunit vaccines were found to be 
comparable to those elicited by live attenuated bacteria (Dietrich et al., 2006). An extension of 
the subunit approach to vaccine development is the use of recombinant virus as vectors for 
vaccine delivery. Viral vectors exploit the efficient transfer of genetic material essential 
throughout viral evolution and offer a number of advantages over traditional vaccines. They are 
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able to elicit both potent cytotoxic T cell and antibody responses required for the clearance of 
viruses and intracellular pathogens, such as M. tuberculosis. Many viral species have been 
evaluated as recombinant vectors, including vaccinia viruses, alphaviruses, adeno-associated 
viruses, measles viruses and hepatitis B virus. Recombinant viruses, such as adenovirus 
expressing Ag85A (AdAg85A) and modified vaccinia Ankara expressing Ag85A (MVA-
Ag85A), are examples of anti-TB viral vector vaccine candidates (McShane et al., 2004, 
Santosuosso et al., 2006). Recombinant viral vectors are not without their limitations, including 
the generation of immune responses to the vectors themselves, resulting in early clearance of 
the viral vector and inability for repeated applications, such as within prime-boost schemes. In 
the past, AAV vectors have been exploited for gene therapy applications because of their 
ability to transduce a wide range of cell types in different tissues while remaining relatively 
invisible to the immune system, as well as vaccine vectors. 
 The AAV is a replication-deficient parvovirus. Only two genes are present in the 
single-stranded DNA genome of the WT virus, the rep and cap genes, which encode for four 
multifunctional non-structural proteins and three capsid proteins respectively. AAV requires 
co-infection with an adenovirus or herpes simplex virus for productive replication (Buller et al., 
1981, Hoggan et al., 1966). Following internalisation of the virus by the cell, the ssDNA 
genome is released from the capsid and transported to the nucleus, where conversion of the 
genome to dsDNA occurs with subsequent viral gene expression utilising the host cell 
machinery. In rAAV systems, the genes required for replication and packaging are encoded by 
rep and cap in one plasmid and are transfected with the expression cassette harbouring the 
desired transgene. The resulting cytoplasmic transgene product may be loaded onto the MHC 
class I molecules, however, evidence of human factor IX delivered by the rAAV was processed 
and presented to CD4+ T cells by MHC class II molecules has also been reported (Chen et al., 
Chapter 4. Novel Anti-TB Vaccine Based on rAAV Encoding M. tuberculosis Antigens 
 
107 
2006). Thus rAAVs are capable of inducing both CD4+ and CD8+ T cells responses specific for 
the transgene product. 
 In this chapter, the application of rAAV serotype 2 as a delivery vector for an anti-TB 
vaccine was explored. One advantage of rAAV is the efficient delivery of mycobacterial genes 
at the site of immunisation leading to prolonged, low dose antigen production, and sustained 
activation of T cell responses. The expressed proteins can be presented by both MHC class I 
and II molecules to CD8+ and CD4+ T cells respectively, and the robust immune response may 
be superior to those elicited by DNA immunisation alone. The development of an effective 
rAAV-based vaccine for tuberculosis would have the desired property of vector stability, with 
the potential of needle-free administration, while taking advantage of established large-scale 
good manufacturing practice (GMP) production procedures for vaccine manufacturing (Allay 
et al., 2011). 
  
4.2 Results 
4.2.1 Construction of the recombinant AAV serotype 2 genome encoding the 
fusion antigen Ag85B-64-ESAT. 
The AAV is a non-enveloped virus that encapsulates its ssDNA genome within a capsid 
composing of the structural proteins VP1, VP2 and VP3 encoded by the cap gene. To produce 
rAAV virus encoding the fusion antigen consisting of mycobacterial proteins, Ag85B, 
MPT64190-198 and ESAT-6, a plasmid harbouring the expression cassette for an in-frame fusion 
of the antigens flanked by the AAV serotype 2 ITR was constructed (Figure 4.1). The entire 
gene encoding ARAP4 under the control of the RSV promoter was excised from the pAAV-
ARAP4 plasmid by digestion with the HindIII restriction enzyme. The fragment encoding the 
fusion antigen was amplified from DNA3-Ag85B-64-ESAT using two sets of PCR 
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oligonucleotide primers (Table 2.4). The resulting two amplicons were mixed, denatured, and 
then re-annealed to produce a fragment encoding the Ag85B-64-ESAT fusion construct with 
cohesive HindIII ends (Figure 4.1B), and the purified DNA fragment was ligated into an empty 
pAAV plasmid to produce a 6 kb plasmid construct, pAAV-Ag85B-64-ESAT (Figure 4.1A).  
 
4.2.2 Production of rAAV serotype 2 encoding Ag85B-64-ESAT. 
The separation of genome-containing rAAV viral particles from the inactive empty viral 
particles and cellular debris is essential for the purification of functional virus. Following a 
triple-plasmid transfection of HEK293T cells with pAAV-Ag85B-64-ESAT, pHLP19 
encoding cap and rev (Figure 4.2A) for AAV2, and pAdeno5 encoding the Adenovirus-5 
helper genes (Figure 4.2B), the transfected cells were lysed, and the crude rAAV viral 
preparation was subjected to CsCl gradient centrifugation. Prior to further virus purification, 
primers specific for the Ag85B gene sequence were used to detect the presence of the rAAV-
Ag85B-64-ESAT virus in each of the 1 ml CsCl fractions. The presence of the rAAV virus 
encoding Ag85B-64-ESAT was indicated by the amplification of a 282 bp amplicon. One ng of 
DNA3-Ag85B-64-ESAT served as the positive control and 1 µl of the undiluted or 10-fold 
diluted samples for each fraction were used as templates for the PCR reactions, followed by 
visualisation on a 2.5% agarose gel. While 282 bp bands were detected in many of the fractions, 
the signals from fractions 6 to 8 were clearly the strongest across the whole range, as well as 
the positive control (Figure 4.3).  
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Figure 4.1. Plasmid map of the pAAV vector encoding the fusion antigen, Ag85B-64-
ESAT, and the PCR confirmation of the fusion antigen.  
The pAAV plasmid contains the AAV2 inverted terminal repeats (ITR), flanking the expression cassette carrying 
the mycobacterial fusion construct under the control of the promoter and enhancer form RSV (3’ LTR from RSV) 
and the SV40 polyadenylation (SV40 polyA) sequence. (A) The plasmid map of pAAV-Ag85B-64-ESAT; the 
fusion antigen was cloned into the pAAV plasmid using HindIII cohesive ends. (B) PCR confirmation of Ag85B-
64-ESAT, lane M, 10 kb DNA marker. Lane 1, negative control. Lane 2, annealing at 55˚C. Lane 3, 56˚C. Lane 4, 
DNA3-Ag85B-64-ESAT. Lane 5, restriction digest of pAAV-Ag85B-64-ESAT with HindIII.  
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Figure 4.2. Plasmids encoding the structural and non-structural components for rAAV 
packaging.  
Construction of rAAVs in vitro requires the transfection of a eukaryotic cell line with plasmids harboring the 
capsid and non-structural genes and adenovirus helper elements in addition to a plasmid encoding the AAV ITRs. 
(A) The plasmid pHlp19 encoding the AAV serotype 2 Cap and Rep proteins under the control of the modified 
native p5 promoter. (B) The plasmid pAdeno5 encoding the essential adenovirus 5 helper genes E4A, E2 and VA 
required for in vitro packaging of the AAV virion. 
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Figure 4.3. Detection of AAV2 genome encoding the Ag85B-64-ESAT fusion construct in 
viral fractions separated by CsCl density gradient centrifugation.  
HEK293T cells were collected 72 h after triple transfection with AAV2 packaging plasmids and lysed by 4 rounds 
of freeze-thaw treatment. Viral particles from the cellular lysate were concentrated by ammonium sulphate 
precipitation. Extra-viral DNA was digested with Benzonase and then the viral particles were purified by gradient 
centrifugation in CsCl (1.37 g/ml) at 186232.8 ×g for 48 h with the SW41Ti rotor. One ml fractions were 
collected, and the presence of rAAV2-Ag85B-64-ESAT was detected by PCR with pAAV-Ag85B-64-ESAT 
plasmid serving as positive control. Neat or 10-fold diluted preparations of 1 µl of fractions 1-12 or 1 ng of the 
positive control plasmid were used in each reaction. 
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4.2.3 Quantification of rAAV2-Ag85B-64-ESAT by qPCR. 
In order to use the rAAV virus in in vivo experiments, it was important to determine the 
amount and concentration of the rAAV viral particles produced following large-scale 
transfection of HEK293T. 
 To establish a qPCR for rAAV2-Ag85B-64-ESAT, the plasmid pAAV2-Ag85B-64-
ESAT was used as template (Figure 4.1A). This plasmid contains the genetic sequence of the 
entire rAAV-Ag85B-64-ESAT genome. Oligonucleotide primers specific for the fusion antigen, 
Ag85B-64-ESAT, were used for the qPCR amplification (Table 2.4). After the determination 
of the concentration of the plasmid preparation using the NanoDrop 2000c, a stock solution 
with the concentration of 500 ng/ml and 10-fold serial dilutions of the control  plasmid were 
made. To determine the linear dynamic range of the rAAV2-Ag85B-64-ESAT qPCR, the serial 
dilutions of pAAV2-Ag85B-64-ESAT were assayed within 6 logs (1.0 × 102 to 1.0 × 106 
plasmid copies), with each dilution tested in triplicates (Figure 4.4). Within this range the 
rAAV2-Ag85B-64-ESAT qPCR displayed a linear correlation coefficient (r2) of 0.998 with a 
slope of -3.567 and an amplification efficiency of 90.7% (Figure 4.5). 
 To determine the concentration of the purified rAAV2-Ag85B-64-ESAT virus, 10-fold 
serial dilutions of the unknown viral stock were prepared and 10-4, 10-5 and 10-6 dilutions of the 
unknown stock were used in the qPCR assay. For the qPCR quantification, 2 µl of each 
dilution were tested in triplicates, using the defined serial dilutions of the pAAV2- Ag85B-64-
ESAT plasmid for the calculation of the standard curve. The cycle threshold (Ct) for the 
rAAV2-Ag85B-64-ESAT samples were 20.91 cycles for the 10-4 dilution and 23.59 cycles for 
the 10-5 dilution, and the calculated initial viral genome copy numbers were 2.53 × 105 and 
4.47 × 104, respectively. To obtain the final virus titre from the pAAV2-Ag85B-64-ESAT 
standard, the single-stranded viral genome (vg) were corrected by a factor of two and then 
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multiplied by the dilution factor followed by the template volume to obtain genome titres of 
1.35 × 1012 vg/ml and 1.10 × 1012 vg/ml for 10-3 and 10-4 sample dilutions, respectively. 
 
4.2.4 rAAV2-Ag85B-64-ESAT elicits an immune response in a dose-dependent 
fashion. 
To determine the optimal dose for rAAV immunisation in mice, C57BL/6 mice were 
immunised twice at two-weekly intervals with various doses of rAAV-Ag85B-64-ESAT 
ranging from 109 to 1012, and rested for four weeks. The antigen-specific T cell responses of 
the splenocytes following Ag85B and peptide 25 stimulation were then tested by IFN-γ 
ELISpot. Following stimulation with Ag85B at 10 µg/ml, mice immunised with rAAV2-
Ag85B-64-ESAT displayed increasing frequencies of antigen-specific IFN-γ secreting cells as 
the dose of rAAV immunisations was increased. This suggests that the vaccine-specific T cell 
responses were induced in a dose-dependent manner (Figure 4.6A). The increasing frequencies 
of antigen-specific IFN-γ secreting cells plateaued at 1011 vg/dose. When the splenocytes were 
stimulated with peptide 25 at 10 µg/ml, similar levels of peptide-specific T cell responses were 
observed (Figure 4.6B). The Ag85B-specific IFN-γ responses in mice immunised with 100 µg 
of DNA3-Ag85B-64-ESAT were higher than those in mice immunised with rAAV2-Ag85B-
64-ESAT at all doses, and these difference were also evident following stimulation with 
peptide 25 (Figure 4.6B). 
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Figure 4.4. Quantification of purified rAAV2-Ag85B-64-ESAT virus by quantitative-PCR 
using primers specific for Ag85B.  
Following identification of virus containing fractions, the fractions were pooled and dialysed overnight against 5% 
glycerol v/v PBS. The dialysed virus and six 10-fold serial dilutions of pAAV-Ag85B-64-ESAT ranging from 1.0 
× 102 to 1.0 × 106 plasmid copies were analysed by QPCR using primers specific for internal region of the Ag85B 
gene. The panels are (A) examples of the qPCR amplification and (B) the dissociation profiles of the products.  
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Figure 4.5. Calculation of the viral titre of the purified rAAV2-Ag85B-64-ESAT.  
A representative standard curve for the quantification of rAAV2-Ag85B-64-ESAT viral sample.  Six 10-fold-
dilution steps ranging from 1.0 × 102 to 1.0 × 106 copies of the plasmid pAAV-Ag85B-64-ESAT were used to 
generate the standard curve. The mathematical formula used for the calculation of plasmid copy numbers from the 
amount of standard DNA molecules used in the QPCR reaction is shown. 
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Figure 4.6. The induction of Ag85B-specific T cell responses following immunisation with 
rAAV2-Ag85B-64-ESAT.  
C57BL/6 mice were immunised twice at two-weekly intervals by i.m.i with either 100 µg of the plasmid DNA3-
Ag85B-64-ESAT or purified rAAV2-Ag85B-64-ESAT at doses ranging from 1012 to 109 vg and with pcDNA3 as 
the negative control. The frequencies of antigen-specific IFN-γ producing cells were measured by IFN-γ ELISpot 
following stimulation with (A) Ag85B at 10 µg/ml and (B) peptide 25 at 3 µg/ml. The data are the means + SEM 
for 3 mice and are representative of two independent experiments. The statistical significance of the differences 
between groups were analysed by one-way ANOVA with a Bonferroni post-hoc test (*, p≤0.05; ***, p≤0.005). 
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4.2.5 Immunisation with rAAV2-Ag85B-64-ESAT induced vaccine-specific 
CD4+ T cell responses. 
The primary function of a vaccine is to prime the immune system with particular pathogen-
associated antigens, which will result the efficient induction of the immune response upon 
subsequent infection with the pathogen and clearance of the infection. DNA immunisation with 
plasmids encoding the mycobacterial antigens Ag85B and ESAT-6 have demonstrated efficient 
priming of CD4+ T cell responses and protective efficacy (Kamath et al., 1999a). To assess the 
rAAV as a vaccine delivery vector, rAAV serotype 2 harbouring the expression cassette for the 
fusion antigen, Ag85B-64-ESAT was used for i.m.i. C57BL/6 mice were immunised three 
times in two-weekly intervals with the rAAV2-Ag85b-64-ESAT virus and the control virus, 
rAAV2-mCherry, as well as the positive control plasmid, DNA3-Ag85b-64-ESAT and the 
negative control, pcDNA3. Four weeks after the final immunisation, the T cell proliferative 
response was measured by [3H]-thymidine incorporation, and the frequency of IFN-γ-secreting 
T cells as well as the levels of antigen-specific IFN-γ production were assessed in splenocytes 
by ELISpot and ELISA, respectively. When the splenocytes were stimulated with Ag85B, cells 
from both rAAV-Ag85B-64-ESAT and plasmid DNA-immunised mice proliferated in an 
antigen dose-dependent manner (Figure 4.7A). The proliferative responses primed by DNA 
immunisation were greater than those following immunisation with rAAV-Ag85B-64-ESAT, 
and this was statistically significant following Ag85B stimulation at 0.3 and 1 µg/ml (p≤0.05, 
Figure 4.7A). No [3H]-Thymidine incorporation was detected in the cells from negative control 
plasmid- or rAAV-immunised mice.  
 Stimulation of the splenocytes from both the rAAV2-Ag85B-64-ESAT and DNA3-
Ag85B-64-ESAT immunised mice with 3 µg/ml of Ag85B resulted in frequencies of antigen-
specific IFN-γ secreting cells significantly greater than in mice immunised with the pcDNA3 
or rAAV2-mCherry controls (Figure 4.7B). When mice immunised with rAAV2-Ag85B-64-
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ESAT was stimulated with Ag85B, a frequency of 215 ± 9 SPC/106 splenocytes was detected. 
Immunisation with plasmid DNA resulted in frequencies of IFN-γ secreting cells 
approximately two-fold greater than after rAAV immunisation, while background levels of 
IFN-γ secreting cells were seen in the pcDNA3- and rAAV2-mCherry-immunised mice (Figure 
4.7B). Similar numbers of IFN-γ secreting cells were detected when the splenocytes were 
stimulated with peptide 25 at 10 µg/ml (Figure 4.7C).  
 The levels of IFN-γ secreted into the culture supernatants following 72 h of antigen 
stimulation reflected the frequencies of cells secreting IFN-γ in the 16 h ELISpot assays. 
Following stimulation with Ag85B, cells from the rAAV2-Ag85B-64-ESAT-immunised mice 
secreted 475 ± 10 pg/ml of IFN-γ. The level of IFN-γ secreted by cells from the plasmid DNA 
immunised mice were again significantly greater than the levels secreted by the cells from the 
rAAV-immunised mice (p≤0.005, Figure 4.7D). Similar levels of IFN-γ were secreted 
following stimulation with peptide 25 (Figure 4.7E). 
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Figure 4.7. The induction of antigen-specific IFN-γ  responses against Ag85B in rAAV2-
Ag85B-64-ESAT immunised mice.  
C57BL/6 mice were immunised thrice at two weekly intervals by i.m.i. with either 100 µg of DNA3-Ag85B-64-
ESAT or 1011 vg rAAV2-Ag85B-64-ESAT and with the plasmid pcDNA3 or rAAV2-mCherry as respective 
negative controls. Four weeks following the final immunisation, (A) the Ag85B-specific T cell proliferation was 
measured by [3H]-thymidine incorporation, (■) DNA3-Ag85b-64-ESAT, (!) rAAV2-Ag85B-64-ESAT, (!) 
pcDNA3 and (▲) rAAV2-mCherry immunised mice. (B) The frequencies of IFN-γ secreting cells were 
enumerated by the ELIspot assay following ex vivo stimulation with Ag85B at 10 µg/ml and (C) peptide 25 at 10 
µg/ml. Following 72 h stimulation the levels of IFN-γ in the culture supernatants were measured with an IFN-γ 
ELISA (D and E). The data shown are the means + SEM for 4 mice, and are representative of two independent 
experiments. The statistical significance of the differences between groups for the [3H]-thymidine incorporation 
assay were analysed using the Student’s t-test, while the differences for the ELISpot and ELISA data were 
analysed by one-way ANOVA with the Turkey’s post-hoc test (*, p≤0.05;&**, p≤0.01;&***, p≤0.005).  
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4.2.6 Immunisation with rAAV2-Ag85B-64-ESAT induced vaccine-specific 
CD8+ T cell responses. 
When splenocytes from rAAV2-Ag85B-64-ESAT immunised mice were stimulated with the 
CD8+ T cell epitope, MPT64190-198, at 10 µg/ml, the frequency of IFN-γ producing T cells was 
significantly higher than in splenocytes from mice immunised with pcDNA3 or rAAV2-
mCherry (p≤0.05, Figure 4.8A). However, the frequency of peptide-specific IFN-γ-producing 
cells remained significantly higher in mice immunised with DNA3-Ag85B-64-ESAT than 
those immunised with rAAV2-Ag85B-64-ESAT (p≤0.005, Figure 4.8A). Following 72 h of 
MPT64190-198 peptide stimulation, no T cell proliferation was detected by [3H]-thymidine 
incorporation (data not shown). The levels of IFN-γ secreted into the culture supernatants in 
response to MPT64190-198 reflected the frequencies of specific T cells . Cells from rAAV2-
Ag85B-64-ESAT immunised mice secreted 1121 ± 24 pg/ml of IFN-γ, and this was  
significantly less than the level of IFN-γ secreted by cells from DNA3-Ag85B-64-ESAT 
immunised mice (p≤0.005, Figure 4.8B). No IFN-γ was detected in the culture supernatant of 
cells from pcDNA3 or rAAV2-mCherry immunised mice. 
 
4.2.7 Immunisation with rAAV2-Ag85B-64-ESAT induced antibody response to 
the vaccine-encoded antigen. 
To determine the effects of immunisation with rAAV2-Ag85B-64-ESAT on the levels of 
antigen-specific antibodies, sera from C56BL/6 mice immunised as described above were 
collected weekly during the course of the immunisation schedule, and the serum levels of 
Ag85B-specific IgG were detected by an IgG ELISA. The titre of Ag85B-specific IgG was 
determined by the dilution of the serum at which the absorbance was greater than that of serum 
from a naïve mouse plus three standard deviations. The level of Ag85B-specific IgG in the 
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rAAV2-Ag85B-64-ESAT was only detectable 4 weeks after the initial immunisation, and the 
titre of antigen-specific IgG increased from 56 to 1,142 in week 5. By contrast, one week after 
DNA3-Ag85B-64-ESAT immunisation, high levels of Ag85B-specific IgG could be detected 
in the immunised mice. The titre increased from 1,168 to 10,618 and remained at this level 
throughout the course of the experiment (Figure 4.9A). 
 At 5 weeks, strong antibody responses were observed in the DNA3-Ag85B-64-ESAT 
immunised mice while a modest level of Ag85B-specific IgG was detected in the rAAV2-
Ag85B-64-ESAT immunised mice (Figure 4.9B). No Ag85B-specific IgG was detected in the 
pcDNA3 or rAAV2-mCherry immunised mice.  
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Figure 4.8. The induction of antigen-specific IFN-γ  responses against the CD8+ T cell 
epitope MPT64190-198 in rAAV2-Ag85B-64-ESAT immunised mice.  
C57BL/6 mice were immunised thrice at two weekly intervals with either 100 µg of DNA3-Ag85B-64-ESAT or 
1011 vg rAAV2-Ag85B-64-ESAT and with the plasmid pcDNA3 or rAAV2-mCherry as negative controls. Four 
weeks following the final immunisation, the number IFN-γ secreting cells were enumerated by ELIspot following 
ex vivo stimulation with (A) MPT64190-198 at 10 µg/ml and (B) the levels of IFN-γ in the culture supernatants were 
measured with an IFN-γ ELISA following 72 h of stimulation. The data shown are the means + SEM for 4 mice, 
and are representative of two independent experiments. The statistical significance of the differences between 
groups were analysed by one-way ANOVA with the Turkey’s post-hoc test (***, p≤0.005). 
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Figure 4.9. The induction of antigen-specific antibody responses against Ag85B in mice 
immunised with rAAV2-Ag85B-64-ESAT.  
C57BL/6 mice were immunised twice at two weekly intervals by i.m.i with either 100 µg of DNA3-Ag85B-64-
ESAT or 1011 vg rAAV2-Ag85B-64-ESAT and with the plasmid pcDNA3 or rAAV2-mCherry as respective 
negative controls. (A) Venous blood from DNA3-Ag85B-64-ESAT (!) or rAAV(-Ag85B-64-ESAT (■) 
immunised animals were collected weekly via the submandibular veins, and the Ag85B-specific antibody titres in 
the sera were analysed by an IgG ELISA. (B) The Ag85B-specific antibody titre of (■) DNA3-Ag85b-64-ESAT, 
(▲) rAAV2-Ag85B-64-ESAT, (!) pcDNA3 and (!) rAAV2-mCherry immunised mice at four weeks post-
immunisation, The data are antibody levels in sera pooled from 4 mice and are the means of triplicates, and the 
results are representative of two independent experiments. 
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4.2.8 The protective efficacy of the rAAV2-Ag85B-64-ESAT vaccine. 
To assess the protective efficacy of the rAAV2 vaccine, C57BL/6 mice were immunised three 
times in two-weekly intervals with the rAAV2-Ag85b-64-ESAT virus, the control virus, 
rAAV2-mCherry, DNA3-Ag85b-64-ESAT and the negative control, pcDNA3. Six weeks after 
the last immunisation, the mice were challenged with 100 cfu of virulent M. tuberculosis, 
H37Rv by aerosol, and four weeks later the bacterial loads in the lungs and the spleen were 
enumerated. Immunisation with rAAV2-Ag85B-64-ESAT did not result in a significant 
reduction in the bacterial load of the lungs follow M. tuberculosis H37Rv infection. By 
contrast, immunisation of mice with DNA3-Ag85B-64-ESAT resulted in significant reduction 
in the bacterial load in the lungs, 0.5 log10 CFU lower than in the pcDNA3 immunised mice 
(p≤0.01), and a 0.4 log10 CFU lower than in the rAAV2-Ag85B-64-ESAT mice (p≤0.01) 
(Figure 4.10A). BCG immunisation also provided a significant reduction in the bacterial loads 
by 1.1 log10 CFU in the lungs of infected mice (p≤0.005, Figure 4.10A). The level of protective 
efficacy in the spleen reflected that observed in the lungs. Immunisation with rAAV2-Ag85B-
64-ESAT did not provide significant protection against the dissemination of the infection to the 
spleen compared to immunisation with pcDNA3 or rAAV2-mCherry. Mice immunised with 
DNA3-Ag85B-64-ESAT displayed a 0.52 log10 CFU reduction in the bacterial load in the 
spleen, and this was significantly lower than in pcDNA3 and the rAAV2-Ag85B-64-ESAT 
immunised mice (p≤0.001 and p≤0.01, respectively, Figure 4.10B). Immunisation with BCG 
resulted in a 1.32 Log10 reduction in CFU in the spleen, and this protected significantly more 
effectively than DNA3-Ag85B-64-ESAT against bacterial dissemination (p≤0.001, Figure 
4.10B). 
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Figure 4.10. The effects of rAAV2-Ag85B-64-ESAT immunisation on the protective 
efficacy against M. tuberculosis challenge.  
C57BL/6 mice were immunised three times at two weekly intervals with either 100 µg of DNA3-Ag85B-64-
ESAT or 1011 vg rAAV2-Ag85B-64-ESAT,  and with the plasmid pcDNA3 or rAAV2-mCherry as respective 
negative controls. Mice were rested for six weeks following the final immunisation and then challenged with 100 
CFU of aerogenic M. tuberculosis H37Rv. Four weeks later the bacterial loads in (A) the lungs and (B) the spleen 
were enumerated. The data shown are the means + SEM for 5 mice, and are representative of two independent 
experiments. The statistical significance of the differences between groups were analysed by one-way ANOVA 
with the Turkey’s post-hoc test (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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4.2.9 The effects of a prime-boost immunisation regime utilising DNA3-Ag85B-
64-ESAT and rAAV2-Ag85B-64-ESAT on vaccine-induced CD4+ T cell 
responses. 
While rAAV2-Ag85B-64-ESAT immunisation stimulated both CD4+ and CD8+ T cell 
responses against the mycobacterial antigens, it failed to induce protective immunity against M. 
tuberculosis. To assess the potential of using the rAAV as a booster vaccine following DNA 
immunisation, C57BL/6 mice were immunised with either DNA3-Ag85B-64-ESAT or 
pcDNA3 twice, at two-weekly intervals, then boosted two weeks later with a single 
immunisation with 1011 vg of rAAV2-Ag85B-64-ESAT. Four weeks after the booster 
immunisation, the antigen-specific IFN-γ responses in the spleen were assessed by IFN-γ 
ELISpot and ELISA. When stimulated with Ag85B at 10 µg/ml, splenocytes from mice 
boosted with the rAAV2-Ag85B-64-ESAT virus did not display significantly increased 
frequencies of IFN-γ secreting cells compared to cells from mice immunised with DNA3-
Ag85B-64-ESAT alone. Splenocytes from mice that had been immunised with a single dose of 
rAAV2-Ag85B-64-ESAT displayed significant numbers of IFN-γ secreting cells compared to 
splenocytes from the pcDNA3 immunised mice (p≤0.001), but this was significantly lower 
than those following DNA3-Ag85B-64-ESAT immunisation or following a booster 
immunisation with rAAV-Ag85B-64-ESAT (p≤0.001, Figure 4.11A). The same effect was 
observed when the splenocytes were stimulated with peptide 25 at 3 µg/ml. While a booster 
immunisation with rAAV2-Ag85B-64-ESAT following priming with DNA3-Ag85B-64-ESAT 
did not significantly increase the number of peptide-specific IFN-γ secreting cells over DNA 
immunisation alone, splenocytes from mice immunised with rAAV2-Ag85B-64-ESAT or 
DNA3-Ag84B-64-ESAT alone resulted in significant numbers of peptide-specific IFN-γ 
secreting cells (p≤0.001, Figure 4.11B). Immunisation with plasmid DNA remained 
significantly superior to rAAV for priming antigen-specific IFN-γ secretion by CD4+ T cells. 
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When the levels of IFN-γ were measured in the culture supernatants following 72 h of Ag85B 
stimulation, the levels of IFN-γ secreted by cells from the rAAV2-Ag85B-64-ESAT boosted 
mice were greater than those secreted by mice immunised with DNA3-Ag85B-64-ESAT alone, 
but the increase was not statistically significant. Cells from mice primed with DNA3-Ag85B-
64-ESAT alone, however, resulted in significantly higher levels of antigen-specific IFN-γ 
secretion than mice immunised with rAAV2-Ag85B-64-ESAT alone (p≤0.01, Figure 4.11C). 
This increased effect was more apparent when the cells were stimulated with peptide 25 at 3 
µg/ml (Figure 4.11D). 
 
4.2.10 The effects of a prime-boost immunisation regime utilising DNA3-Ag85B-
64-ESAT and rAAV2-Ag85B-64-ESAT on vaccine-induced CD8+ T cell 
responses. 
To assess the effect of the DNA prime and rAAV boost immunisation regime on the generation 
of vaccine-specific CD8+ T cells, mice were immunised with DNA3-Ag85B-64-ESAT then 
boosted with rAAV2-Ag85B-64-ESAT and were compared to mice immunised DNA3-Ag85B-
64-ESAT or rAAV2-Ag85B-64-ESAT alone, and pcDNA3. The frequencies of antigen-
specific IFN-γ producing cells and the level of IFN-γ secreted were detected by ELISpot and 
ELISA, respectively. Following 16 h of stimulation with MPT64190-198 peptides at 3 µg/ml, the 
frequency of peptide-specific IFN-γ secreting cells in the mice that received the rAAV2-
Ag85B-64-ESAT booster immunisation was 764 ± 24 SPC/106 splenocytes, and this was not 
significantly different to the frequency of 704 ± 29 SPC/106 splenocytes achieved in mice 
immunised with DNA3-Ag85B-64-ESAT alone. Immunisation with rAAV2-Ag85B-64-ESAT 
resulted in a significant number of peptide-specific IFN-γ secreting cells, but remained lower 
than those immunised with DNA3-Ag85B-64-ESAT (p≤0.001, Figure 4.12A). The amount of 
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IFN-γ secreted following 72 h of MPT64190-198 peptide stimulation reflected the number of 
peptide-specific IFN-γ secreting cells after 16 h of peptide stimulation. In both assays, there 
was a trend for rAAV2-Ag85B-64-ESAT to increase the antigen-specific responses, but this 
increase was not statistically significant (Figure 4.12B).  
 
4.2.11 The effects of a prime-boost immunisation regime utilising DNA3-Ag85B-
64-ESAT and rAAV2-Ag85B-64-ESAT on antibody responses. 
To determine the effect of boosting DNA vaccine with rAAV2-Ag85B-64-ESAT on the 
antigen-specific antibody response, mice were immunised as stated above, and the levels of 
Ag85B-specific IgG in the serum samples four weeks after the final immunisation measured by 
an IgG ELISA. Booster immunisation with rAAV2-Ag85B-64-ESAT did not increase the titre 
of Ag85B-specific IgG in the DNA immunised mice. Interestingly, a single immunisation with 
rAAV2-Ag85B-64-ESAT resulted in an Ag85B-specific titre of 1,833, which was significantly 
higher than the pcDNA3 immunised mice (p≤0.05). The titre of Ag85B-specific IgG in the 
DNA3-Ag85B-64-ESAT immunised mice was significantly higher than that in rAAV 
immunised mice (p≤0.01, Figure 4.13). 
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Figure 4.11. The effects of heterogeneous prime-boost vaccination with DNA and rAAV2 
encoding Ag85B-64-ESAT on antigen-specific IFN-responses.  
C57BL/6 mice were immunised twice, two weeks apart by i.m.i with 100 µg of DNA3-Ag85B-64-ESAT or the 
plasmid pcDNA3 as the negative control. Two weeks after the second immunisation, the DNA3-Ag85B-64-
ESAT-immunised mice were either boosted with 1011 vg of rAAV2-Ag85B-64-ESAT or given a third DNA3-
Ag85B-64-ESAT immunisation. Four weeks after the booster immunisation the number IFN-γ secreting cells 
were enumerated by the ELIspot assay following ex vivo stimulation with (A) Ag85B at 10 µg/ml and (B) peptide 
25 at 3 µg/ml. Following 72 h of stimulation, the levels of IFN-γ in the culture supernatant were measured with an 
IFN-γ ELISA (C and D). The data shown are the means + SEM for 4 mice and are representative of two 
independent experiments. The statistical significance of the differences between groups were analysed by one-way 
ANOVA with the Turkey’s post-hoc test (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 4.12. The effects of heterogeneous prime-boost vaccination with DNA and rAAV2 
encoding Ag85B-64-ESAT on the antigen-specific CD8+ T cell IFN-responses.  
C57BL/6 mice were immunised twice, two weeks apart by i.m.i with 100 µg of DNA3-Ag85B-64-ESAT or the 
plasmid pcDNA3 as the negative controls. Two weeks after the second immunisation, the DNA3-Ag85B-64-
ESAT-immunised mice were either boosted with 1011 vg of rAAV2-Ag85B-64-ESAT or given a third DNA3-
Ag85B-64-ESAT immunisation. Four weeks after the booster immunisation the number IFN-γ secreting cells 
were enumerated by the ELIspot assay following ex vivo stimulation with (A) MPT64190-198 peptides at 3 µg/ml 
and following 72 h of stimulation, (B) the levels of IFN-γ in the culture supernatant were measured with an IFN-γ 
ELISA. The data shown are the means + SEM for 4 mice, and are representative of two independent experiments. 
The statistical significance of the difference between groups were analysed by one-way ANOVA with the 
Turkey’s post-hoc test (*, p≤0.05;&***, p≤0.005). 
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Figure 4.13. The effects of heterogeneous prime-boost vaccination with DNA and rAAV2 
encoding Ag85B-64-ESAT on the Ag85B-specific humoural response.  
C57BL/6 mice were immunised twice, two weeks apart with 100 µg of DNA3-Ag85B-64-ESAT or the plasmid 
pcDNA3 as the negative controls. Two weeks after the second immunisation, the DNA3-Ag85B-64-ESAT-
immunised mice were either boosted with 1011 vg of rAAV2-Ag85B-64-ESAT or given a third DNA3-Ag85B-64-
ESAT immunisation. Four weeks following the booster immunisation, blood was collected by cardiac puncture, 
and the Ag85B-specific antibody titre in the serum was analysed by an IgG ELISA. The data represent serum 
pooled from 4 mice and are the means of triplicate log10 IgG titres and are representative of two independent 
experiments. The statistical significance of the differences between groups were analysed by one-way ANOVA 
with Turkey’s post-hoc test (*, p≤0.05;&**, p≤0.01). 
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4.2.12 The effects of a DNA3-Ag85B-64-ESAT and rAAV2-Ag85B-64-ESAT 
prime-boost immunisation regime on the protective efficacy. 
To investigate the effects of a prime-boost immunisation regime using DNA3-Ag85B-64-
ESAT and rAAV encoding the same antigen fusion on the protective efficacy of DNA 
immunisation against M. tuberculosis infection, mice were immunised as described above and 
challenged with M. tuberculosis H37Rv six weeks after the final immunisation. Four weeks 
following aerosol challenge the bacterial loads in the lungs and the spleen were enumerated. 
Mice immunised with DNA3-AG85B-64-ESAT displayed a 0.4 log10 reduction in the bacterial 
CFU in the lungs compared to pcDNA3-immunised mice, and boosting the DNA-primed mice 
with rAAV2-Ag85B-64-ESAT did not provide any further significant reduction to the bacterial 
load (Figure 4.14A). Immunisation with rAAV2-Ag85B-64-ESAT alone did not result in 
significant reduction in the bacterial load compared to pcDNA3 immunisation. BCG 
immunisation resulted in 1.2 log10 CFU reduction in the lung, and this was significantly greater 
than the DNA-immunised mice (p≤0.001, Figure 4.14A).  
 The bacterial loads in the spleen displayed similar findings. Boosting with rAAV2-
Ag85B-64-ESAT did not further reduce the bacterial dissemination seen in mice immunised 
with DNA3-Ag85B-64-ESAT alone, while BCG immunisation provided 1.4 log10 CFU 
reduction in the bacterial load in the spleens of infected mice. Immunisation with rAAV2-
Ag85B-64-ESAT alone did not provide protection against bacterial dissemination compared to 
mice immunised with the control plasmid, pcDNA3 (Figure 4.14B). 
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Figure 4.14. The effects of heterogeneous prime-boost vaccination with DNA and rAAV2 
encoding Ag85B-64-ESAT on the protective efficacy against M. tuberculosis challenge.  
C57BL/6 mice were immunised twice, two weeks apart by i.m.i with 100 µg of DNA3-Ag85B-64-ESAT or the 
plasmid pcDNA3 as the negative controls. Two weeks after the second immunisation, the DNA3-Ag85B-64-
ESAT-immunised mice were either boosted with 1011 vg of rAAV2-Ag85B-64-ESAT or given a third DNA3-
Ag85B-64-ESAT immunisation. Mice were rested for six weeks following the booster immunisation and then 
challenged with 100 CFU of aerogenic M. tuberculosis H37Rv. Four weeks later the bacterial loads in (A) the 
lungs and (B) the spleen were enumerated. The data shown are the means + SEM for 5 mice and are representative 
of two independent experiments. The statistical significance of the differences between groups were analysed by 
one-way ANOVA with the Turkey’s post-hoc test (*, p≤0.05;&**, p≤0.01;&***, p≤0.005).  
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4.3 Discussion 
Despite developments in vaccines over the last 15 years, no single anti-TB vaccine candidate 
has been found to outperform the only licensed vaccine, BCG. In this chapter, the potential of 
using rAAV as a vaccine vector for anti-TB immunisation was explored and compared with 
DNA immunisation. Plasmid DNA vaccines have been studied intensely recently because of 
their immunogenicity, relative ease of manufacture and good safety profile (Saade and 
Petrovsky, 2012). Immunisation with plasmid DNA constructs, including DNA3-Ag85B-64-
ESAT, stimulates both CD4+ and CD8+ T cells responses (Figures 4.6-8). The general 
consensus for their mode of action is that following the transfection of both myocytes and DCs 
by the plasmids, expression of the encoded transgene occurs resulting in antigen presentation 
through MHC class I and activation of CD8+ T cells. Antigens secreted or released into the 
extracellular environment are then endocytosed and presented via the MHC class II pathway to 
the TCR on antigen-specific CD4+ T cells. Unmethylated CpG sequences present within the 
vaccine DNA molecules activate TLR-9, providing the activation signal for both plasmacytoid 
DCs and B cells (Kojima et al., 2002). 
 Previously, the combination of separate DNA vaccines expressing Ag85B, MPT64 and 
ESAT-6 was shown to induce protective immunity against M. tuberculosis (Kamath et al., 
1999a). In order to use these three antigens in rAAVs, an in-frame fusion of the three genes 
encoding M. tuberculosis Ag85B, MPT64190-198 and ESAT-6 was constructed and cloned into 
the pAAV plasmid vector. Following triple plasmid tranfection of HEK293 cells with pAAV-
Ag85B-64-ESAT and the helper plasmids, virus encoding the fusion antigen was detected 
using Ag85B-specific oligonucleotide primers in benzonase-treated cellular lysate preparations, 
indicating that DNA molecules harbouring the transgene were indeed encapsulated and 
protected from the effects of non-specific enzyme digestion (Figure 4.3). The same pair of 
Ag85B-specific primers was utilised to quantitate the purified recombinant viral preparations. 
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This molecular method of qualification determines the number of viral particles with 
encapsulated genomes harbouring the transgene, and thus provides a representation of the 
functional rAAV titre. Following qPCR, the resulting product disassociation curve and linear 
standard curve indicated a single PCR product was produced (Figure 4.4A and B). The yield of 
rAAV were typically between 1200 and 12000 DNase-resistant particles (DRP)/cell following 
large–scale plasmid transfection and purification. This recombinant viral yield was consistent 
with that reported in other studies producing rAAVs using similar methods (Aucoin et al., 
2008).  
 The expression of the fusion antigens was confirmed by the development of Ag85B-
specific T cell responses in mice immunised with the rAAV2-Ag85B-64-ESAT vector (Figure 
4.6). Ag85B-64-ESAT was only detected 7 d after in vitro transduction, and this may be due to 
the relatively late onset of transgene expression by rAAV2 following transduction (2-4 weeks). 
Other serotypes of rAAV, such as 1, 6, 7, 8 and 9, have demonstrated earlier expression of 
luciferase in vivo (Zincarelli et al., 2010). The Ag85B-64-ESAT fusion protein was not 
detected by immunoblotting with anti-Ag85B antibodies in rAAV-Ag85B-64-ESAT 
transduced HT1080 cells in vitro. This may have been due to the low levels of antigen 
expression with rAAV2. Nevertheless, antigen expression was confirmed in vivo by the 
induction of the Ag85B-specific T cell responses (Figure 4.6). Mice immunised with as low as 
109 vg of the rAAV displayed transgene-specific T cell activation. Mice immunised with the 
higher doses of 1011 or 1012 vg resulted in strong and equivalent levels of Ag85B- and peptide 
25-specific IFN-γ T cell responses. The dose of 1011 vg was selected for subsequent studies. 
These doses were consistent with those used in studies using i.m. injection of rAAV (Zincarelli 
et al., 2010, Qiao et al., 2011, Wang et al., 2011b). In the study conducted by Wang et al. 
(2011), increasing the injection dose from 1011 to 5 × 1011 resulted in increased cFIX 
expression, but did not increase the transgene-specific antibody responses, indicating that 
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higher doses of rAAV during immunisation were not required for the induction of a vaccine-
specific immune responses. 
 The rAAV2-Ag85B-64-ESAT was clearly immunogenic (Figure 4.7). Nevertheless, the 
IFN-γ secreting responses in mice after rAAV immunisation were significantly lower than 
those primed by DNA immunisation in all experiments. Further, the induction of these antigen-
specific T cells by rAAV did not translate into increased protection against M. tuberculosis 
infection (Figure 4.10). The failure of rAAV2-Ag85B-64-ESAT to induce protective efficacy 
against M. tuberculosis may be due to a number of reasons associated with the biology of 
AAVs. 
 By contrast, promising levels of protective efficacy were reported for rAAV-based 
vaccine vectors against various experimental viral infections (Du et al., 2008, Li et al., 2012, 
Zhou et al., 2010). Immunisation with rAAV1 or rAAV2 encoding human papillomavirus 
(HPV) tumour antigens from serotypes 16 and 18 fused to HSP70 induced both CD8+ T cells 
and IFN- responses, resulting in protection against tumour challenge (Zhou et al., 2010). 
Immunisation against Dengue virus with rAAV8 or rAAVrh32.33 encoding the viral antigen 
79E resulted in antigen production in vivo, and induced long-lasting antibody responses 
resulting in neutralisation of homologous Dengue virus (Li et al., 2012). rAAV-based viral 
vectors against both influenza or the SARS coronavirus induced both Th2 and Th1 T cell 
responses and was protective against respective homologous viral challenge (Du et al., 2008, 
Sipo et al., 2010). rAAV immunisation can activate various arms of the immune system. These 
studies demonstrate that dependent on the pathogen and the antigens used, the vaccine-induced 
T cell or antibody responses are sufficient to neutralise infectious viral particles and provide 
protective efficacy. Interestingly, the serotype of rAAV used during immunisation can have 
substantial effect on the outcome of the immunisation. For instance, rAAV1 encoding HPV 
Chapter 4. Novel Anti-TB Vaccine Based on rAAV Encoding M. tuberculosis Antigens 
 
139 
tumour antigens was more effective at generating IFN-γ secreting CTL than rAAV2 expressing 
the same antigen cassette (Zhou et al., 2010), while immunisation with rAAV8 induced higher 
levels of Dengue virus 79E-specific antibodies titres than immunisation with rAAV.rh32.33 (Li 
et al., 2012). 
 rAAV-based vaccines against more complex pathogens, such as malaria, were not as 
successful in inducing protective immunity. Immunisation with rAAV encoding the malarial 
antigens MSP4 and MSP5 elicited the production of MSP4/5-specific antibodies, but failed to 
induce protective efficacy (Logan et al., 2007). Attempts to enhance the responses to rAAV 
immunisation through fusion of the antigen to the complement molecule, C3d, did not increase 
the vaccine-induced responses, but was also detrimental for the induction of the antigen-
specific antibody responses (Logan et al., 2010). MSP4/5 fused with the CTLA-4-Ig co-
stimulatory molecule delivered by rAAV1 resulted in improved antibody responses at the low 
immunisation dose of 109 vg, but higher doses of 1012 and10 13 vg induced B cell tolerance 
(Logan et al., 2009). Genetic immunisation delivered with the rAAV system is not as straight 
forward are previously thought. The types of tissue transduced, the level of antigen expression 
and the immunogenicity of the rAAV virus particles, which are determined by the serotypes if 
the rAAV virus, and each of these factors, which may influence the induction of vaccine-
specific immune responses and protective immunity against pathogen challenge. 
 The levels of the Ag85B-64-ESAT fusion protein expression following i.m.i of rAAV2-
Ag85B-64-ESAT may not have reached the threshold required for secondary T cell expansion 
within the tested timeframe of four weeks. Four weeks post-immunisation may be the earliest 
time point required for transgene expression in vivo, and this may explain the lack of 
significant boost to the vaccine effect. Nonetheless, an increasing trend in both IFN- 
responses and protection were observed for the rAAV2-Ag85B-64-ESAT boosted animals 
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suggesting extension of the resting time may allow for higher expression of Ag85B-64-ESAT 
and improved expansion of the antigen-specific T cells (Figures 4.11-14). 
 In addition to antigen expression, successful priming of the adaptive immune response 
requires presentation of these antigens under specific conditions. Indeed, one feature that made 
rAAV an attractive system for gene therapy was the relatively reduced activation of both the 
innate and adaptive immune responses by rAAV compared to other viral vectors (Zaiss et al., 
2002). The conditions that are essential for the induction of the adaptive immune response can 
be broken down into four stages or signals. Signal 0 is the activation of the innate immune 
system. Signal 1 is the presentation of the antigen through the formation of the immune 
synapse, composed of MHC class I or II engaged to the TCRs on CD8+ or CD4+ T cells 
respectively. Signal 2 is the engagement of the co-stimulatory molecules, such as CD80/86 
with CD28 or CD40-CD40L interaction, and finally Signal 3, the secretion of immune-
modulating cytokines, such as IL-12 or IL-4. The lack of protective immunity induced by 
rAAV immunisation may be explained by the inability of the virus to satisfy one or more of 
these conditions of vaccine-antigen presentation. Although AAV was initially considered to 
provide a weak activation signal for early innate immunity, rAAVs do activate pDCs through 
TLR-9, and this contributes to the development of CD8+ T cell responses to the transgene 
product (Zhu et al., 2009). This explains the robust MPT64-specific CD8+ T cell responses 
developed in rAAV2-Ag85B-64-ESAT immunised mice (Figure 4.6 and 4.12).  
 rAAV stimulated both MHC class I and II-restricted T cells responses. There are 
several routes this could have occurred. Following rAAV transduction of muscle cells and 
expression of the transgene product, some cells die and release their cellular content and 
antigen may be available for presentation on MHC Class I and II molecules. Although MHC 
class II molecules are not detectable on muscle fibres under physiological conditions, 
expression of MHC class I and II molecules, as well as the non-classical MHC class Ib 
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molecule, occur under inflammatory conditions, such has increased levels of pro-inflammatory 
cytokines IFN-γ, TNF-α, IL-1 and MIP-1α (Mantegazza et al., 1991, Nagaraju et al., 2000). 
Under these conditions, the skeletal muscle cells can function as a facultative APC (Wiendl et 
al., 2005). This is particularly applicable for MHC class I antigen presentation (Nagaraju et al., 
2000) and is consistent with the response observed following restimulation with MPT64190-198 
peptides (Figure 4.6). The direct genetic transfer of plasmid DNA into APCs is thought to be 
responsible or the induction of the vaccine-specific responses following DNA immunisation 
(Fu et al., 1997, Iwasaki et al., 1997). This contrasts the little to no transduction of DC by 
AAVs, suggesting it was more likely that the transgene product is expressed by the transfected 
muscle cells and then processed and presented to T cells by DCs (Xu and Walker, 2011). This 
may explain the generation of vaccine-specific CD4+ T cells (Figure 4.5) and the provision of 
T cell help needed for the generation of the antigen-specific IgG (Figure 4.8). A recent study 
has reported the induction of a more robust CTL response following improved DC transduction 
through amino acid modification of the AAV2 capsid protein (Aslanidi et al., 2012). 
 In addition to efficient antigen presentation, the engagement of co-stimulatory 
molecules, such as CD80/86 binding to CD28, is important for the priming of adaptive T cell 
responses. In addition, the interaction of CD40L with CD40 contributes to the T cell required 
by B cells for proliferation and production of high affinity antibodies. The expression levels of 
these co-stimulation molecules are dependent on the activation states of the APCs at the time 
of T cell priming, and the lack of these co-stimulatory signals will result in T cell anergy or 
deletion. AAVs provide limited inflammatory signals even during normal infections (Zaiss et 
al., 2002), and the degree of co-stimulatory molecules expressed during rAAV transduction 
may be less than ideal for the effective clonal expansion of naïve CD8+ T cells. A number of 
recent studies have reported that while antigen-specific CD8+ T cells are generated after rAAV 
immunisation, these T cells remain functionally impaired. One study using a rAAV expressing 
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the HIV gag antigen demonstrated that primed gag-specific CD8+ T cells were unable to 
expand upon secondary antigen exposure (Lin et al., 2007b). Impaired IL-2 secretion by the 
primed CD8+ T cells resulted in reduced T cell proliferation and generation of central memory 
T cells (Lin et al., 2007a). Furthermore, co-immunisation with TLR activating adjuvant could 
not restore the functional impairment of the primed CD8+ T cells. T cells primed by rAAVs 
also expressed increased levels of markers for cellular exhaustion, such as CTLA-4 and PD-1 
(Spahn et al., 2011). 
 Another important determinant for the generation of an effective T cell response is the 
cross-talk of soluble signals between the naïve T cell and APC within the immunological 
synapse. Pro-inflammatory cytokines, in particular IL-12, are important for the priming of a 
Th1 type T cell responses as well as the licensing of cytotoxic CD8+ T cells. AAV transduction 
does not provide the necessary signals for APC activation and maturation (Jooss et al., 1998). 
Under these conditions, little or no IL-12 is secreted by the APCs and thus no signal 3 is 
provided during the immunological synapse between the APC and the naïve T cells. While 
naïve CD8+ T cells can undergo multiple rounds of cell division upon brief exposure to antigen 
presentation and co-stimulation, the majority of these cells either do not survive or do not 
develop effector function. In order to achieve optimal clonal expansion of antigen-specific 
CD8+ T cells, extended exposure to IL-12 is required (Curtsinger et al., 2003). Although the 
rAAV2-Ag85B-64-ESAT vaccine stimulated a robust level of MPT64190-198-specific IFN- 
secreting CD8+ T cells, this was insufficient for protection against aerogenic M. tuberculosis 
infection (Figure 4.10). 
 A role for subunit vaccines against TB is to boost the responses induced by BCG 
immunisation. A requirement for this is the ability to elicit strong CD4+ and CD8+ T cell 
responses. Attenuated viral vaccine vectors that are unable to replicate but are capable of 
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eliciting strong T cell responses, such as fowlpoxvirus (FPV) and MVA, are candidates as 
booster vaccines (Skeiky and Sadoff, 2006). AAV viruses are both replication deficient and 
able to induce a robust CD8+ T cell response. However, a heterologous prime-boost 
immunisation experiment using rAAV2-Ag85B-64-ESAT to boost immune responses primed 
with plasmid DNA encoding Ag85B-64-ESAT did not result in a significant increase in the 
frequency of antigen-specific CD4+ T cells (Figures 4.11 and 4.12), nor did it provide 
increased protective efficacy against M. tuberculosis challenge (Figure 4.14).  
 In summary, rAAV immunisation was able to generate both CD4+ and CD8+ T cell 
responses to encoded mycobacterial antigens, but this did not provide significant boosting 
following DNA immunisation in C57BL/6 mice, or translate into protective immunity against 
M. tuberculosis infection. By contrast, DNA immunisation alone reliably induced protective 
immunity against M. tuberculosis. Therefore, rAAVs are not suitable as vaccine vector for use 
against M. tuberculosis and other intracellular pathogens that require well balanced CD4+ and 
CD8+ T cell responses for effective control. 
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5.1  Introduction 
Protective immunity against M. tuberculosis requires the generation of a Th1 type T cell 
response against the mycobacterial antigens. Upon antigen recognition, T cells and T cell-
derived cytokines and cytotoxic molecules are essential for the direct activation of the infected 
macrophages or their cytolysis. One consequence of the activation of APCs during M. 
tuberculosis infection is the secretion of proinflammatory cytokines, such as IL-12 and IL-18 
(Kinjo et al., 2002, Zhang et al., 1994). IL-12 is a heterodimeric cytokine consisting of p35 and 
p40 subunits linked by disulphide bonds (Podlaski et al., 1992). The major source of IL-12 are 
DCs, as well as activated macrophages. The production of IL-12 is upregulated during the 
innate immune response against intracellular pathogens. IL-12 is important for the 
orchestration of the adaptive immune responses and is pivotal for the development of the Th1 
type CD4+ T cell responses (Trinchieri, 2003). IL-12 is a member of the IL-12 family of 
closely related cytokines, along with IL-23, IL27 and more recently IL-35. Mice deficient in 
the shared IL-12p40 subunit are unable to produce IL-12 or IL-23 and are highly susceptible to 
M. tuberculosis infection (Cooper et al., 1997).  
Previous studies in this laboratory have demonstrated that co-immunisation with 
plasmid encoding IL-12 (pCL-mIL-12) with DNA3-Ag85B acted as an effective adjuvant 
during DNA immunisation, resulting in both increased antigen-specific IFN-γ secretion by 
CD4+ T cells, and reduced pulmonary bacterial numbers following aerosol infection with M. 
tuberculosis (Palendira et al., 2002, Wozniak et al., 2006a). The protective efficacy resulting 
from DNA vaccines co-immunised with the plasmid IL-12 adjuvant was comparable to the 
effects of BCG immunisation (Palendira et al., 2002). The co-delivery of plasmid IL-12 with a 
DNA vaccine encoding the 35 kDa major membrane protein of Mycobacterium avium also 
enhanced the protected efficacy of DNA-35 against virulent M. avium infection (Martin et al., 
2003).  
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 AAVs are small, single-stranded DNA parvoviruses, and in addition to being non-
pathogenic in humans, they also possess a number of desirable features making them suitable 
for a genetic transfer system to deliver cytokines. For example, helper virus proteins encoded 
by helper viruses, such as adenovirus or herpes simplex virus, are essential for the productive 
replication of AAVs, and this requirement reduces the risk of insertional mutagenesis of the 
host genome, the major safety concern faced by lentiviral and other integrative viral vectors 
(Weitzman et al., 1994). These replication-deficient AAV particles are able to transduce a 
broad range of replicating and non-replicating cells, resulting in long-termed expression of the 
transgene following in vivo administration (Zincarelli et al., 2008). Moreover, the ability to 
generate high-titre recombinant virus in vitro has made rAAV an attractive system for gene 
therapy for the treatment of diseases such as haemophilia B, cystic fibrosis, Parkinson’s disease 
and other monogenic diseases (Manno et al., 2006, Wagner et al., 1999). 
To assess the feasibility of using rAAV vectors to deliver IL-12 as either a pre-exposure 
vaccine adjuvant or as an immunotherapeutic agent following M. tuberculosis infection, the 
genes encoding the p35 and p40 subunits of murine IL-12 (mIL-12) linked by the foot-and-
mouth disease virus (FMDV) 2A sequence, were cloned into the rAAV genome, and a serotype 
2 rAAV encoding mIL-12 was produced. The FMDV 2A sequence encodes a 20 aa self-
cleaving peptide which releases the p40 and p35 subunits of IL-12 from the expressed single 
polypeptide molecule to allow the correct folding and disulphide bond formation between the 
two subunits (Chaplin et al., 1999). This recombinant virus was tested for its ability to produce 
functional IL-12 after transduction, and the effects of co-delivery with a DNA vaccine 
encoding a fusion of mycobacterial antigens, DNA3-Ag85B-64-ESAT. The effects of rAAV2-
mIL-12 on the induction of the immune response and the activation of vaccine-specific 
responses were assessed by T cell recall and serological assays. The protective efficacy was 
examined by enumerating the bacterial load in the lungs and the spleen at the peak of the 
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infection following an aerosol challenge with virulent M. tuberculosis. The effects of the 
delivery of rAAV2-mIL-12 as an immunotherapy during M. tuberculosis infection were also 
assessed. 
 
5.2 Results 
5.2.1 Construction of recombinant AAV serotype 2 encoding mIL-12 
To produce recombinant AAV virus encoding mIL-12, the plasmid encoding the expression 
cassette for mIL-12 flanked by the AAV serotype 2 (AAV2) ITR was constructed. The entire 
ORF encoding ARAP4 downstream of the RSV promoter was removed from pAAV2-ARAP4 
by digestion with the HindIII restriction enzyme. The ORF encoding p35-2A-p40 (mIL-12) 
contains an internal HindIII site, which enables the preparation of a DNA fragment with 
cohesive HindIII ends. The ORF encoding mIL-12 was amplified from pCl-mIL-12 using two 
sets of oligonucleotide primers (Table 2.4). The resulting two amplicons were mixed, 
denatured, and then re-annealed to produce the fragment encoding mIL-12 with cohesive 
HindIII ends. The purified DNA fragment was ligated into the HindIII-digested pAAV-ARAP4 
to produce the 6.5 kb pAAV-mIL-12 plasmid (Figure 5.1A). Digestion of pAAV-mIL-12 with 
HindIII released two fragments from the plasmid, a 650 bp and a 1060 bp fragment 
corresponding to the p35 and p40 subunits of IL-12 respectively (Figure 5.1B). 
 
5.2.2 Production of mIL-12 following transfection with pAAV-mIL-12 plasmid 
The expression of functional mIL-12 requires the translation and correct folding of both the 
p35 and p40 subunits to form the heterodimeric cytokine. To confirm the expression of the 
mIL-12 transgene from the pAAV-mIL-12 plasmid, HEK293T cells at a density of 3.5 × 105 
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cells/well were transfected with 1 µg of the pAAV2-mIL-12 plasmid. HEK293T cells 
transfected with pAAV-ARAP4 plasmid served as the negative control, while transfection with 
pCl-mIL-12 served as the positive control. The culture supernatant was collected after 48 h and 
the rmIL-12 was detected with an IL-12p40 ELISA. The levels of IL-12 were 10-fold higher in 
the supernatants of pAAV-mIL-12 and pCl-mIL-12 transfected cells than in the cells 
transfected with the negative control plasmid, pAAV-ARAP4 (Figure 5.2), confirming that IL-
12p40 was expressed from pAAV-mIL-12. 
 
5.2.3 Production of rAAV-mIL-12 virus 
5.2.3.1 DNA encoding mIL-12 was detected in CsCl fractionated cell lysate. 
Purification of rAAV virus requires the separation of the genome-containing viral particles 
from the empty viral particles and cellular debris by CsCl gradient centrifugation. In order to 
identify the fractions containing the genome containing viral particles for further purification, 
oligonucleotide primers specific for the mIL-12 DNA sequence were used to amplify mIL-12 
DNA present in each of the collected CsCl fractions (Table 2.4). The presence of rAAV2 
genome encoding mIL-12 was indicated by the amplification of a 112 bp amplicon. One ng of 
pCl-mIL-12 served as the positive control and 1 µl or 10 µl of 10-fold dilution from each 
fraction were used as templates for the PCR reactions followed by visualisation on a 2.5% 
agarose gel. Although the 112 bp band was detected in many of the fractions, the signals from 
fractions 6 to 8 were clearly the strongest across the entire range of collected fractions (Figure 
5.3) and these were collected to purify the rAAV-mIL-12 virus for immunological studies. 
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Figure 5.1. Construction of rAAV plasmid encoding genes for IL-12.  
The plasmid encodes the genes for mIL-12 flanked by AAV serotype 2 ITRs. The genes for the p35 and p40 
subunits of mIL-12 are separated by the sequence for the FMDV 2A peptide and expressed under the control of 
the RSV promoter as a single polypeptide. (A) The plasmid map of pAAV2-mIL-12. (B) Restriction enzyme 
digest of pAAV2-mIL-12, M, Hyperladder I MW marker, lane 1, Digest with HindIII to reveal the fragments 
encoding the p35 and p40 subunits (indicated by the red arrows). Lane 2, Digested with BglII to linearise the 
plasmid. Lane 3, uncut plasmid. 
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Figure 5.2. Expression of mIL-12 following transfection with pAAV2-mIL-12.  
HEK-293T cells cultured at a density of 3.5 × 106 cells were transfected with 1 µg of pAAV2-mIL-12, pCl-mIL-
12 or the control plasmid pcDNA3. After 48h, the culture media were collected, and the levels of mIL-12 were 
measured by an IL-12p40 ELISA and expressed as absorbance at the wavelength of 405 nm with the absorbance 
at the wavelength of 492 nm subtracted. The data shown are the means ± S.E.M for triplicate transfections. The 
statistical significance of the difference between groups were analysed by the Student’s t-test (***, p≤0.005). 
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Figure 5.3. Detection of AAV2 genome encoding mIL-12 in fractions of viral particles 
separated by CsCl density gradient centrifugation. 
HEK293T cells were collected 72 h post-transfection with the AAV2 packaging plasmid cocktail and lysed by 4 
rounds of freeze-thaw treatment. Viral particles from the cellular lysates were concentrated by ammonium 
sulphate precipitation. Extra-viral DNA was digested with benzonase, and then the viral particles were purified by 
gradient centrifugation in CsCl (1.37 g/ml) at 186232.8 ×g for 48 h with the SW41Ti rotor. One ml fractions 
were collected, and the presence of rAAV2-mIL-12 was detected by PCR. 
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5.2.4 Quantification of rAAV2-mIL-12 by qPCR 
In order to use the rAAV virus for in vivo experiments, it was important to determine the 
amount and concentration of the rAAV viral particles produced following large-scale virus 
packaging in HEK293T. 
To establish a qPCR for rAAV2-mIL-12, the plasmid pAAV2-mIL-12 was used as an 
amplification template (Figure 5.1A). This plasmid contains the entire genome for rAAV2-
mIL-12. Oligonucleotide primers specific for the transgene, mIL-12, were used for the qPCR 
amplification (Table 2.4). After the exact determination of the concentration of the plasmid 
preparation optically using the NanoDrop, a 500 ng/ml stock solution and 10-fold serial 
dilutions of the plasmid were prepared. To determine the linear dynamic range of the rAAV2-
mIL-12 qPCR, the serial dilutions of pAAV2-mIL-12 were assayed across 6 logs (1.43 × 103 to 
1.43 × 108 plasmid copies), with each dilution assayed in triplicates (Figure 5.3 and 5.4). 
Within this range the rAAV2-mIL-12 qPCR displayed a linear correlation coefficient (R2) of 
0.999 with a slope of -3.116 and an amplification efficiency of 109.3% (Figure 5.5). 
To determine the concentration of the purified rAAV2-mIL-12, 10-fold serial dilutions 
of the unknown viral stock were prepared, and two dilutions 10-3 and 10-4, of the unknown 
stock were used in the assay. For the qPCR quantification, two µl of each dilution were 
assayed in triplicates, using the defined serial dilutions of the pAAV2-mIL-12 plasmid for the 
calculation of the standard curve. The cycle thresholds (Ct) for the rAAV2-mIL-12 samples 
were 18.13 cycles for the 10-3 dilution and 21.53 cycles for the 10-4 dilution, and the calculated 
initial viral genome copy numbers were 1.35 × 106 and 1.10 × 105, respectively (Figure 5.5). 
To obtain the final virus titre from the pAAV2-mIL-12 standard, the single-stranded viral 
genome (vg) were corrected by a factor of two and then multiplied by the dilution factor 
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followed by the template volume to obtain genome titres of 1.35 × 1012 vg/ml and 1.10 × 1012 
vg/ml for 10-3 and 10-4 sample dilutions, respectively. 
 
5.2.5 mIL-12 is produced following transduction with CsCl fractions. 
To confirm the presence of functional rAAV2-mIL-12 virus within the CsCl fractions 
following two rounds of CsCl gradient centrifugation, one µl of each fraction was used to 
transduce HT1080 cells. The resulting supernatants were collected after 48 h, and the levels of 
mIL-12 were detected by IL-12p40 ELISA (Figure 5.6A). Transduction with fraction 04 
resulted in the highest level of mIL-12p40 production (240 pg/ml), while transduction with 
fractions 05, 06, 08 and 09 resulted in moderate levels of mIL-12 production (Figure 5.6A). 
 
5.2.6 Transduced cells produce IL-12 
To test both the function and the transgene expression profile of the purified rAAV2-mIL-12 
virus following purification, HT1080 cells at a density of 4 × 105 were transduced with the 
purified rAAV2-mIL-12 stock at an MOI of 1000 and the levels of IL-12p40 in the culture 
supernatant were measured at 5, 7, 10 and 14 days post-transduction time points by an ELISA 
for murine IL-12p40. Culture supernatant from untreated HT1080 cells and HT1080 cells 
transfected with pCl-mIL-12 served as the negative and positive controls, respectively for the 
assay. The levels of murine IL-12p40 in the culture supernatant of rAAV2-mIL-12 transduced 
cells at day 5 post-transduction was 91 pg/ml, and this was more than 8-times greater than the 
untreated cells. The level of IL-12p40 increased to 141 pg/ml and 241 pg/ml at days 7 and 10 
respectively, and the highest level of IL-12p40 occurred at day 14 post-transduction with an 
IL-12p40 concentration of 684 pg/ml. The maximum level of IL-12p40 produced following 
transfection with the positive control, pCl-mIL-12, was 1308 pg/ml (Figure 5.6B and C). 
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5.2.7 rAAV2-mIL-12 transduced cell produce biologically active IL-12 
One of the functions of mIL-12 is to stimulate IFN-γ secretion from T and NK cells. To assess 
whether the mIL-12 produced following rAAV2-mIL-12 transduction was biologically active, 
it was tested for the capacity to stimulate IFN-γ production by naïve splenocytes. The mIL-12 
released into the supernatants of rAAV2-mIL-12 transduced cells or pCL-mIL-12 transfected 
cells were captured onto microtitre plates, using supernatants from untreated cells as the 
negative control. This effect was compared with the IFN-γ production caused by serial 
dilutions of recombinant mIL-12. When the levels of IFN-γ secretion were plotted against 
concentration of IL-12, the resultant standard curve had a R2 co-efficient of 0.99347 (Figure 
5.7A). No IFN-γ was detected in supernatants from the untreated HT1080 cells, while 
supernatants from the pCL-mIL-12-transfected cells induced IFN-γ secretion equivalent to 
1402 ± 149 pg/ml of rmIL-12. The levels of IFN-γ secreted by the splenocytes cultured in 
wells coated with the supernatants from rAAV2-mIL-12-transduced cells were comparable to 
the effects of plasmid mIL-12 and were equivalent to 945 ± 182 pg/ml of rmIL-12 (Figure 
5.7B).  
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Figure 5.4. Quantification of purified rAAV2-mIL-12 virus by qPCR using mIL-12-
specific primers. 
Following identification of virus-containing fractions, the fractions were pooled and dialysed overnight against 
5% glycerol v/v PBS. The dialysed pooled fractions containing rAAV2-mIL-12 virus and 6 serial dilutions of 
pAAV-mIL-12, ranging from 500 ng/ml to 5 pg/ml, were analysed by QPCR using primers-specific for internal 
region of the mIL-12 gene. (A) The qPCR amplification and (B) the product disassociation profiles are shown. 
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Figure 5.5. Calculation of the viral titre of the purified rAAV2-mIL-12. 
A representative standard curve for the quantification of rAAV2-mIL-12 viral samples. Six 10-fold-dilution steps 
ranging from 1.43 × 103 to 1.43 × 108 copies of the plasmid pAAV-mIL-12 were used to generate the standard 
curve for quantification.  
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Figure 5.6. Expression of mIL-12 by HT1080 cells following transduction with rAAV2-
mIL-12. 
The presence of mIL-12 in the culture supernatant was determined using an IL-12p40 sandwich ELISA and 
expressed as absorbance at the wavelength of 405 nm subtracted by the absorbance at the wavelength of 492 nm. 
(A) Transduction of 1.0 × 105 HT1080 cells with one µl of each of the crude CsCl fractions following 
centrifugation. (B) Transduction of 5.0 × 105 HT1080 cells with purified rAAV2-mIL-12 virus with a MOI of 
1000. Culture supernatants were collected at days 5, 7, 10 and 14. (C) 5.0 × 105 HT1080 cells were transfected 
with either 1 µg of pCl-mIL-12 or control plasmid pcDNA3. After 48 h, the levels of mIL-12 in the culture 
supernatant were measured and served as a positive control for mIL-12 production. 
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Figure 5.7. The production of biologically functional mIL-12 following transduction with 
rAAV2-mIL-12.  
mIL-12 from the culture supernatants of rAAV2-mIL-12 transduced and pCl-mIL-12 transfected HT1080 cells as 
well as murine IL-12p70 standards were captured onto flat bottom ELISA plates coated with anti-IL-12p40 mAb 
(C15.6). Fresh splenocytes from C57BL/6 at a density of 5 × 106 per well supplemented with recombinant mouse 
IL-2 (12.5 U/ml) were cultured in the wells for 48 h, and the concentrations of IFN-γ in the culture supernatants 
were measured by IFN-γ ELISA. (A) mIL-12 standard curve constructed using absorbance at 405 nm following an 
IFN-γ ELISA and the concentration of mIL-12 used to pre-treat the wells. (B) Concentrations of biologically 
active mIL-12 in the culture supernatants of the rAAV2-mIL-12 transduced HT1080 cells.  
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5.2.8 The effects of co-immunisation with rAAV2-mIL-12 on DNA vaccine-
induced CD4+ T cell responses. 
Plasmid delivery of mIL-12 during immunisation enhances both the antigen-specific 
proliferative and IFN-γ producing T cell responses to the vaccine-encoded antigens (Palendira 
et al., 2002, Wozniak et al., 2006a). To examine effects of co-delivery of mIL-12 by rAAV 
virus on the antigen-specific responses to DNA vaccine-encoded antigens, C57BL/6 mice were 
immunised with either the DNA vaccine DNA3-Ag85B-64-ESAT or the control DNA vaccine, 
pcDNA3, with rAAV2-mIL-12, the control rAAV virus, rAAV2-mCherry, or the plasmid, pCl-
mIL-12. The T cell proliferative response was assessed by [3H]-Thymidine incorporation and 
the antigen-specific IFN-γ responses by ELISpot. DNA3-Ag85B-64-ESAT alone induced a 
significant T cell proliferative response (Figure 5.8E). The level of antigen-specific T cell 
proliferation following restimulating with Ag85B was not significantly increased for 
splenocytes from the AAV2-mIL-12 co-immunised mice. There was a significant increase, 
however, in the antigen-specific T cell proliferation in the splenocytes from the pCl-mIL-12 
co-immunised mice (p≤0.05, Figure 5.8A). 
When the splenocytes from immunised mice were stimulated in vitro with Ag85B, the 
frequency of IFN-γ producing cells from the mice immunised with both the DNA3-Ag85B-64-
ESAT and the AAV2-mIL-12 adjuvant was comparable to the effects of that in mice 
immunised with DNA3-Ag85B-64-ESAT alone, at 1 µg/ml and 10 µg/ml (Figure 5.8B and C, 
respectively). By contrast, the frequency of IFN-γ producing cells from mice immunised with 
DNA3-Ag85B-64-ESAT and pCl-mIL-12 was significantly enhanced (p≤0.01) by more than 
two-fold. Interestingly, after 72 h of stimulation with Ag85B at 10 µg/ml, the levels of IFN-γ 
secreted by the splenocytes from mice co-immunised with DNA3-Ag85B-64-ESAT and 
AAV2-mIL-12 were more than 5-times greater (2564 ± 425 pg/ml) than the levels induced by 
the DNA3-Ag85B-64-ESAT vaccine alone (476 ± 98 pg/ml, p≤0.05) and this increase was 
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comparable to that in the pCl-mIL-12 co-immunised group (Figure 5.8D and E). The levels of 
IFN-γ secreted were undetectable in both groups immunised with the pcDNA3 alone or 
pcDNA3 with the control, rAAV-mCherry. 
To examine further the CD4+ T cell responses to the vaccine-encoded antigen, Ag85B, 
splenocytes from the immunised mice were stimulated in vitro with the peptide 25. There was 
no increase in peptide-specific T cell proliferation in mice co-immunised with DNA3-Ag85B-
64-ESAT and rAAV2-mIL-12. There was, however, significantly enhanced antigen-specific T 
cell proliferation in the pCl-mIL-12 co-immunised mice restimulated with 0.3 µg/ml of peptide 
25 (Figure 5.9A). In addition, splenocytes from mice co-immunised with pCl-mIL-12 
demonstrated significantly enhanced antigen-specific IFN-γ responses after 16 h of stimulation 
by IFN-γ ELISpot (p≤0.005) and after 72 h of stimulation by IFN-γ ELISA (p≤0.01) assays. 
There were no peptide-specific IFN- T cell responses in the splenocytes from pcDNA3 and 
the rAAV2-mIL-12 virus immunised mice. Although the frequency of IFN-γ producing cells 
from the rAAV2-mIL-12 co-immunised mice, 113 ± 70 SFC/106 splenocytes, was 3-fold 
higher than in mice immunised with DNA3-Ag85B-64-ESAT alone, 37 ± 23 SFC/106 
splenocytes, this increase was not statistically significant (Figure 5.9B and C). After 72 h of 
stimulation, the splenocytes of rAAV2-mIL-12 co-immunised mice displayed significantly 
enhanced levels of secreted IFN-γ over the mice immunised with DNA3-Ag85B-64-ESAT 
alone, 1876 ± 565 pg/ml and 341 ± 116 pg/ml respectively (p≤0.05) (Figure 5.9D and E). 
 
5.2.9 Effect of co-immunisation with rAAV2-mIL-12 on DNA vaccine-induced 
CD8+ T cells responses. 
The dominant H-2b-restricted CD8+ T cell response to the mycobacterial protein, MPT64, is 
directed at the epitope MPT64190-198. To examine the effect of the adjuvant IL-12 during the 
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priming of CD8+ T cell responses by DNA vaccines, mice were immunised as previously 
described and MPT64190-198-specific CD8+ T cell responses were studied 4-weeks after the final 
immunisation. An IFN--secreting CD8+ T cell response of 242 ± 52 SFC/106 splenocytes 
was observed in the DNA3-Ag85B-64-ESAT immunised mice at 0.3 µg/ml, while no IFN-γ 
producing CD8+ T cells were detected in both the pcDNA3 and the rAAV2-mIL-12 immunised 
controls. The frequencies of MPT64190-198-specific IFN-γ producing CD8+ T cells in mice co-
immunised with rAAV2-mIL-12 and pCl-mIL-12 was more than double that of the mice 
immunised with the DNA vaccine alone (Figure 5.10A). Following peptide stimulation for 72 
h, there were significant increases in levels of secreted IFN- in both the rAAV2-mIL-12 and 
pCL-mIL-12 co-immunised mice compared to the DNA vaccine only control (Figure 5.10C 
and D). 
To study further the effect of co-immunisation with rAAV2-mIL-12 on antigen-specific 
CD8+ T cells generated during DNA immunisation, the frequency of MPT64190-198-specific 
CD8+ T cells were enumerated by direct ex vivo tetramer staining. Immunisation with DNA3-
Ag85B-64-ESAT significantly increased the numbers of H2-Db-MPT64190-198 tetramer+ CD8+ 
cells compared to the pcDNA3 immunised control mice (p≤0.05). The numbers of tetramer 
positive cells in the DNA3-Ag85B-64-ESAT immunised mice was increased by co-
immunisation with rAAV2-mIL-12 from 7.45 × 104 cells/spleen to 1.24 × 105 cells/spleen, 
however, this increase was not statistically significant. Co-immunisation with pCl-mIL-12 
significantly increased the number of H2-Db MPT64190-198 tetramer positive cells to 1.86 × 105 
cells/spleen (p≤0.05, Figure 5.11). 
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Figure 5.8.  The effects of co-immunisation with rAAV2-mIL-12 on DNA vaccine-induced 
Ag85B-specific T cell responses. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, (A) the 
Ag85B-specific T cell proliferation was measured by [3H]-thymidine incorporation, (●) DNA3-Ag85b-64-ESAT 
alone, (■)rAAV2-mIL-12 and (▲)pCl-mIL-12 co-immunised mice, open symbols represent the respective 
controls. The number IFN-γ secreting cells were enumerated by the ELIspot assay following ex vivo stimulation 
with Ag85B at (B) 1 µg/ml and (C) 10 µg/ml. Following 72 h stimulation with Ag85B at (D) 1 µg/ml and (E) 10 
µg/ml, the levels of IFN-γ in the culture supernatants were measured with an IFN-γ ELISA. The data shown are 
the means ± SEM for 4 mice and are representative of two independent experiments. The statistical significance of 
the difference between groups were analysed by one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 5.9. The effects of co-immunisation with rAAV2-mIL-12 on DNA vaccine-induced 
Ag85B-specific CD4+ T cell responses. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, (A) the 
peptide 25-specific T cell proliferation was measured by [3H]-thymidine incorporation, (●) DNA3-Ag85b-64-
ESAT alone, (■)rAAV2-mIL-12 and (▲)pCl-mIL-12 co-immunised mice, open symbols represent the respective 
controls. The number IFN-γ secreting cells were enumerated by the ELIspot assay following ex vivo stimulation 
with peptide 25 at (B) 0.3 µg/ml and (C) 3 µg/ml. Following 72 h stimulation with peptide 25 at (D) 0.3 µg/ml and 
(E) 3 µg/ml, the levels of IFN-γ in the culture supernatant were measured with an IFN-γ ELISA. The data shown 
are the means ± SEM for 4 mice and are representative of two independent experiments. The statistical 
significance of the difference between groups were analysed by one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, 
p≤0.005). 
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Figure 5.10. The effects of co-immunisation with rAAV2-mIL-12 on DNA vaccine-
induced MPT64-specific CD8+ T cell responses. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, the 
number IFN-γ secreting cells were enumerated by the ELIspot assay following ex vivo stimulation with MPT64190-
198 peptide at (A) 0.3 µg/ml and (B) 3 µg/ml. Following 72 h stimulation with MPT64190-198 peptide at (C) 0.3 
µg/ml and (D) 3 µg/ml, the levels of IFN-γ in the culture supernatant were measures with an IFN-γ ELISA. The 
data shown are the means ± SEM for 4 mice and are representative of two independent experiments. The 
statistical significance of the difference between groups were analysed by one-way ANOVA (*, p≤0.05;& **, 
p≤0.01;&***, p≤0.005). 
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Figure 5.11. The effects of co-immunisation with rAAV2-mIL-12 on the frequency of 
MPT64190-98 tetramer-specific CD8+ T cell responses induced by DNA3-Ag85B-64-ESAT. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, 
splenocytes were labeled with α-CD3 and α-CD8 mAbs, and the H2-Db-MPT64190-198 tetramer. (A) A 
representative dot-blot and (B) the total number of H2-Db-MPT64190-198 tetramer positive cells in the spleen. The 
data shown are the means ± SEM for 4 mice and are representative of two independent experiments. The 
statistical significance of the differences were determined by one-way ANOVA, *, p≤0.05. 
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5.2.10 Effects of co-immunisation with rAAV2-mIL-12 on the DNA vaccine-
induced antibody response. 
To investigate the antigen-specific antibody response induced by plasmid DNA immunisation 
and co-delivery of mIL-12 with rAAV, mice were immunised with DNA3-Ag85B-64-ESAT 
alone or co-immunised with either rAAV2-mIL-12 or pCl-mIL-12 and the Ag85B-specific IgG 
titres were determined. Immunisation with DNA3-Ag85B-64-ESAT resulted in a high anti-
Ag85B IgG titre. Co-immunisation with rAAV2-mIL-12 had no effect on the antigen-specific 
IgG titre. By contrast, co-immunisation with pCl-mIL-12 reduced the antigen-specific IgG titre 
significantly (p≤0.05), when compared DNA3-Ag85B-64-ESAT immunisation alone or co-
immunisation with rAAV2-mIL-12. No Ag85B-specifc IgG responses above background were 
detected in mice immunised with pDNA3 alone (Figure. 5.12). This reduction in antibody 
response to the DNA vaccine encoded antigen following co-immunisation with pCl-mIL-12 
has previously been observed with different vaccine antigens (Martin et al., 2003, Palendira et 
al., 2002). 
 
5.2.11 Co-immunisation with rAAV2-mIL-12 and DNA vaccine restores the 
antigen-specific CD4+ T cells responses in IL-12p40-/- mice. 
To examine whether rAAV2-mIL-12 was able to complement and restore the antigen-specific 
T cell responses in IL-12p40 deficient mice during DNA immunisation, IL-12p40-/- mice were 
co-immunised with the DNA vaccine, DNA3-Ag85B-64-ESAT or the control DNA vaccine 
plasmid, pcDNA3, with either rAAV2-mIL-12, control rAAV2-mCherry virus or the plasmid, 
pCl-mIL-12. Four weeks after the final immunisation, splenocytes were harvested and 
stimulated ex vivo with Ag85B (Figure 5.13), peptide 25 (Figure 5.14) or MPT64190-198 peptide 
(Figure 5.15) to recall the vaccine-induced T cell responses. When the splenocytes from IL-
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12p40-/- mice were stimulated with Ag85B at 1 µg/ml or 3 µg/ml, little or no IFN-γ producing 
cells or IFN-γ production could be detected in the pcDNA3 alone, rAAV2-mIL-12 or pCl-mIL-
12 co-immunised mice. Mice immunised with DNA3-Ag85B-64-ESAT alone displayed a 
modest response of 49 ± 18 SFC/106 splenocytes when stimulated with 1 µg of Ag85B per ml. 
This was significantly increased by co-immunisation with rAAV2-mIL-12 and pCl-mIL12 
(Figure 5.13A). A similar effect was observed following stimulation with Ag85B at a 
concentration of 3 µg/ml (Figure 5.13B). Following 3 d of Ag85B stimulation, there were 
modest increases in the level of IFN-γ secretion by the IL12p40-/- mice immunised with 
DNA3-Ag85B-64-ESAT. This response was significantly increased by co-immunisation with 
rAAV2-mIL-12 and pCl-mIL-12 (Figure. 5.13C and D). The increase in the level of IFN-γ was 
comparable between rAAV2-mIL-12 and pCl-mIL-12 co-immunised mice.  
Stimulation of splenocytes with peptide 25 resulted in similar patterns of increased 
IFN-γ responses in both the 16 h ELISpot and the 72 h IFN-γ release assays. There were no 
detectable IFN-γ T cell responses in control mice receiving pcDNA3, rAAV2-mIL-12 and pCl-
mIL-12 co-immunisation. Splenocytes from mice immunised with DNA3-Ag85B-64-ESAT 
responded with frequencies of IFN-γ production at 73 ± 40 and 252 ± 57 SFC/106 splenocytes 
when stimulated with 1 µg/ml and 10 µg/ml of the peptide, respectively (Figure 5.14A and B). 
The rAAV2-mIL-12 co-immunised mice displayed a greater than 2-fold increase in the 
frequency of peptide-specific IFN-γ secreting T cells at both stimulation concentrations, while 
co-immunisation with pCl-mIL-12 only displayed an enhanced antigen-specific response when 
stimulated with 1 µg/ml of peptide 25 (Figure. 5.14A). Following 72 h stimulation with peptide 
25, both rAAV2-mIL-12 and pCl-mIL-12 co-immunised mice demonstrated detectable level of 
peptide-specific IFN-γ secretion. There are no detectable IFN-γ responses in DNA3-Ag85B-
64-ESAT recipients. By contrast, mice co-immunised with rAAV2-mIL-12 and pCl-mIL-12 
showed moderately strong IFN-γ responses (Figure. 5.14C and D). 
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The vaccine-specific proliferative response was measured after 72 h of stimulation with 
either Ag85B (Figure 5.15E and F) or peptide 25 (Figure 5.14E ad F). There were minimal 
levels of proliferation in response to Ag85B stimulation and no proliferative response to 
peptide 25 in the DNA3-Ag85B-64-ESAT-immunised mice. Co-immunisation with rAAV2-
mIL-12 significantly increased the Ag85B-specific proliferative response at 1 µg/ml (p≤0.05, 
Figure 5.13E). Co-immunisation with DNA3-Ag85B-64-ESAT and rAAV2-mIL-12 or pCl-
mIL-12 restored the proliferative response to peptide 25, which was absent in the DNA3-
Ag85B-64-ESAT recipient mice (Figure 5.14E and F). 
 
5.2.12 Co-immunisation with rAAV2-mIL-12 and DNA vaccine enhances the 
antigen-specific CD8+ T cells responses in IL-12p40-/- mice. 
The CD8+ T cell responses were also assessed in IL-12p40 deficient mice following co-
immunisation with rAAV2-mIL-12 and DNA3-Ag85B-64-ESAT. Splenocytes from 
immunised mice were stimulated with the H2-Db-restricted CD8+ T cell epitope, MPT64190-198 
at both 1 µg/ml and 10 µg/ml and the peptide-specific T cell responses were measured at 16 h 
and 72 h by IFN-γ ELIspot and ELISA, respectively. The IL-12p40 deficient mice developed a 
strong peptide-specific CD8+ T cell response, and this was not further enhanced by co-delivery 
with rAAV2-mIL-12 or pCl-mIL-12. The peptide-specific IFN-γ response was 1247 ± 17 
SFC/106 splenocytes in the DNA3-Ag85B-64-ESAT immunised mice following stimulation 
with MPT64190-198 peptide at 1 µg/ml (Figure 5.15A). Mice co-immunised with DNA3-Ag85B-
64-ESAT and rAAV2-mIL-12 or pCl-mIL-12 displayed comparable responses of 1128 ± 47 
SFC/106 and 1405 ± 86 SFC/106 splenocytes, respectively (Figure. 5.15B).  
Following 72 h of stimulation with the MPT64190-198 peptide at 1 µg/ml, splenocytes from the 
DNA3-Ag85B-64-ESAT immunised mice released significant levels of IFN-γ into the culture 
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supernatant, and the levels were similar in mice co-immunised with rAAV2-mIL-12 and pCl-
mIL-12, at 1859 ± 394 pg/ml and 1200 ± 220 pg/ml of IFN-γ, respectively (Figure. 5.15C). 
The same patterns of IFN-γ producing cells and secretion were observed following stimulation 
with 10 µg/ml of the MPT64190-198 peptide (Figure. 5.15D). There were no responses in mice 
receiving rAAV2-mIL-12 and pCl-mIL-12 without the DNA vaccine. 
 
5.2.13 Effects of co-immunisation with rAAV2-mIL-12 on the protective efficacy 
of the DNA vaccine against M. tuberculosis. 
To assess whether the effects of rAAV2-mIL-12 co-delivery with the DNA vaccine translated 
to enhanced protective efficacy, C57BL/6 mice were immunised as described above, along 
with mice that had received s.c. immunisation with BCG, which served as the positive control. 
The immunised mice were challenged with aerogenic M. tuberculosis six weeks following the 
final immunisation. The bacterial loads of the mice immunised DNA3-Ag85B-64-ESAT alone 
were significantly reduced by 0.62 Log10 in the lungs and 1.16 Log10 in the spleen, p≤0.0001 
and p≤0.001, respectively when compared to mice which had received pcDNA3 immunisation 
(Figure 5.16). Co-immunisation with rAAV2-mIL-12 or pCl-mIL-12 did not result in a further 
increase in protective efficacy compared to the DNA3-Ag85B-64-ESAT vaccine alone. 
Interestingly, co-immunisation of pcDNA3 with pCl-mIL-12 resulted in a significant reduction 
in bacterial numbers of 0.35 Log10 (p≤0.001, Figure 5.16A) in the lungs compared to recipients 
of pcDNA3 alone. Immunisation with BCG reduced the bacterial loads significantly by 0.92 
Log10 in the lungs and 1.65 Log10 in the spleen (Figure. 5.16). Therefore the DNA3-Ag85B-64-
ESAT vaccine conferred significant protection against pulmonary and disseminated M. 
tuberculosis infection, and although both the plasmid- and rAAV-delivered IL-12 increased 
Chapter 5. Delivery of mIL-12 by rAAV as an adjuvant for anti-TB vaccines 
 
174 
CD4+ and CD8+ T cell responses to the vaccine-encoded antigens, this was not sufficient to 
increase the protective efficacy of this DNA vaccine. 
 
5.2.14 Effects of co-immunisation with rAAV2-mIL-12 and DNA vaccine on the 
T cell responses to M. tuberculosis infection. 
Successful immunisation with subunit DNA vaccines encoding mycobacterial antigens results 
in increased T cell responses to the vaccine-encoded antigens following M. tuberculosis 
challenge. To test whether co-delivery of rAAV2 encoding mIL-12 at the time of DNA 
immunisation resulted in increased T cell responses to the vaccine-encoded antigens in IL-
12p40-deficient mice, IFN- T cell responses to the vaccine-encoded antigens were assessed 
post-challenge in the MLN, lungs and spleen. 
The antigen-specific T cell responses in the draining lymph nodes were assessed at the 
peak of infection, four-weeks after aerogenic M. tuberculosis challenge. When the MLN cells 
were stimulated for 16 h with 3 µg/ml of Ag85B, the DNA3-AG85B-64-ESAT-immunised 
mice responded to the Ag85B stimulation, with a frequency of 390 ± 131 SFC/106 cells, 
however the largest response in IFN-producing cells was observed in the mice co-immunised 
with DNA3-Ag85B-64-ESAT and rAAV2-mIL-12 (Figure 5.17A). Interestingly, those mice 
co-immunised with pCL-mIL-12 displayed lower frequencies of IFN-γ producing cells in the 
draining lymph node (Figure 5.17). Mice immunised with pcDNA3 alone, or co-immunised 
with pcDNA3 and either rAAV2-mIL-12 or pCl-mIL-12 responded with no more than 198 ± 
69 SFC/106 cells, while interestingly Ag85B-specific responses were undetectable in the BCG 
immunised mice. Similar responses were observed when the cells were stimulated with either 1 
µg/ml of peptide 25 or 10 µg/ml of M. tuberculosis CFP (Figures 5.18B and D, respectively).  
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When the cells from the MLN were stimulated with 1 µg/ml of MPT64190-198, the 
frequencies of peptide-specific IFN-γ production were 53 ± 23 and 55 ± 11 SFC/106 cells in the 
mice immunised with DNA3-Ag85B-64-ESAT alone and pCl-mIL-12 co-immunised mice, 
respectively. Mice which had received rAAV2-mIL-12 co-immunisation resulted in an increase 
in the CD8+ T cell IFN- γ response of more than three-fold to 175 ± 56 SFC/106 cells (p≤0.01). 
No peptide-specific responses were detected in the pcDNA3 alone, or either IL-12 adjuvant co-
immunised mice (Figure 5.17C). 
In the lungs, IL-12p40-/- mice immunised with the DNA vaccine alone did not prime for 
enhanced CD4+ T cell responses to Ag85B (Figure 5.18A), or peptide 25 (Figure 5.18B). There 
was a trend for co-immunisation with rAAV2-mIL-12 and pCl-mIL-12 to increase the 
frequency of IFN--producing cells in response to stimulation with 3 µg/ml of Ag85B Figure 
5.18A). Following stimulation with peptide 25, plasmid mIL-12 co-immunisation also led to a 
significant increase in the frequency of IFN- producing cells (p≤0.01 Figure 5.18B). Co-
immunisation with pCl-mIL-12 alone resulted in an increase in the frequency of responding 
cells to M. tuberculosis CFP stimulation (Figure 5.18D). By contrast, stimulation of the 
pulmonary cell suspension with 1 µg/ml of MPT64190-198 resulted in strong peptide-specific 
IFN-γ responses in both the DNA3-Ag85B-64-ESAT alone and the DNA3-Ag85B-64-ESAT 
and rAAV2-mIL-12 or pCl-mIL-12 co-immunised mice. Co-immunisation with the IL-12 
producing adjuvants did not result in further increases to the T cell responses induced by the 
DNA vaccine. No detectable IFN-γ-secreting cells were detected in the pcDNA3 alone or those 
co-immunised with pcDNA3 and the IL-12 adjuvants (Figure 5.18C). 
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Figure 5.12. The effects of co-immunisation with rAAV2-mIL-12 on DNA vaccine-
induced Ag85B-specific IgG antibody responses. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, blood 
was collected by cardiac puncture, and the Ag85B-specific antibody titres in the sera was determined by an IgG 
ELISA. The data represent the means for the log10 IgG titres for sera pooled from 4 mice in each group tested in 
triplicate and are representative of two independent experiments. The statistical significance of the differences 
between groups were analysed by one-way ANOVA (*, p≤0.05;&**, p≤0.01). 
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Figure 5.13. Co-immunisation with rAAV2-mIL-12 restored IFN-γ-secreting T cell 
responses against Ag85B in IL-12p40-/- mice immunised with DNA3-Ag85B-64-ESAT. 
IL-12p40-/- mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-
mIL-12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as 
the positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, 
splenocytes were stimulated ex vivo with Ag85B at (A) 1 µg/ml or (B) 3 µg/ml and the number IFN-γ secreting 
cells were enumerated by the ELIspot assay. Following 72 h stimulation with Ag85B at (C) 1 µg/ml or (D) 3 
µg/ml the levels of IFN-γ in the culture supernatant were measured with an IFN-γ ELISA and the Ag85B-specific 
T cell proliferation was measured by [3H]-Thymidine incorporation following antigen stimulation at both 
concentrations (E and F, respectively). The data shown are the means ± SEM for 4 mice and are representative of 
two independent experiments. The statistical significance of the differences between groups were analysed by 
one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 5.14. Co-immunisation with rAAV2-mIL-12 restored the IFN-γ-secreting CD4+ T 
cell responses against Ag85B240-254 in IL-12p40-/- mice immunised with DNA3-Ag85B-64-
ESAT.  
IL-12p40-/- mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-
mIL-12 or the negative control, rAAV2-mCherry virus. Mice were co-immunisation with the plasmids pCl-mIL-
12 as positive control and pcDNA3 as negative plasmid control. Four weeks following the final immunisation, 
splenocytes were stimulated ex vivo with peptide 25 at (A) 1 µg/ml or (B) 10 µg/ml and the number IFN-γ 
secreting cells were enumerated by the ELIspot assay. (C) Following 72 h stimulation with peptide 25 at 1 µg/ml 
the levels of IFN-γ in the culture supernatant were measured with an IFN-γ ELISA, (C) following stimulation with 
10 µg/ml of peptide 25 and (D) the peptide 25-specific T cell proliferation following stimulation with 1 µg/ml or 
(F) 10 µg/ml of peptide 25 was measured by [3H]-Thymidine incorporation,. The data shown are the means ± 
SEM for 4 mice and are representative of two independent experiments. The statistical significance of the 
differences between groups were analysed by one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
  
Chapter 5. Delivery of mIL-12 by rAAV as an adjuvant for anti-TB vaccines 
 
180 
 
  
Chapter 5. Delivery of mIL-12 by rAAV as an adjuvant for anti-TB vaccines 
 
181 
 
Figure 5.15. Co-immunisation with rAAV2-mIL-12 did not increase the IFN-γ-secreting 
CD8+ T cell responses against MPT64 in IL-12p40-/- mice immunised with DNA3-Ag85B-
64-ESAT.. 
IL-12p40-/- mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-
mIL-12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmid pCl-mIL-12 as 
positive control and pcDNA3 as negative plasmid control. Four weeks after the final immunisation, the number 
IFN-γ secreting cells in the spleen were enumerated by the ELIspot assay following stimulation ex vivo with 
MPT64190-198 peptide at (A) 1 µg/ml or (B) 10 µg/ml. The levels of IFN-γ in the culture supernatant were 
measured by IFN-γ ELISA following stimulation with MPT64190-198 peptide at (C) 1 µg/ml or (D) 10 µg/ml for 72 
h.. The data shown are the means ± SEM for 4 mice and are representative of two independent experiments. The 
statistical significance of the differences between groups were analysed by one-way ANOVA (*, p≤0.05;& **, 
p≤0.01;&***, p≤0.005). 
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Figure 5.16. Co-immunisation with rAAV2-mIL-12 did not increase the protective 
efficacy of DNA3-Ag85B-64-ESAT against M. tuberculosis infection. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry virus. Mice were co-immunised with the plasmids pCl-mIL-12 as the 
positive control and pcDNA3 as negative plasmid control. Mice were rested for six weeks following the final 
immunisation and then challenged with aerosol M. tuberculosis H37Rv. BCG-immunised mice received 106 cfu 
s.c. 12 weeks before challenge with M. tuberculosis. Four weeks later, the bacterial loads in (A) the lungs and (B) 
the spleen were enumerated. The data shown are the means ± SEM for 5 mice and are representative of two 
independent experiments. The statistical significance of the differences between groups were analysed by one-way 
ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 5.17. Co-immunisation with rAAV2-mIL-12 increases antigen-specific IFN-γ-
secreting T cell responses in the draining lymph nodes of M. tuberculosis-infected mice. 
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry. Mice were also co-immunised with the plasmid pCl-mIL-12 as 
positive control or pcDNA3 as negative plasmid control, rested for six weeks and then challenged with aerogenic 
M. tuberculosis H37Rv. BCG-immunised mice received 106 cfu s.c. 12 weeks before challenge with M. 
tuberculosis. Four weeks later, the MLN were harvested and stimulated ex vivo with (A) Ag85B at 3 µg/ml, (B) 
peptide 25 at 1 µg/ml, (C) MPT64190-198 at 1 µg/ml and (D) CFP at 3 µg/ml, and the number IFN-γ-secreting cells 
were enumerated by the ELIspot assay. The data shown are the means ± SEM for 5 mice and are representative of 
two independent experiments. The statistical significance of the differences between groups were analysed by 
one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 5.18. Co-immunisation with rAAV2-mIL-12 increases antigen-specific IFN-γ-
secreting T cell responses in the lungs of M. tuberculosis-infected mice.  
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry. Groups of mice were also co-immunised with the plasmid pCl-mIL-
12 as the positive control or pcDNA3 as negative plasmid control, rested for six weeks and then challenged with 
aerogenic M. tuberculosis H37Rv. Four weeks later, the right superior lobe of the lung was harvested and the cells 
stimulated ex vivo with (A) Ag85B at 3 µg/ml, (B) peptide 25 at 1 µg/ml, (C) MPT64190-198 at 1 µg/ml and (D) 
CFP at 3 µg/ml, and the number IFN-γ-secreting cells were enumerated by the ELIspot assay. The data shown are 
the means ± SEM for 5 mice and are representative of two independent experiments. The statistical significance of 
the differences between groups were analysed by one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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Figure 5.19. Co-immunisation with rAAV2-mIL-12 did not increase antigen-specific IFN-
γ-secreting T cell responses in the spleen of M. tuberculosis-infected mice.  
C57BL/6 mice were co-immunised at two weekly intervals with DNA3-Ag85B-64-ESAT and either rAAV2-mIL-
12 or the negative control, rAAV2-mCherry. Groups of mice were also co-immunised with the plasmid pCl-mIL-
12 as the positive control or pcDNA3 as negative plasmid control, rested for six weeks and then challenged with 
aerogenic M. tuberculosis H37Rv. BCG-immunised mice received 106 cfu s.c. 12 weeks before challenge with M. 
tuberculosis. Four weeks later, the spleens were harvested and stimulated ex vivo with (A) Ag85B at 3 µg/ml, (B) 
peptide 25 at 1 µg/ml, (C) MPT64190-198 at 1 µg/ml and (D) CFP at 3 µg/ml, and the number IFN-γ-secreting cells 
were enumerated by the ELIspot assay. The data shown are the means ± SEM for 5 mice and are representative of 
two independent experiments. The statistical significance of the differences between groups were analysed by 
one-way ANOVA (*, p≤0.05;&**, p≤0.01;&***, p≤0.005). 
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When splenocytes of M. tuberculosis-infected mice were restimulated with 3 µg/ml of 
Ag85B, Mice immunised with DNA3-Ag85B-64-ESAT had a frequency of IFN- production 
of 1145 ± 271 SFC/106 splenocytes (Figure 5.19A). The antigen-specific response was further 
increased to 1924 ± 241 SFC/106 splenocytes in mice co-immunised with DNA3-Ag85B-64-
ESAT and pCl-mIL-12. By contrast, no increase in IFN-γ producing cells was observed in 
mice co-immunised with DNA3-Ag85B-64-ESAT and rAAV2-mIL-12. Immunisation with 
pcDNA3 alone or co-immunisation with pcDNA3 and rAAV2-mIL-12 or pCl-mIL-12 resulted 
in lower frequencies of IFN- producing cells , which were less than 508 ± 115 SFC/106 
splenocytes, than recipients of the DNA3-Ag85B-64-ESAT vaccine (Figure 5.19A). Mice 
immunised with BCG displayed undetectable antigen-specific IFN- responses to all antigen 
used for stimulation (Figure 5.19). When splenocytes from these same infected mice were 
restimulated with either peptide 25 (Figure 5.19B) or M. tuberculosis CFP (Figure 5.19D), 
splenocytes from mice immunised with DNA3-Ag85B-64-ESAT alone or co-immunised with 
pCl-mIL-12 resulted in measurable antigen-specific IFN-γ responses above controls, while 
mice co-immunised with DNA3-Ag85B-64-ESAT and rAAV2-mIL-12 resulted in diminished 
antigen-specific IFN-γ responses (Figure 5.19B). 
Following stimulation with the MPT64190-198 peptide a weak response was seen in the 
splenocytes of mice immunised with DNA3-Ag85B-64-ESAT alone. Interestingly, co-
immunisation with rAAV2-mIL-12 increased the response more than five-fold to 499 ± 158 
SFC/106 splenocytes and co-immunisation with pCl-mIL-12 further increased the response 
significantly to 1133 ± 265 SFC/106 splenocytes (p≤0.01, Figure 5.19C). 254 ± 64 SFC/106 
splenocytes of IFN-  production was observed in the pcDNA3 and pCl-mIL-12 co-
immunised mice. 
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5.2.15 Intranasal delivery of rAAV2-mIL-12. 
One of the advantages of the rAAV system is their broad range of tissue specificity (Zincarelli 
et al., 2008). Intranasal (i.n.) delivery of rAAV2 results in successful transduction of the 
bronchial epithelium, and therefore pulmonary delivery of rAAV2-mIL-12 should increase the 
expression of IL-12 at the site of M. tuberculosis infection and therefore enhance the host T 
cell response to clear the infection. To test whether i.n. administration of rAAV2-mIL-12 
results in production of IL-12, both C57BL/6 and IL-12p40-/- mice were inoculated by the i.n. 
route with 1011 vg of either rAAV2-mIL-12 or the control virus, rAAV2-ARAP4, and the 
levels of IL-12p40 in the serum were measured by an IL-12p40 ELISA over the following 
three weeks (Figure 5.20). The levels of IL-12p40 in the WT mice were all greater than 2000 
pg/ml, and WT mice treated with i.n. rAAV2-mIL-12 did not show a significant increase in 
serum IL-12 compared to WT mice treated with i.n. rAAV2-ARAP4, with the exception of day 
7, when the serum IL-12p40 levels in rAAV2-mIL-12-treated WT mice (2677 ± 271 pg/ml) 
were higher than those treated with the control virus (1708 ± 67 pg/ml). 
 As expected, the baseline levels of IL-12p40 in the serum of IL-12p40-/- mice were low, 
and treatment with i.n. rAAV2-mIL-12, but not the control virus, significantly increased the 
serum levels of IL-12p40 to 796.18 ± 123.28 pg/ml at 14 days post-treatment (p≤0.001). The 
serum IL-12p40 level was further increased to 971.72 ± 143.45 pg/ml at 21 days post-treatment 
(p≤0.05). Therefore, IL-12 was produced in vivo following i.n. inoculation of rAAV2-mIL-12. 
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Figure 5.20. Intranasal administration of rAAV2-mIL-12 partially restores the level of Il-
12p40 in the sera of IL-12p40-/- mice. 
1011 vg of rAAV2-mIL-12 or the control rAAV2 virus were delivered to male C57BL/6 (black lines) and IL-
12p40-/- (Red lines) mice by intranasal administration. Blood were collected weekly at days 1, 7, 14 and 21, and 
the serum samples were stored at -30˚C. The levels of IL-12p40 in the sera were measured by an IL-12p40 ELISA. 
The data shown are the means ± SEM for 5 mice. The statistical significance of the differences between treated 
and untreated groups were analysed by the Student’s t-test (*, p≤0.05;&***, p≤0.005). 
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5.2.16 The effects of intranasal delivery of rAAV2-mIL-12 on T cell responses to 
M. tuberculosis infection. 
To determine whether i.n. administration of rAAV2-mIL-12 to the lungs will enhance the 
cellular response to M. tuberculosis infection. C57BL6 mice were inoculated with 1011 vg of 
rAAV2-mIL-12 or control rAAV2-mCherry virus five days prior to aerogenic M. tuberculosis 
infection, rested for 42 days and then the levels of M. tuberculosis-specific IFN-γ responses 
and the bacterial burden in the lungs and the spleen were determined. Cells harvested from the 
lungs, MLN and spleen were stimulated with M. tuberculosis CFP, peptide 25 or the CD8+ 
epitope, TB10.44-11. Treatment with rAAV2-mIL-12 prior to M. tuberculosis challenged had no 
impact on the frequency of IFN-γ-producing cells to these antigens in the lungs, MLN and 
spleen (Figure 5.21). The response to the M. tuberculosis dominant CD8+ T cell epitope, 
TB10.4190-198, was high in both the lungs and the spleen (Figure 5.21B and C). An increase in 
the amount of IFN-γ secreted into the culture supernatant was also observed in the spleen 
following 72 h stimulation with CFP and peptide 25 (Figure 5.21D).  
 The effect of i.n. administration of rAAV2-mIL-12 five days before aerosol challenge 
with M. tuberculosis on the bacterial load was examined. There was a small, but significant, 
reduction in bacterial numbers in both the lungs and the spleen six weeks post-challenge. The 
mean bacterial burden in the lung was reduced by 19,750 CFU in the rAAV2-mIL-12 treated 
mice (p≤0.01, Figure 5.22A). Similar decreases in the bacterial burden were also observed in 
the spleens of infected mice. The mean bacterial load was reduced from 24,800 ± 2,689 CFU in 
the spleens of the control rAAV2 treated mice to 15,520 ± 2,670 CFU in the spleens of 
rAAV2-mIL-12 treated mice (p≤0.01, Figure 5.22B). Therefore, prior administration of 
rAAV2-mIL-12 before M. tuberculosis infection resulted in a small reduction in the bacterial 
load in the lungs.  
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Figure 5.21. Intranasal administration of rAAV2-mIL-12 does not increase the antigen-
specific IFN-γ-secreting T cell  responses during infection with M. tuberculosis.  
1011 vg of rAAV2-mIL-12 or the control rAAV2 virus were delivered to C57BL/6 mice by intranasal 
administration 5 days before infection with aerogenic M. tuberculosis H37Rv. Six weeks after infection, the MLN, 
Spleen and right superior lobe of the lung were harvested, and cellular homogenates were stimulated in vitro with 
10 µg/ml of peptide 25, TB10.44-11 or CFP and 3 µg/ml of Con A as the positive control. The number of antigen-
specific IFN-γ producing cells in (A) the lungs, (B) MLN and (C) the spleen were enumerated by an IFN-γ 
ELIspot. (D) The levels of IFN-γ secreted by splenocytes were measured following 72 h of antigenic stimulation 
with an IFN-γ ELISA. The data shown are the means ± SEM for 5 mice. The statistical significance of the 
differences between groups were analysed by the Student’s t-test. 
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Figure 5.22. Intranasal administration of rAAV2-mIL-12 does reduce the bacterial 
burden following infection with M. tuberculosis.  
1011 vg of rAAV2-mIL-12 or the control rAAV2 virus were delivered to C57BL/6 mice by intranasal 
administration 5 days before infection with aerogenic M. tuberculosis H37Rv. Six weeks after infection, the 
bacterial loads in (A) the lungs and (B) the spleen were enumerated. The data shown are the means ± SEM for 5 
mice. The statistical significance of the difference between groups were analysed by the Student’s t-test, *, p≤0.05.&
& &
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5.3 Discussion 
The importance of the adaptive immunity in the host response to mycobacterial infections is 
well established; in particular, the necessity for Th1 type CD4+ T cells in orchestrating multiple 
arms of the adaptive immune response against the invading pathogen. The production of IL-12 
by infected DC not only stimulates the secretion of IFN-γ by surrounding NK cells (Feng et al., 
2006), but also initiates the differentiation of naïve CD4+ T cells and encourages their 
development into Th1 T cells. Subsequently, the activated T cells are recruited to the sites of 
infection and secrete IFN-γ, TNF-α and LT-α to activate macrophages for the killing of the 
invading pathogens. Thus both IL-12 and IFN-γ are essential cytokines for the control of TB in 
mice and humans. The delivery of exogenous IL-12 by plasmid co-immunisation has 
previously been shown to significantly increase antigen-specific IFN-γ secretion and T cell 
proliferation in anti-TB DNA vaccine-immunised C57BL/6 mice. In those experiments, an 
increase in the protective efficacy of the DNA vaccine was also observed (Palendira et al., 
2002, Wozniak et al., 2006b). In addition, the co-delivery plasmid mIL-12 into IL-12p40-/- 
mice with anti-TB DNA vaccine restored both antigen-specific T cell responses and protective 
efficacy to levels close to those in DNA vaccine-immunised WT mice (Wozniak et al., 2006a). 
In this study, the genes encoding the p35 and p40 subunits of mIL-12 linked by the 
FMDV 2A self-cleaving peptide were cloned into the plasmid, pAAV-ARAP4, for the 
production of rAAV2-mIL-12. It was hypothesised that the sustained expression of the rAAV-
encoded IL-12 during DNA immunisation may be superior to the transitory expression of mIL-
12 from a plasmid DNA vector. The availability of the rAAV2-mIL-12 also allowed the 
assessment of pulmonary delivery of mIL-12 as an immune-modulating therapy during 
experimental M. tuberculosis infection in order to enhance immune responses in the lung and 
the clearance of the invading pathogen. 
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The transfection of HEK293T cells with the pAAV2-mIL-12 plasmid construct resulted in the 
detection of the p40 subunit of mIL-12 in the culture supernatant. Even though the expression 
of mIL-12 from the pAAV2-mIL-12 is driven by the RSV promoter and expression from pCl-
mIL-12 is driven by the CMV IE promoter, the levels of IL-12 in the supernatants of pAAV2-
mIL-12 transfected cells were similar to those following transfection of HEK293T cells with 
pCl-mIL-12. The RSV promoter was reported to have lower expression than the CMV IE 
promoter in vivo following delivery by plasmid DNA (Ponder et al., 1991). While this was not 
observed in the in vitro transfection experiments in this study, this may be due to the saturating 
concentration of plasmid DNA and high efficiency of cell transfection using the calcium 
phosphate. To characterise the function of the rAAV virus, large-scale packaging of the 
recombinant virus was achieved through transfection of HEK293T cells with three plasmids 
encoding the pAAV2-mIL-12 genome, AAV structural proteins and the adenovirus helper 
elements. Multiple enrichment and purification steps were required to obtain pure preparations 
of rAAV from the crude cellular lysate, because majority of the virus is retained in the 
cytoplasm after virus assembly. The conventional stepwise ammonium sulphate precipitation 
followed by multiple rounds of CsCl gradient centrifugation was used. The presence of AAV 
in the CsCl fractions was detected a targeted PCR assay using primers-specific for the mIL-12 
DNA sequence, and this was confirmed by in vitro transduction of HT1080 cells. Both the 
precipitation and gradient centrifugations steps introduce some loss and/or inactivation of viral 
particles.  
qPCR was used to quantify the rAAV2 particles, and the viral titre was calculated from 
a standard curve constructed from the amplification of plasmid samples of known copy 
numbers and molecular weight (Figure 5.5). One limitation of using molecular methods of 
quantification is that this quantifies the rAAV in terms of genome containing viruses rather 
than the infectious titre. Conventionally, infectious viral titres were obtained through 
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determining the plaque forming units. rAAV however, lacks the ability to form plaques during 
productive replication. One way to obtain the infectious titre is to assay transgene expression in 
the transduced cells after transduction with decreasing dilutions of the viral stock. The mIL-12 
in our construct was not fused or tagged to a fluorescent protein marker, and this makes the 
accurate detection of the transgene expression technically difficult. While determining the 
infectious titre is beneficial, qPCR remained the most suitable and reproducible method for 
virus quantification for this study.  
Detectable levels of mIL-12 were observed in the culture supernatants of HT1080 cells 
five days after transduction with purified rAAV2-mIL-12 virus. The levels of mIL-12 in the 
culture supernatants increased significantly to day 14 after transfection (Figure 5.6B), but still 
remained lower than the levels observed following cellular transfection with pCl-mIL-12. The 
delay in transgene expression may be attributed to the kinetics of AAV transduction, while the 
lower mIL-12 expression may be caused by both the slower AAV kinetics of transgene 
expression and promoter activity of the RSV promoter. One possible rate-limiting step for 
transgene expression following AAV transduction is the necessity for second strand synthesis 
following uncoating of the virion and transport to the cell nucleus (Thomas et al., 2004). 
Although expression of mIL-12 following rAAV transduction was less than after transfection 
with pCl-IL-12, the mIL-12 expressed by the transduced cells clearly displayed biological 
activity. The ability of the mIL-12 from the rAAV-transduced cells to induce IFN-γ production 
by splenocytes was comparable to the effect of mIL-12 produced by the pIL-12-transfected 
cells (Figure 5.7). The levels of IFN-γ induced were also consistent with the levels of IL-12p40 
measured in the culture supernatants of the transduced cells (Figure 5.7B).  
Co-delivery of rAAV2-mIL-12 as an adjuvant during plasmid DNA immunisation 
provided a promising trend for increased T cell proliferation, frequencies of antigen-specific 
IFN-γ-secreting cells and IFN-γ production following stimulation with Ag85B or the dominant 
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IAb-restricted CD4+ T cell epitope, peptide 25. These effects on the CD4+ T cell response were 
statistically significant only at some antigen concentrations, for example with Ag85B at 10 
µg/ml (Figure 5.8C) and peptide 25 at 3 µg/ml (Figure 5.9C). The co-immunised mice also 
showed trends for increased numbers of MPT64190-198-specific CD8+ T cells and IFN-γ 
production on restimulation with MPT64190-198 (Figure 5.10A and D). Nevertheless, the effects 
of co-immunisation with rAAV2-mIL-12 on both CD4+ and CD8+ T cell responses were not as 
consistent or significant as those of pCl-mIL-12 plasmid when used as an adjuvant for DNA3-
Ag85B-64-ESAT6. There are a number of possible explanations for the fact rAAV2-mIL-12 
was less effective than pCl-mIL-12 for increasing CD4+ and CD8+ T cell responses to the 
vaccine-encoded antigens; first, the level of transgene expression follow rAAV transduction; 
second, the kinetics of transgene expression; third, the tissue tropism of rAAV transduction and 
fourth, inactivation of the infectious potential of rAAV particles during purification. 
The expression of mIL-12 from the rAAV construct was driven by the RSV promoter 
(Figure 5.1). The rationale behind this choice of promoter for gene expresseion was that the 
RSV promoter has been reported to provide more sustained transgene expression than the 
CMV IE promoter (Chen et al., 2008). The levels of transgene expression driven by the RSV 
promoter was reported to be lower than those driven by the CMV EI promoter with other 
transgenes (Arita et al., 2008, Chen et al., 2008). One way to increase the transgene expression 
in recombinant viral expression systems is to include the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) into the expression cassette. This WPRE is a cis-
acting element and has been demonstrated to exploit the CRM-1-dependent nuclear export 
pathway to enhance expression from various promoters including the RSV promoter (Loeb et 
al., 1999).  
The rAAV vector and plasmid DNA are inherently different gene delivery vectors, with 
different modes of genetic transfer and gene expression mechanisms. Intramuscular injection of 
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plasmid DNA is an established method of gene transfer for both gene therapy and genetic 
immunisation. Although the exact mechanism for cell entry of the plasmid and expression of 
the plasmid-encoded transgene has not been fully elucidated, transgene mRNA from 
intramuscular injected plasmid DNA has been detected as early as day seven, and the 
expression of the protein was detected up to 45 d post-injection (Leger et al., 2011). By 
contrast, the mechanisms of cellular transduction and gene expression by AAV vectors are 
better understood. In order for transgene expression to occur in the rAAV-transduced cell, a 
series of key events are initiated following cellular binding; this includes cellular entry and 
uncoating of the viral capsid and intracellular trafficking to the nucleus where second-strand 
synthesis of the rAAV transcript occurs (Thomas et al., 2004). Each of these steps may present 
an obstacle for gene expression following cellular transduction by rAAV. In addition to 
second-strand DNA synthesis, which has been deemed the rate-determining step, both nucleus 
transport and capsid uncoating are bottlenecks for transgene expression after rAAV 
transduction. Experiments using rAAVs expressing GFP under the control of the CMV 
promoter determined that the peak of GFP expression is 22 d post-injection, with expression 
lasting for more than 80 d (Zincarelli et al., 2008). In another study there was no detectable 
expression of luciferase driven by the CMV promoter from AAV2 until 29 d post-injection 
(Zincarelli et al., 2008). Given the different onset of transgene expression following treatment 
with plasmid DNA and rAAV, the expression of mIL-12 after rAAV2-mIL-12 co-
immunisation may have been temporally mismatched with the expression of the fusion protein 
from DNA3-Ag85B-64-ESAT. One way to overcome this is to perform co-immunisation with 
rAAV expressing the vaccine antigen and rAAV2-mIL-12 or to use rAAV that co-expresses 
both the antigen cassette and mIL-12 in order to ensure synchronised expression of the two 
components after immunisation. Alternatively, the onset of mIL-12 expression could be 
accelerated by the adoption of self-complementing rAAV (scAAV) constructs. These scAAV 
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initiate intramolecular base-pairing following capsid uncoating, and abolish the rate-
determining step of second-strand DNA synthesis (McCarty et al., 2003). Intramuscular 
delivery of scAAV encoding GFP displayed strong GFP expression within one week post-
injection, and after two weeks the GFP expression from the scAAV-transduced muscles was 50 
times greater than the GFP expressed from tissue transduced with standard rAAV (Wang et al., 
2003). The type of cell within the muscle tissue, which are transduced by the rAAV and 
produce the encoded mIL-12, may differ significantly from the cells, which are transiently 
transfected by the plasmid DNA. In the current study, the fate of the injected rAAV was not 
characterised. Although the serotype 2 rAAV used in the current study is able to transduce a 
wide range of cell and tissue types (Summerford and Samulski, 1998), the tissue tropism for 
transduction may be an important factor in determining both the spatial distribution and the 
level of expression of IL-12. DCs, in particular, are the main source of IL-12 production during 
normal infections. Intramuscular injection of rAAV has been reported to result in relatively 
poor transduction of APC (Jooss et al., 1998). In a contrasting study, however, efficient 
transduction and expression of the encoded transgene followed ex vivo transduction of human 
monocyte-derived DCs. These studies outline the importance of efficient viral transduction in 
order to obtain phenotypic changes in vivo. In addition, the levels of expression driven from the 
RSV promoter were found to be variable in different transduced cell types (Maass et al., 2003). 
While tissue tropism and promoter activity is important for rAAV-mediated transgene 
expression, there remains a possibility that some of the rAAV viruses injected were inactivated 
during the purification procedure, resulting in the delivery of a lower than expected amount of 
functional viral particles. More recently, iodixanol has been used as an alternative density 
medium for small-scale rAAV purifications. Iodixanol has a much lower toxicity compared to 
CsCl; it also prevents aggregation of rAAV particles and does not reduce infectivity 
(Auricchio et al., 2001). Alternatively, purification processes based on ion-exchange 
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chromatography has also been developed to produce highly pure viral preparations with less 
reduction in virus activity (Qu et al., 2007). This method separates virus on the basis of the net 
charge of proteins on the viral capsid and results in a final viral preparation that has superior 
infectivity to virus purified by CsCl gradient centrifugation (Koerber et al., 2007). The rAAV2-
mIL-12 used in this study may have been affected by one or more of these factors and will 
require further optimisation to achieve the optimal transduction and subsequent transgene 
expression to permit assessment of its effectiveness as an adjuvant for DNA vaccination. 
While rAAV2-mIL-12 did not produce a consistent increase in T cell responses in WT 
mice, the exogenous mIL-12 produced by rAAV-mediated delivery did undoubtedly 
compensate for the IL-12 deficiency in IL-12p40-/- mice and resulted in increased CD4+ T cell 
responses to the DNA vaccine-encoded antigen (Figure 5.13-15). We speculate that while the 
expression of mIL-12 following transduction may be lower than that achieved by plasmid 
delivery, the expression is sustained for a longer duration. An alternative explanation may be 
that the positive effects of the rAAV-mediated mIL-12 delivery on the vaccine-induced 
responses were more pronounced in IL-12p40-/- mice because it was not masked by the 
presence of endogenous IL-12. Surprisingly, the results indicate that the CD8+ T cell responses 
induced by the DNA vaccine developed independently of IL-12 and these responses in IL-
12p40-/- mice were not further enhanced by the exogenous delivery of mIL-12. Although IL-12 
is thought to be essential for the development of a functional Th1 response, DNA vaccines 
induced both antigen-specific IFN-γ responses as well as protection against infection in IL-
12p40-/- mice in at least one other study (Ehigiator et al., 2007). Further, IFN-γ-secreting CD8+ 
T cell responses to Encephalitozoon cuniculi infection were dampened, but not abolished, in 
IL-12p40-/- mice (Moretto et al., 2010). Activation of TLR by the pathogen or signalling 
through co-stimulatory molecules, such as CD27 or OX40, are suggested mechanisms for the 
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IL-12 independent development of the CD8+  T cell responses (Sanchez and Kedl, 2012, 
Dannull et al., 2005).  
One advantage of using recombinant viral vectors is the ability to explore the non-invasive 
routes of vaccine delivery, such as oral or i.n. delivery. Intrapulmonary delivery of  rAAV2-
mIL-12 could be tested as an anti-TB gene therapy. Increased levels of IL-12 in the serum was 
detected in IL-12p40-/- mice 10 d after i.n. delivery, and the levels were further increased at 14 
d post-delivery, but they did not reach levels in WT  mice (Figure 5.20). When WT mice were 
treated with the rAAV2-mIL-12, no increase in serum mIL-12 could be detected. Moreover, 
expression of the exogenous IL-12 in the lungs of WT mice did not translate into increased 
antigen-specific IFN-γ secreting responses following aerosol challenge with M. tuberculosis 
(Figure 5.21). This suggests that although mIL-12 is produced following i.n. delivery of 
rAAV2-mIL-12, the cytokine is not produced at sufficient levels to have an impact on T cell 
responses. Nevertheless, the rAAV2-mIL-12 treated mice did have marginal decreases in the 
bacterial burden in both the lungs and spleen (Figure 5.22). While the issues of expression 
kinetics, promoter activity and tissue tropism also apply to i.n. delivery of rAAV, additional 
factors such as loss of inoculum, location of viral transduction, site of bacterial replication and 
antigen presentation are also important for the effectiveness for the IL-12 gene therapy. To rule 
out the effect of losing the inoculum into the oesophagus during i.n. delivery, intra-tracheal 
inoculation may be used to effectively test transduction of lung cells. Although AAV serotype 
2 has demonstrated a wide degree of tissue tropism, including the lung epithelium, some 
studies have suggested higher doses may be required for adequate transgene expression in vivo 
(Halbert and Miller, 2004). The expression of cytokines that promote macrophage and DC 
activation, as well as polarising to the Th1 type T cell responses, in theory, should aid the 
development of an anti-TB response. The use of alternative AAV serotypes such as serotypes 5 
or 6 may result in the transduction of peripheral lung tissue in closer proximity to the sites of 
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infection (Seiler et al., 2006, Halbert et al., 2007). Alternatively, higher levels of mIL-12 may 
be sufficient for the cytokine to co-localise at the sites of infection. Excessive over-production 
of IL-12 in the lung may lead to exacerbation of inflammatory response and further exacerbate 
pathology, although our results indicate that sub-optimal expression was achieved (Figure 
5.20). Further experiments optimising the dose of rAAV2-mIL-12 delivery and assessing the 
activation state of DCs and macrophages in the lung may better characterise the effects of mIL-
12 therapy in the lungs. 
In summary, rAAV encoding mIL-12 was produced and induced the expression of mIL-12 
following both in vitro cellular transduction and in vivo delivery. Co-immunisation with 
rAAV2-mIL-12 and a plasmid vaccine encoding Ag85B-64-ESAT successfully complemented 
functional IL-12 deficiency in IL-12p40-/- mice and enhanced the vaccine-induced antigen-
specific IFN-γ responses. Co-immunisation in WT mice resulted in a trend for increased T cell 
responses to DNA vaccine-encoded antigens. The delivery of rAAV2-mIL-12 as an anti-TB 
genetic therapy did not further enhance the T cell responses to the commonly known 
immunogenic M. tuberculosis antigens. Nevertheless, a small, but statistically significant, 
reduction in the bacterial burden was observed in the M. tuberculosis-infected mice treated 
with i.n. rAAV2-mIL-12. These results indicate that both i.m.i and i.n. delivery of rAAV-mIL-
12 require further optimisation, before this rAAV-mIL-12 could be deployed as a molecular 
adjuvant for anti-TB vaccines or as a possible gene therapy vector against M. tuberculosis 
infection.
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6.1 Introduction 
The first generation subunit vaccines currently in clinical trials contain only a small number of 
the possible M. tuberculosis antigens recognised by genetically diverse human populations, and 
there is the need to expand this repertoire of candidate antigens. Criteria for the inclusion of M. 
tuberculosis proteins in subunit vaccines include their recognition by T cells of M. 
tuberculosis-infected humans, their ability to induce protective immunity in experimental 
infection, and their suitability for mass production and formulation with adjuvants (Reed and 
Lobet, 2005). 
 MPT83 (Rv2873) is a cell wall-associated lipo-glycoprotein of M. tuberculosis, whose 
function is unknown, although it has been suggested based on sequence analysis that MPT83 
may play a role in the adhesion to host cells and dissemination (Hewinson et al., 1996). MPT83 
has a secretory signal sequence and is a close homologue of another secreted protein, MPT70.  
MPT70 (Rv2875) has 69.3% homology to MPT83, without the signal sequence; at the DNA 
sequence level and 66% homology at the amino acid level (Figures 6.1 and 6.2, respectively) 
(Cole et al., 1998). Its homologues in M. bovis, MPB83 and MBP70, are sero-dominant 
antigens during M. bovis infection in both cattle and badgers (Wiker et al., 1998, Lesellier et al., 
2008). DNA vaccination studies in cattle revealed that MPB83 is immunogenic, generating 
strong T cell and B cell responses (Cai et al., 2005a, Chambers et al., 2000, Vordermeier et al., 
2000). Interestingly, pre-treatment of animals with anti-MPB83 antibodies resulted in increased 
survival during M. bovis infection (Chambers et al., 2004). The expression of MBP83 varies 
between different strains of M. bovis BCG, and this is caused by a point mutation in the 
positive regulator, Sigma factor K (SigK) (Charlet et al., 2005). During in vitro culture, M. 
tuberculosis expresses relatively small quantities of MPT83 and MPT70, but the expression 
level of MPT83 is significantly increased during infection (Hewinson et al., 1996).  
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Figure 6.1. ClustalW multiple sequence alignment of the amino acid sequence MPT83 
and MPT70 of M. tuberculosis. 
The amino acid sequence of Rv2873 (MPT83) was compared for its homology with Rv2875 (MPT70). Single 
fully conserved residues are represented by (∗) and conservation of weak groups between the two protein 
sequences is denoted by (.). The residues highlighted in yellow represent the respective signal sequences and 
green represent the region of O-linked glycosylation for MPT83. 
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Figure 6.2. Comparison of Rv2873 and Rv2875 from M. tuberculosis and M. bovis. 
The complete DNA sequence encoding Rv2873 from M. tuberculosis and M. bovis (MPT83 and MPB83, 
respectively), and Rv2875, the homologous secreted protein from M. tuberculosis and M. bovis  (MPT70 and 
MPB70, respectively) were analysed using the ClustalW multiple alignment algorithm. The asterisks represent the 
nucleotides conserved between all sequences. 
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 In this chapter MPT83 was expressed as a recombinant protein, and its 
immunoreactivity was examined in both human and experimental tuberculosis. Immunisation 
with plasmid DNA encoding MPT83 was used to study the MPT83-specific IFN-γ-secreting T 
cell responses in mice. Overlapping peptides spanning the entire sequence of MPT83 were 
used to identify the H-2b-restricted CD4+ and CD8+ T cell epitopes of MPT83. Then MPT83 
was tested as DNA and recombinant protein subunit vaccines for its capacity to induce 
protective immunity against aerosol M. tuberculosis infection. 
 
6.2 Results 
6.2.1 Expression and characterisation of recombinant MPT83.  
The full length MPT83 was expressed as a recombinant protein in E. coli BL21 (DE3) using 
the pET19b expression vector with an N-terminal 6-HIS-tag. The expression was driven under 
the control of the T7 promoter without IPTG induction (Figure 6.3A, lane 3), and the protein 
was then solubilised and purified using the Talon Co2+-based metal affinity resin (Figure 6.3A, 
lane 5). The purified rMPT83 protein with the N-terminal HIS-tag was refolded, and a single 
protein with a relative molecular mass (Mr) of 28 kDa was identified following separation by 
12% SDS-PAGE (Figure 6.3B). This compares to the predicted molecular mass of 25.6 kDa 
for MPT83 with the additional N-terminal polyhistidine tag. 
 
6.2.2 MPT83 is recognized as a T cell antigen during M. tuberculosis infection.  
To determine whether rMPT83 is recognised by murine T cells during M. tuberculosis 
infection, splenocytes from C57BL/6 mice, which had been infected aerogenically with M. 
tuberculosis, were stimulated either with rMPT83 or M. tuberculosis CFP as the positive 
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control. The number of antigen-specific IFN-γ secreting T cells was enumerated by the 
ELISpot assay (Figure 6.3C). rMPT83 protein elicited a mean antigen-specific IFN-γ response 
of 746 ± 169 SPC/106 cells, compared to 911 ± 148 SPC/106 cells for CFP-stimulated 
splenocytes and 45 ± 7 SFC/106 cells in unstimulated splenocytes (Figure 6.3C). This indicated 
that MPT83 was a relatively immuno-dominant T cell antigen in M. tuberculosis-infected 
C57BL/6 mice.  
 
6.2.3 Location of the MPT83 protein within M. tuberculosis. 
To determine the location of MPT83 in M. tuberculosis, high-titre antibodies against MPT83 
were raised in mice immunised subcutaneously with rMPT83 in MPLA/DDA vaccine adjuvant 
formulation and used to probe sub-cellular preparations of M. tuberculosis by immunoblotting 
(Figure 6.4). Native MPT83 in M. tuberculosis fractions was detected as a band at 25 kDa, 
while the rMPT83 was detected at 28 kDa. MPT83 was abundant in the whole cell lysate 
(Figure 6.4, lane 8), and weaker bands were detected in Tx-114 soluble fraction, representing 
membrane integral proteins (Figure 6.4, lane 4) and cell wall protein fractions (Figure 6.4, lane 
5 and 6). By contrast, no MPT83 was detected in the fractions containing cytoplasmic proteins 
(Figure 6.4, lane 3) and the culture filtrate proteins (Figure 6.4, lane 7). 
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Figure 6.3. The expression and detection of the recombinant MPT83 protein.  
Full-length mpt83 was cloned into pET19b and expressed in E. coli BL21. (A) The expression of rMPT83 in E. 
coli BL21 with and with IPTG induction. Lane 1, molecular weight marker; lane 2, E. coli BL21 control; lane 3, 
rMPT83 expression with no IPTG induction; lane 4, rMPT83 expression with 1 mM IPTG; lane 5, purified 
rMPT83. (B) Following purification by Co2+ affinity chromatography the 28 kDa purified protein was visualized 
by SDS-PAGE. Lane 1, Molecular weight markers; lane 2, purified rMPT83 500 ng. (C) The number of antigen-
specific IFN-γ- secreting T cells (mean ± SEM) in splenocytes from M. tuberculosis-infected C57BL/6 mice (n=3) 
following stimulation with rMPT83, M. tuberculosis culture filtrate protein (CFP) and media alone for 16 h. The 
data are representative of two independent experiments, and the statistical significance was determined by the 
Student’s t-test (**, p < 0.01).  
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Figure 6.4. Location of the MPT83 protein in M. tuberculosis.  
Sub-cellular preparations of M. tuberculosis were separated by SDS-PAGE. The separated proteins were stained 
with Coomassie blue (top) or transferred to PVDF membrane and probed with mouse anti-MPT83 polyclonal Ab 
(bottom). Lane 1, Molecular weight marker; lane 2, purified rMPT83 protein, indicated by the red pointer; lane 3, 
cytoplasmic proteins; lane 4, Tx114 fraction; lane 5, cell wall fraction; lane 6, soluble cell wall fraction; lane 7, 
culture filtrate proteins; lane 8, whole cell lysate. 
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6.2.4 Human T cell responses to MPT83.  
M. bovis MBP83, which has an identical amino acid sequence to MPT83, is highly 
immunogenic in both cattle and other ruminants (Wedlock et al., 2003, Lyashchenko et al., 
2008). To study whether MPT83 is recognised during human M. tuberculosis infection, 
PBMCs from 28 patients with active TB (13 males, 15 females, ages 22-74) and 20 tuberculin 
skin test (TST)-negative subjects (10 males, 10 females, ages 22-53) were tested for MPT83-
specific proliferative and IFN-γ T cell responses. PBMCs from subjects with active TB 
proliferated significantly more to MPT83 (mean [3H]-thymidine incorporation 5,869 CPM) 
than those from TST-negative subjects (641 CPM) (p<0.0001), with 20/28 TB patients having 
an MPT83-specific proliferative response of ΔCPM >3,000 compared to 1/20 TST-negative 
subjects (Figure 6.5). A similar increase in proliferation were observed when the PBMCs were 
stimulated with M. tuberculosis CFP, with 25/25 TB patients having CFP-specific proliferative 
response of ΔCPM >3,000 compared to 6/20 TST-negative subjects. Analysis of the culture 
supernatants revealed significantly higher levels of secreted IFN-γ from the PBMCs of active 
TB subjects (mean 325 pg/ml) than those of TST-negative subjects (mean of 20 pg/ml) 
following stimulation with rMPT83 (p<0.0001) (Figure 6.6). In all, 21/28 TB patients had an 
MPT83-specific IFN-γ T cell response of >100 pg/ml compared to 1/20 TST-negative subjects. 
All TB patients had a CFP-specific IFN-γ response of >100 pg/ml compared to 6/20 TST-
negative subjects. 
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Figure 6.5. Recognition of MPT83 during M. tuberculosis infection in humans.  
Antigen-specific T cell proliferation of PBMCs from M. tuberculosis-infected patients (TB) (n=28) and tuberculin 
skin test-negative subjects (TST−ve) (n=20) in response to M. tuberculosis CFP (circles) or rMPT83 (triangles) 
protein, at 10 g/ml, were measured by the mean incorporation of [3H]-thymidine in M. tuberculosis antigen-
stimulated triplicate wells minus the incorporation in control wells stimulated with media alone (∆CPM). The 
horizontal lines represent the median for each group. The statistical significance of the differences between groups 
was determined by the Mann-Whitney U-test (****, p ≤ 0.0001). 
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Figure 6.6. MPT83 induces IFN-γ secretion during M. tuberculosis infection in humans.  
The levels of antigen-specific IFN- secreted into the culture supernatants were measured in PBMCs from M. 
tuberculosis-infected patients (TB) (n=28) and tuberculin skin test-negative subjects (TST−ve) (n=20) using an 
IFN- ELISA. The mean levels of IFN- in triplicate wells stimulated with media alone were subtracted from 
the mean levels in the wells stimulated with CFP or rMPT83 at 10 µg/ml. The horizontal lines represent the 
median level of IFN- for each group. The statistical significance of the differences between groups were 
determined by the Mann-Whitney U-test (****, p ≤ 0.0001). 
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6.2.5 Immunogenicity of DNA-MPT83.  
To investigate the immunogenicity of MPT83 as a DNA vaccine in mice, both C57BL/6 and 
BALB/c mice were immunised with DNA-MPT83 three times at two-weekly intervals and the 
antigen-specific IFN-γ secreting T cell responses were measured four weeks after the final 
immunisation by IFN-γ ELISpot and ELISA. C57BL/6 mice immunised with DNA-MPT83 
displayed significantly increased frequencies of MPT83-specific IFN-γ-secreting splenocytes 
than those immunised with the control vaccine, pcDNA3 (p≤0.01, Figure 6.7A). Following 
stimulation with rMPT83 for 72 h, the levels of IFN-γ released into the culture supernatant 
were also significantly increased by greater than 10-fold in the DNA-MPT83-immunised mice 
(2406 ± 584 pg/ml) compared to levels secreted by cells from mice immunised with the control 
DNA vaccine (124 ± 44 pg/ml, p≤0.05, Figure 6.7B). 
 Similar patterns of the IFN-γ secreting T cell responses to rMPT83 were observed in 
the DNA-MPT83-immunised BALB/c mice. The frequency of antigen-specific IFN-γ 
producing cells from the DNA-MPT83 immunised mice were double those of mice immunised 
with pcDNA3 (p≤0.001, Figure 6.8A). The levels of IFN-γ secreted into the culture supernatant 
following 72 h of antigen stimulation were more than 10-fold higher in mice immunised with 
DNA-MPT83 compared to the level secreted by cells of mice immunised with the control DNA 
(p≤0.0001, Figure 6.8B). These results indicate that MPT83 was able to induce potent T cell 
responses as a plasmid DNA vaccine following i.m.i in at least two separate mice strains. 
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Figure 6.7. Antigen-specific T cell responses to immunisation with DNA-MPT83 in 
C57BL/6 mice.  
C57BL/6 mice (n=3) were immunised three times at two-weekly intervals with 100 µg DNA-MPT83 or pcDNA3 
control vector by i.m.i. Four weeks after the final immunisation, splenocytes were harvested and stimulated ex 
vivo with either rMPT83 (10 µg/ml) or Con A (3 µg/ml). (A) The numbers of IFN- secreting cells/106 
splenocytes following 16 h of antigen stimulation were enumerated by ELISpot. (B) The levels of IFN-γ released 
into the culture supernatants of triplicate wells following 72 h of antigen stimulation were measured by IFN-γ 
ELISA. Data shown are the means ± SEM, and the statistical significance of differences between groups was 
determined by the Student’s t-test (***, p < 0.001; **, p < 0.01), and are representative of three independent 
experiments.  
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Figure 6.8. Antigen-specific T cell responses to immunisation with DNA-MPT83 in 
BALB/c mice.  
BALB/c mice (n=3) were immunised three times at two-weekly intervals with 100 µg DNA-MPT83 or pcDNA3 
control vector by i.m.i. Four weeks after the final immunisation, splenocytes were harvested and stimulated ex 
vivo with either rMPT83 (10 µg/ml) or Con A (3 µg/ml). (A) The numbers of IFN- secreting cells/106 
splenocytes following 16 h of antigen stimulation were enumerated by ELISpot. (B) The levels of IFN-γ released 
into the culture supernatants of triplicate wells following 72 h of antigen stimulation were measured by IFN-γ 
ELISA. Data shown are the means ± SEM, and the statistical significance of differences between groups was 
determined by the Student’s t-test (***, p < 0.001) and are representative of three independent experiments.  
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6.2.6 Murine T cell Epitopes within MPT83.  
Having established that MPT83 induces T cell responses following M. tuberculosis infection 
and DNA-MPT83 immunisation, the pattern of responses to 22 overlapping 15-mer peptides 
spanning the length of MPT83 protein (Table 6.1) were next examined in order to identify the 
immuno-dominant T cell epitopes within MPT83. In C57BL/6 mice immunised with DNA-
MPT83, the frequencies of IFN-γ producing cells were the highest in splenocytes stimulated 
with peptides 13 (MPT83121-135) and 14 (MPT83131-145) (Figure 6.9A). Weaker responses were 
also observed when cells were stimulated with peptide 9 (MPT8381-95), peptide 5 (MPT8341-55) 
and peptide 1 (MPT831-15). When the binding of class II MHC molecules to the T cell receptors 
on CD4+ T cells were inhibited using anti-L3T4a mAb (GK1.5), responses to peptides 13 and 
14 remained unaffected, whereas the response to peptide 9 was abolished (Figure 6.9B). Weak 
responses to peptides 1 and 5 were also not affected by inhibition of CD4+ T cell responses. 
This suggests that peptide 9 contains an H-2b-restricted CD4+ T cell epitope and peptides 13 
and 14 an H-2b-restricted CD8+ T cell epitope. When the same peptides were tested on the 
splenocytes of DNA-MPT83-immunised BALB/c mice, only stimulation with peptide 16 
(MPT83151-165) resulted a significant IFN-γ T cell response (Figure 6.10A). There was partial 
reduction in the response to peptide 16 following anti-L3T4a mAb treatment (Figure 6.10B). 
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Table 6.1. Overlapping 15-mer peptides spanning MPT83. 
Peptide Amino Acid Sequence Position  
1 MINVQAKPAAAASLA 1  
2           AASLAAIAIAFLAGC 11  
3                     FLAGCSSTKPVSQDT 21  
4                               VSQDTSPKPATSPAA 31  
5 TSPAAPVTTAAMADP 41  
6          AMADPAADLIGRGCA 51  
7                    GRGCAQYAAQNPTGP 61  
8                              NPTGPGSVAGMAQDP 71  
9 MAQDPVATAASNNPM 81  
10           SNNPMLSTLTSALSG 91  
11                     SALSGKLNPDVNLVD 101  
12                               VNLVDTLNGGEYTVF 111  
13 EYTVFAPTNAAFDKL 121  
14           AFDKLPAATIDQLKT 131  
15                     DQLKTDAKLLSSILT 141  
16                               SSILTYHVIAGQASP 151  
17 GQASPSRIDGTHQTL 161  
18           THQTLQGADLTVIGA 171  
19                     TVIGARDDLMVNNAG 181  
20                               VNNAGLVCGGVHTAN 191  
21 VHTANATVYMIDTVL 201  
22      ATVYMIDTVLMPPAQ 206  
 
 To confirm the identity of H-2b-restricted T cell epitopes, CD4+ and CD8+ T cells from 
the spleens of DNA-MPT83-immunised mice were purified by FACS and stimulated with 
irradiated syngeneic splenocytes and the peptides 1, 5, 9, 13, and 14, and the IFN-γ T cell 
responses measured by ELISpot. Modest IFN-γ T cell responses to peptides 5 and 9 were 
observed with the purified CD4+, but not CD8+, T cells (Figures. 6.11A and B). By contrast, a 
high frequency of IFN-γ producing T cells was observed following stimulation of purified 
CD8+ T cells with peptide 13 alone, and not with the CD4+ T cells. Therefore, peptide 13 
contains a dominant H-2b-restricted CD8+ T cell epitope, while peptides 5 and 9 may contain 
CD4+ T cell epitopes. 
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Table 6.2. Sequence of overlapping peptides spanning peptides 13 and their epitope 
prediction scores. 
Peptide name Sequence SYFPEITHI scores H2-Kb H2-Db 
13    EYTVFAPTNAAFDKL - - 
13-1    EYTVFAPTN 0 3 
13-2     YTVFAPTNA 0 4 
13-3      TVFAPTNAA 0 0 
13-4       VFAPTNAAF 0 8 
13-5        FAPTNAAFD 0 21 
13-6         APTNAAFDK 0 2 
13-7          PTNAAFDKL 0 12 
13-8           TNAAFDKLA 0 2 
13-8.2           TNAAFDKL  22 
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Figure 6.9. Identification of H-2b-restricted T cell peptide epitopes in MPT83.  
C57BL/6 mice (n=3) were immunised with 100 µg of DNA-MPT83 or pcDNA3 control vector by i.m.i three 
times at two-weekly intervals. Four weeks post-immunisation splenocytes were harvested and stimulated ex vivo 
with rMPT83 (10 µg/ml), one of 22 MPT83 15-mer peptides (overlapping by five residues) (10 µg/ml) or Con A 
(3 µg/ml). (A) The numbers of peptide-specific and MPT83-specific IFN-γ-secreting T cells were measured by 
ELISpot after 16 h stimulation; and (B) by ELISpot following inhibition of CD4+ T cells with the anti-CD4 
monoclonal antibody (GK1.5). Data are the means ± SEM for replicate samples from the three mice, and are 
representative of two independent experiments.  
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Figure 6.10. Identification of H-2d-restricted T cell peptide epitopes in MPT83.  
BALB/c mice (n=3) were immunised with 100 µg of DNA-MPT83 or pcDNA3 control vector by i.m.i three times 
at two-weekly intervals. Four weeks post-immunisation splenocytes were harvested and stimulated ex vivo with 
rMPT83 (10 µg/ml), one of 22 MPT83 15-mer peptides (overlapping by five residues) (10 µg/ml) or Con A (3 
µg/ml). (A) The numbers of peptide-specific and MPT83-specific IFN-γ-secreting T cells were measured by 
ELISpot after 16 h stimulation; and (B) by ELISpot following inhibition of CD4+ T cells with the anti-CD4 
monoclonal antibody (GK1.5). Data are the means ± SEM for replicate samples from the three mice and are 
representative of two independent experiments.  
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Figure 6.11. Confirmation of H-2b-restricted T cell epitopes in MPT83.  
C57BL/6 mice (n=3) were immunised with 100 µg of DNA-MPT83 or pcDNA3 control vector by i.m.i three 
times at two-weekly intervals. Four weeks post-immunisation, mice were harvested, and the pooled splenocytes 
were labelled with anti-CD3-PerCP, anti-CD4-Alexaflour 700 and anti-CD8-APC-Cy7 mAbs and the CD4+ and 
CD8+ T cells were separated by FACS. The CD4+ (A) and CD8+ (B) T cells were stimulated with irradiated 
splenocytes and the peptides 1, 5, 9, 13 and 14 (10 µg/ml), MPT83 (10 µg/ml) or Con A (3 µg/ml), and the 
antigen-specific IFN-γ responses were measured by ELISpot after 16 h. Data represent the means for replicate 
samples from three wells of each treatment and are representative of two independent experiments.  
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6.2.7 Minimal H-2b-restricted CD8+ T cell epitope in MPT83.
To resolve further the H-2b-restricted CD8+ T cell epitope, the binding scores of nonameric and 
octameric peptides within peptide 13 to both H-2Kb and H-2Dd haplotypes of class I MHC 
molecules were examined using the MHC binding prediction algorithm SYFPEITHI 
(Rammensee et al., 1999) (access via: www.syfpeithi.de). The octameric peptide MPT83128-135 
(TNAAFDKL) had the highest predicted binding for H-2Db molecules with a score of 22. The 
nonameric peptides MPT83127-135 (PTNAAFDKL) and MPT83125-133 (FAPTNAAFD) were 
second and third with binding scores of 12 and 8 respectively. No peptides within peptide 13 
were predicted to bind H-2Kb molecules. Splenocytes from DNA-MPT83 immunised mice 
were then stimulated with the set of octameric and nonameric peptides within peptide 13, and 
these are summarised in Table 6.2. Splenocytes from both pcDNA3 and DNA-MPT83 
immunised mice responded to stimulation with the mitogen Con A. Only two out of the nine 
peptides induced IFN-γ T cell responses. Stimulation with peptide MPT83127-135 induced the 
highest frequency of IFN-γ producing cells, followed by peptide MPT83128-135. In both 
instances the frequencies of IFN-γ producing cells were not as high as those induced by 
stimulation with the original 15-mer peptide 13 (Figure 6.12). Overall these results indicate 
that the 9-mer, MPT83127-135 contains a MHC-I Db-restricted CD8+ T cell epitope. 
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Figure 6.12. Minimal CD8+ T cell epitope within peptide 13 of MPT83.  
C57BL/6 mice (n=3) were immunised with 100 µg DNA-MPT83 (!) or pcDNA3 (") control vector by i.m.i 
three times at two-weekly intervals. Four weeks post-immunisation, the mice were harvested and the splenocytes 
were stimulated with nonameric peptides spanning the sequence of peptide 13 and overlapping by one residue 
(Table 6.2) at 10 µg/ml, MPT83 (10 µg/ml) and Con A (3 µg/ml) and number of peptide-specific IFN-γ secreting 
T cells were measured by ELISpot after 16 h. Data shown are the means ± SEM for triplicate samples from three 
mice and are representative of two independent experiments. The statistical significance of differences was 
determined by the Student’s t-test (*, p < 0.05; ***, p < 0.001, ****, p < 0.0001).  
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6.2.8 Protective efficacy of MPT83 DNA and protein vaccines.
The protective efficacy of MPT83 as DNA and protein vaccine was assessed in C57BL/6 mice. 
Following three immunisations with DNA-MPT83 or pcDNA3 and rested for six weeks, 
C57BL/6 mice were infected aerogenically with M. tuberculosis, and the bacterial loads in the 
lungs and spleen were enumerated four weeks after infection. Immunisation with DNA-MPT83 
conferred significant protection in both the lungs (p<0.001) and the spleen (p<0.001) compared 
to control DNA vaccine (Figures 6.13A and B). C57BL/6 mice were also immunised with 
rMPT83 in MPLA/DDA adjuvant or adjuvant alone three times, rested six weeks and 
challenged with M. tuberculosis. The recombinant protein in MPLA/DDA also stimulated 
significant protection compared to adjuvant alone, with at least 1.0 log10 protection in both the 
lung (p<0.0001) and the spleen (p<0.05) (Figure 6.13C and D). BCG immunisation also 
induced protection in both the lung and spleen (Figure 6.13). 
 Antigen-specific T cell responses in the draining MLN were also assessed after M. 
tuberculosis challenge. Both the immunised and control mice developed IFN-γ responses to M. 
tuberculosis CFP (Figure 6.14A). Mice immunised with DNA-MPT83, but not control DNA or 
MPT83/MPLA/DDA, were primed to mount a strong T cell response to the defined CD8+ T 
cell epitope, MPT83127-135 following M. tuberculosis infection (Figure 6.14B). By contrast, M. 
tuberculosis infected mice, which were immunised with rMPT83/MPLA/DDA, developed a 
high frequency of antigen-specific IFN-γ T cells to the whole rMPT83 protein, consistent with 
a CD4+ T cell response, and no significant responses to the defined CD8+ T cell epitope 
(Figure 6.14C). Therefore two different types of subunit vaccines, protein with the TLR-4 
adjuvant, MPLA, and DNA vaccine stimulated similar levels of protection, but different 
patterns of T cell responses after M. tuberculosis infection. 
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Figure 6.13. Protective efficacy induced by DNA-MPT83 and rMPT83 immunisation.  
C57BL/6 mice (n=5) were immunised with (A and B) 100 µg of DNA-MPT83 and control vector pcDNA3 by 
i.m.i. or (C and D) 10 µg of rMPT83 in MPLA/DDA by s.c.i. three times at two-weekly intervals. Six weeks 
following the final immunisation, mice were infected by aerogenic M. tuberculosis H37Rv. Additional mice were 
immunised with 5 × 105 CFU of BCG once by s.c.i. 12 weeks before challenge with M. tuberculosis H37Rv. After 
28 days, mice were sacrificed, and the bacterial loads in the lung and the spleen were determined by enumeration 
CFU following culture on Middlebrook 7H11 media. The data are the means ± SEM and are representative of 
three independent experiments for DNA-MPT83 and two experiments for rMPT83. The statistical significance of 
the differences between groups was determined by analysis of variance (*, p < 0.05, **, p < 0.01, ***, p < 0.001). 
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Figure 6.14. T cell responses following immunisation with DNA-MPT83 and rMPT83 and 
M. tuberculosis challenge.  
C57BL/6 mice (n=5) were immunised with 100 µg of DNA-MPT83 and control vector pcDNA3 by i.m.i. or 10 µg 
of rMPT83 in MPLA/DDA by s.c.i. three times at two-weekly intervals. Six weeks following the final 
immunisation, mice were infected by aerosol with M. tuberculosis H37Rv. Additional mice were immunised with 
5 × 105 CFU of BCG once by s.c.i. 12 weeks before challenge with M. tuberculosis H37Rv. After 28 days, mice 
were sacrificed, and the MLN was harvested and stimulated ex vivo with (A) CFP at 3 µg/ml, (B) Peptide 13 at 10 
µg/ml, and (C) MPT83 at 10 µg/ml. The data are the mean ± SEM and are representative of two experiments. The 
statistical significance of the differences between groups was determined by analysis of variance (***, p < 0.001). 
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6.3 Discussion 
M. tuberculosis proteins to be considered for inclusion in anti-TB subunit vaccines must be 
immunogenic in the majority of TB patients, lack cross-reactivity with human proteins, and 
stimulate protective immunity in experimental models of M. tuberculosis infection. To date, 
there are six subunit vaccines based on one or two mycobacterial proteins with these 
characteristics that have entered phase I and II clinical trials (Table 1.1) (Kaufmann et al., 2010, 
Aagaard et al., 2009a, van Dissel et al., 2010, Sander et al., 2009). This study has identified 
MPT83 as an additional candidate with similar features to be considered for inclusion in anti-
TB vaccines. MPT83 was recognised during both murine and human M. tuberculosis infection. 
Peripheral blood T cells from the majority of patients with active TB, but not from tuberculin-
negative healthy subjects, proliferated and secreted IFN-γ in response to rMPT83. Furthermore, 
both plasmid DNA expressing MPT83 and rMPT83 protein vaccine in adjuvant induced 
protective immunity against aerosol infection with M. tuberculosis in mice. 
Expression of the full length Rv2873 with an additional N-terminal His-Tag in the 
pET19b system yielded a recombinant protein with the predicted molecular weight of 25.61 
kDa, compared to 22.07 kDa for the amino acid sequence of MPT83. Interestingly, probing 
different sub-cellular fractions of M. tuberculosis with mouse anti-rMPT83 antisera detected a 
protein band with a relative molecular mass of 25 kDa. This is consistent with previous reports 
that native MPT83 has a Mr of 26 kDa in SDS-PAGE, in part due to the effects of 
glycosylation on the mobility of the protein (Wiker et al., 1991). In this study MPT83 was 
detected in the whole cell lysate (Figure 6.4, lane 8) and Tx-114 detergent soluble fractions of 
M. tuberculosis, suggesting MPT83 is an integral membrane protein (Figure 6.4, lane 4). This 
mirrors studies of MPB83, which reported its presence in the Tx-114 soluble fraction (Malen et 
al., 2008). MPB83 has also been detected on the surface of M. bovis by flow cytometry using 
mAbs (Harboe et al., 1998). 
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The M. bovis MPB83 and the closely related protein MPB70 are major antigens 
recognised during M. bovis infection of cattle, acquired by both natural and experimental 
transmission. Ninety percent of M. bovis-infected cattle develop antibody responses against 
MPB83 (Green et al., 2009), while 78% of develop delayed-type hypersensitivity responses to 
a protein cocktail containing MPB83 (Whelan et al., 2010). Furthermore, badgers are a natural 
reservoir for M. bovis infection, and MPB83 stimulates a strong antibody response in the 
majority of infected animals (Lesellier et al., 2008, Goodger et al., 1994). Both MPB83 and 
MPB70 are abundantly expressed in M. bovis, however MPB83 is retained in the cell 
membrane, while MPT70 is secreted into the culture filtrate (Hewinson et al., 1996). There is 
variable expression of MPB83 in different strains of M. bovis BCG, caused by point mutations 
in both sigK (Charlet et al., 2005) and Rv0444c (Said-Salim et al., 2006), encoding the positive 
regulator and repressor that control the SigK regulon containing both mpb83 and mpb70. The 
wild-type Rv0444c protein in M. tuberculosis is associated with moderate to low levels of 
expression of MPT83 in bacterial cultures (Said-Salim et al., 2006). Nevertheless, MPT83 was 
readily detected in both the whole cell lysate of M. tuberculosis H37Rv and the sub-cellular 
fraction containing the integral membrane proteins. It is also apparent that the protein is 
expressed during infection in vivo, as both TB patients and M. tuberculosis-infected mice 
developed strong IFN-γ T cell responses against MPT83. While the current study examined the 
recognition of MPT83 in patients with active TB, a recent study of both BCG-vaccinated and 
M. tuberculosis-infected healthy subjects in Kuwait reported the recognition of multiple 
MPT83-derived peptides by the majority of subjects, resulting in antigen-induced proliferation 
and IFN-γ production (Mustafa, 2011).  
Immunisation of C57BL/6 mice with MPT83 as either a DNA or protein vaccine 
stimulated strong antigen-specific IFN-γ secreting T cell responses (Figure 6.5). Similar levels 
of immunogenicity were observed in BALB/c mice (Figure 6.6). CD4+ T cells are essential for 
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protective immunity against M. tuberculosis infection, but they are also critical for the 
activation and licensing of CD8+ T cell responses. M. tuberculosis-specific CD8+ T cells 
contribute to protection, especially during the chronic phase of experimental infection in mice 
(van Pinxteren et al., 2000, Nambiar et al., 2010). Overlapping 15-mer peptides spanning the 
MPT83 sequence were used to locate the dominant H-2b-restricted CD8+ T cell epitope within 
the peptide MPT83121-135, and the minimal epitope was defined as MPT83127-135, PTNAAFDKL 
(peptide 13-7). This peptide had the second highest binding score for nonamers predicted to 
bind to H-2Db in both the SYFPEITHI and IEDB epitope prediction algorithms (Table 1). 
Immunisation with DNA-MPT83 primed for strong CD8+ T cell responses to the MPT83127-135 
peptide following M. tuberculosis challenge (Figure 6.12B). Computational analysis of MPT83 
has identified peptides with the potential for binding to multiple human MHC Class I alleles, 
suggesting that human CD8+ T cell epitopes my also exist in the protein (Mustafa, 2011). 
Given that MPT83 was recognised during both human and murine M. tuberculosis 
infections, the robust T cell responses, protective efficacy was examined following M. 
tuberculosis challenge. Immunisation of C57BL/6 mice with either rMPT83 in MPLA/DDA 
adjuvant liposomes or plasmid encoding MPT83 significantly reduced both pulmonary and 
splenic bacterial loads following M. tuberculosis challenge (Figure 6.11). The degree of 
protective efficacy induced by the recombinant protein vaccine was greater than the degree of 
protection induced by an RNA-based vaccine encoding MPT83 in BALB/c mice (Xue et al., 
2004). Furthermore, combinations of DNA vaccines, which included MPT83 as one of several 
secreted proteins, were protective against experimental TB infection (Morris et al., 2000, Cai et 
al., 2005b). DNA immunisation using the M. bovis homolog, MPB83 protected BALB/c mice 
against M. bovis challenge, as well as stimulating T cell responses in immunised cattle 
(Chambers et al., 2000). When tested in the guinea pig model of M. bovis infection, plasmid 
MPB83 significantly reduced the extent of granulomatous infiltration in the lungs, although it 
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did not reduce the bacterial load of M. bovis following aerogenic infection (Chambers et al., 
2002). Early studies with DNA vaccines suggested they may only have limited applicability in 
humans, but more recent investigations administrating DNA vaccines into humans using in 
vivo electroporation resulted in significantly enhanced DNA delivery and stimulated robust 
cellular immune responses, indicating a potential role of DNA vaccination in humans (Vasan et 
al., 2011, Sardesai and Weiner, 2011). This study also demonstrated that immunisation with 
rMPT83 protein in MPLA/DDA liposomes was unequivocally protective. The level of 
protection was considerable, with approximately one log10 reduction in bacterial load induced 
by rMPT83 (Figure 6.11), a similar level to the protection afforded by other M. tuberculosis 
protein vaccines, which are currently in phase I clinical trials (Weinrich Olsen et al., 2001, 
Aagaard et al., 2009b, van Dissel et al., 2010). 
In general, the level of protection stimulated by rMPT83 and other M. tuberculosis 
protein vaccines is less than that induced by BCG, although they have the advantage of 
increased safety over BCG in immune-compromised subjects (Hesseling et al., 2007). The 
potential application of these subunit vaccines is for boosting the effects of infant BCG 
immunisation, or, as demonstrated with DNA encoding Ag85B, for priming with a subunit 
vaccine prior to BCG to increase the protection afforded by BCG vaccination (Derrick et al., 
2004, Feng et al., 2001b). The adjuvant used in the current study, MPLA, is a potent inducer of 
Th1 responses through the activation of TLR-4 (Romero et al., 2011). Interestingly, 
rMPT83/MPLA/DDA primed for stronger IFN-γ T cell responses to the whole protein 
following challenge, while DNA-MPT83 primed for stronger CD8+ T cell responses to 
MPT83127-135, even though they had similar protective efficacies. The development of more 
effective and safe adjuvants for protein anti-TB vaccines, such as the mycobacterial cell wall 
component trehalose-6,6-dimycolate and its synthetic analogue trehalose-6,6-dibehenate, 
which induce both Th1 and Th17 responses (Werninghaus et al., 2009, Schoenen et al., 2010, 
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Henriksen-Lacey et al., 2011), may further increase the protective efficacy and durability of 
these vaccines. In summary, the cell wall lipoprotein, MPT83, is an additional protective 
antigen, which should be considered for inclusion in future anti-TB vaccines. 
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Since the first application of the smallpox vaccine in 1796 by Edward Jenner, prophylactic 
vaccines remains the single most cost-effective and efficient method for preventing infectious 
diseases (Maurice et al., 2009). In spite of intensified research efforts in the past two decades, 
TB continues to be one of the most deadly diseases caused by a single infectious agent (World 
Health Organization., 2010). While the BCG vaccine is the only currently licenced anti-TB 
vaccine, the effectiveness of its deployment is debated. The immunity provided by BCG is 
reported to wane over time and is highly variable between vaccinated individuals of different 
geographical regions (Colditz et al., 1994). The situation has been worsened by the association 
with the HIV epidemic in sub-Saharan Africa, and the emergence of drug-resistant strains of M. 
tuberculosis (Narain et al., 1992, World Health Organization., 2011). For these reasons, a 
vaccine with the ability to prevent active TB disease and hinder further disease transmission is 
one of the goals of the Stop TB global initiative.  
As more information is revealed about the pathology and the immune responses to M. 
tuberculosis infections, the extent of research on more effective anti-TB vaccine candidates 
have increased dramatically (Kaufmann, 2011). These vaccine candidates can be classified into 
three main types, the live attenuated M. tuberculosis vaccines, recombinant BCG vaccines and 
subunit vaccines (Table 1.1). 
Of the subunit vaccines tested in experimental models of infectious diseases and cancer, 
DNA-based vaccines present an attractive option because of their stability and relative ease of 
construction ability in addition to the capacity to induce long-lasting T cell responses. 
Furthermore, DNA vaccines have an excellent safety profile in animal models (Klinman et al., 
2010). Nevertheless, DNA vaccines have failed to stimulate immune responses associated with 
protective efficacy in large animal models and in human clinical trials (Mwau et al., 2004). The 
series of experiments presented in this thesis aimed to improve the immunogenicity and 
consequently the protective efficacy of genetic vaccines against M. tuberculosis infection by 
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modulating the environment, in which the vaccine-specific immune responses are generated. 
These experiments focus specifically on the outcomes of augmenting the four signals essential 
during antigen presentation and T cell activation: signal 0, the activation of the innate immune 
system; signal 1, antigen presentation via delivery of mycobacterial peptides to the MHC 
molecules; signal 2, co-stimulatory signalling and finally signal 3, intercellular cytokine 
signalling through the use of recombinant co-stimulatory molecules, rAAV constructs 
expressing either recombinant cytokines or immunogenic mycobacterial antigens.  
 
7.1 Comparison of rAAV and DNA subunit vaccines 
Immunisation with plasmid DNA is generally immunogenic in mice (Cai et al., 2005a, Hogarth 
et al., 2006, Kamath et al., 1999b, Yuan et al., 2012). The ability of DNA vaccines to generate 
sufficient levels of CD4+ and CD8+ T cell responses are linked to their ability to activate innate 
immune responses (Wang et al., 1998, Fu et al., 1997). The possibility of using rAAV as an 
alternative vaccine vector was explored in Chapter 4. The rationale behind this approach was 
based on the ability of rAAVs to transduce stably both dividing and non-dividing cells, 
resulting in stable transgene expression (Figure 4.9), leading to T cell responses to the 
transgene product (Xu and Walker, 2011, Zhou et al., 2010, Sipo et al., 2010). Moreover, the 
prolonged delivery of low doses of antigen may stimulate detectable protective Th1 responses 
as demonstrated with low-dose BCG immunisation (Kiros et al., 2010). These results 
demonstrate that, while rAAV2-Ag85B-64-ESAT was indeed able to express the virus-
encoded fusion-antigen, ,the levels of antigen-specific responses, measured by the frequency of 
IFN--producing cells and IFN- secretion, were less than those following immunisation 
with plasmid DNA (Figures 4.6-7). To determine if the delivery of rAAV could boost the DNA 
vaccine-induced responses, mice were immunised sequentially with plasmid DNA and then 
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rAAV vectors expressing the same fusion-antigen. Under these conditions, rAAV2-Ag85B-64-
ESAT did not increase the antigen-specific T cell responses above those which received two 
doses of plasmid DNA alone (Figures 4.10-14).  
There are a number of possible explanation for these observations, Firstly, the tissue 
specificity of genetic transfer differ between the two rAAV and DNA vectors (Summerford 
and Samulski, 1998, Wolff and Budker, 2005, Zaiss et al., 2008), and this may be partially 
responsible for the variations in the responses induced by the respective vaccine vectors. 
Secondly, the expression kinetics for the encoded fusion antigen differs between DNA 
transfection and rAAV transduction. This was evident with the notable delay in the emergence 
of antigen-specific antibody responses following rAAV2-Ag85B-64-ESAT immunisation 
compared to DNA immunisation. Thirdly, different promoters were used to drive the 
expression of the fusion-antigens in the DNA and rAAV vaccine candidates, the CMV EI 
promoter for the DNA vaccine and RSV promoter for the rAAV vaccine. While both 
promoters are commonly used in eukaryotic expression systems, it is possible that differences 
in the levels of the antigen expression will influence the extent and quality of antigen 
presentation (signal 1) and the resulting T cell priming (Figure 7.1B). The differences between 
plasmid DNA and rAAV immunisations can be summarised in Figure 7.2. A number of recent 
publications have also reported variability in the immune responses generated following rAAV 
immunisation. The ability to activate the innate immune response differs between different 
serotypes of the AAV, as recently reviewed (Rogers et al., 2011). Although activation of the 
TLR-9-MyD88 signalling pathway does contribute to the response against AAVs, the results 
presented in the current study further demonstrate that rAAV serotype 2 is weak at activating 
innate immune responses and is not suitable as a vaccine vector for TB vaccines. This raises 
the question of whether using adjuvants in combination with rAAV vectors will enhance the 
resulting immune response. Favourable results have been reported on the use of different 
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adjuvants in DNA vaccine formulations. The inclusion to chitosan, cationic nanoparticles as 
well as CpG ODNs in anti-TB DNA vaccines have shown elevated immunogenic as well as 
protective effects (de Sousa et al., 2012, Yu et al., 2012, Feng et al., 2013). In one study, 
however, the activation of DCs using LPS or anti-CD40 antibodies was insufficient to break 
the immune tolerance of Factor IX delivered by rAAVs (Bharadwaj et al., 2010). By contrast, 
another contemporary study described the opposite effect when rAAVs expressing LacZ were 
co-delivered with LPS or CpG ODNs (Somanathan et al., 2010). The incorporation of 
immunogenic peptides into the capsid protein of rAAVs to increase its immunogenicity has 
also been explored (Li et al., 2009). Therefore it is still unclear whether adjuvants in 
combination with rAAV vaccine vectors would increase immunogenicity. 
The duration of transgenes expression following rAAV transduction can occurs over a 
relatively extended period of time, up to 20 d following transduction (Zincarelli et al., 2008). 
Unlike plasmid DNA, each AAV has a ssDNA genome (Figure 7.1A). This ssDNA requires 
transport to the nucleus and the subsequent second-strand DNA synthesis to occur before 
transgene expression is initiated (Ferrari et al., 1996). To accelerate this step, scAAVs have 
been developed, where the ssDNA genomes are self-complementary and fold onto itself to 
form a unique double-stranded molecule (McCarty et al., 2003). These scAAV not only 
provides an accelerated transgene expression following transduction, but they also increase the 
activation of the innate immune system in a TLR-9 dependent manner (Martino et al., 2011). 
The benefits afforded by scAAV come at the cost of reduced size of the viral genome to 
accommodate exogenous transgenes. This effectively halves the size of the genome available 
for the transgene from 4.7 kb to 2.4 kb (McCarty et al., 2003). Alternatively, the utilisation of 
stronger promoters to drive the expression of the fusion-antigen may reduce the time required 
for the onset of transgene expression. Another factor that may influence the level of fusion 
antigen expression is the early clearance of subsequent doses of rAAV2-Ag85B-64-ESAT 
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because of the development of well-documented AAV capsid-specific T cell and B cell 
responses (Mingozzi and High, 2007, McPhee et al., 2006). The use of fluorescent proteins in 
future rAAV delivery experiment may provide better insight into the exact tissues that are 
transduced and provide a simpler approach to studying the kinetics of gene expression 
following rAAV transduction in vivo. While antigen-specific T cells were readily detected 6 to 
10 weeks following the initial rAAV immunisation, the overall level of exposure to the virus-
delivered antigens may be significantly less than plasmid DNA (Figure 7.1B). The net effect of 
these multiple factors is that rAAVs are not suitable vaccine vectors for TB vaccines 
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Figure 7.1 Proposed model for DNA and rAAV based immunisation. 
The onset of transgene expression following i.m.i differs between rAAV vectors or plasmid 
DNA. (A) The levels of transgene expression over time of plasmid DNA (red line) and rAAV 
viral vector (blue line). (B) Levels of fusion-antigen expression (coloured lines) and T cell 
responses (Shaded area) following multiple i.m.i. with DNA3-Ag85B-64-ESAT (red) or 
rAAV2-Ag85B-64-ESAT (blue). Black arrows indication immunisation and red arrow 
indicates aerogenic M. tuberculosis challenge. 
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Figure 7.2 Activation of the immune system following DNA and rAAV immunisation. 
Schematic representations showing activation of the immune system following immunisation 
with either (A) plasmid DNA or (B) rAAV vectors expressing mycobacterial antigens. 
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7.2 The rAAV-mediated delivery of mIL-12.  
The coordinated expression of mIL-12 and mycobacterial antigens from DNA vectors 
increases the protective efficacy of DNA vaccines (Martin et al., 2003, Palendira et al., 2002, 
Wozniak et al., 2006b). As rAAVs transduction may lead to prolonged transgene expression, a 
rAAV2 strain expressing mIL-12 was developed. While rAAV2-mIL-12 co-immunisation 
provided only moderate vaccine-specific T cell responses in co-immunised wild type mice, co-
immunisation of IL-12p40-/- mice with the rAAV2-mIL-12 construct confirmed the capacity of 
the rAAV vector to partially complement the immune defects caused by the p40 deficiency 
(Figures 5.11-15). The delivery of rAAV2-mIL-12 with the DNA vaccine expressing secreted 
M. tuberculosis proteins failed to further enhance the protective efficacy of the anti-TB  DNA 
vaccine (Figure 5.16). 
The possibility for intra-pulmonary delivery of IL-12 using the rAAV system was also 
explored. In these preliminary experiments, delivery of rAAV2-mIL-12 to the lungs of M. 
tuberculosis-infected mice did not alter the post-infection T cell responses against M. 
tuberculosis, but resulted in a small decrease in the pulmonary bacterial numbers (Figures 
5.21-22). This warrants further studies at different time-points following M, tuberculosis 
infection. These experiments utilising rAAV vectors demonstrates the importance of timing 
during the induction of an anti-TB immune response. We propose this model to explain the 
events that occurred following DNA and rAAV immunisation (Figure 7.1A). A similar model 
summarises the co-delivery of rAAV2-mIL-12 with DNA3-Ag85B-64-ESAT (Figure 7.1B). 
Further experiments would be required to determine the reasons for the failure of the 
rAAV vaccine to induce protective efficacy against M. tuberculosis. First, The delayed 
expression of the virus-encoded antigen or encoded IL-12 and the lower T cell responses than 
the DNA vaccines remain the main limitation of this study. Second, a clearer understanding of 
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the mechanism and cell types that are successfully transduced to express the fusion-antigen 
would assist in identifying critical differences between immune responses generated by rAAV 
and DNA vaccines. By taking into consideration the kinetics of the response and levels of 
transgene expression (Figure 7.1A), it may be possible to optimise the timing for rAAV 
administration and measurement of the vaccine-induced immune responses. The delay of the 
time at which the immune response is measured or the time of bacterial challenge to 2-4 weeks 
following the onset of gene expression may allow appropriate time for the development of 
vaccine-specific immune responses, and this may change the outcome of these experiments. 
Third, serotype 2 AAV was chosen for to construct the rAAVs for these experiments because 
of its their tissue specificity, however, there are other rAAV serotypes with limited tissue 
tropisms, and these may transduce muscles or lung tissue more efficiently (Blankinship et al., 
2004, Halbert et al., 2007, Halbert and Miller, 2004). Use of these serotypes may enhance both 
the speed and magnitude of the transgene expression, thus enhancing the resulting vaccine-
specific immune responses.  
 
7.3 Co-stimulatory signaling on DNA vaccine-induced responses 
The exploitation of co-stimulatory molecules to enhance vaccine-induced responses is being 
increasingly explored (Kornbluth and Stone, 2006). The critical role of co-stimulatory 
molecules for the activation and differentiation of T cells (signal 2) make them an ideal target 
for manipulation in order to generate the enhanced immune responses (Duttagupta et al., 2009). 
Co-stimulatory molecules, such as CD40L, have also been used to break tolerance to induce T 
cell responses in experimental tumour vaccine models (Mackey et al., 1997). In this study 
plasmids encoding the co-stimulatory molecules CD40L and GITRL were co-delivered with 
the DNA3-Ag85B-64-ESAT vaccine candidate. These forms of multimeric CD40L and GITRL 
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activate their respective co-stimulatory molecules and enhance the resulting T cell responses in 
distinct ways. When soluble CD40L was co-delivered with the DNA vaccine, an increase in the 
antigen-specific T cell responses occurred. The increases observed were greater following co-
delivery of the dodecameric form of CD40L than with the hexameric form of CD40L (Figures 
3.4-5). This confirms the importance of multimerisation on the potency of CD40L signaling on 
priming the immune response (Stone et al., 2006a). The increased T cell responses  following 
co-delivery of CD40L was most likely due to the activation of CD40 on APCs leading to 
increased secretion of IL-12. Nevertheless, the resulting increase in T cell responses did not 
lead to increased protective immunity (Figure 3.9). 
The co-delivery of plasmids encoding GITRL during DNA immunisation also increased 
the antigen-specific T cell responses, particularly in the CD8+ T cell compartment (Figure 3.5 
and 7). High levels of expression of GITR on T cells means that GITRL can signal T cells 
directly (Ronchetti et al., 2004), and this provides an inflammatory signal causing T cell 
expansion (van Olffen et al., 2009). There is also evidence that activation by GITRL causes 
effector T cells to be resistant to Treg-mediated suppression of the effector response (Shimizu 
et al., 2002). The increased expansion of the IFN-γ-secreting T cells was not associated with an 
increase in the protective efficacy of the DNA vaccine (Figure 3.9). These results suggest that 
for successful immune-modulation by co-stimulatory molecules, a combination of different co-
stimulatory molecules may be required to influence the outcome of the induced T cell 
responses and protective immunity significantly. This concept is being evaluated in clinical 
trials. TRICOM, is an adjuvant platform using recombinant vaccinia virus expressing the co-
stimulatory molecules, B7-1, ICAM-1, and LFA-3. This strategy of combined adjuvants 
induces T cell “hyperstimulation” in preclinical studies (Hodge et al., 1999). An alternative 
strategy uses the enhanced immune-stimulatory potential of co-stimulation while minimising 
the side effects of systemic anti-CD40 antibody (Broos et al., 2012). In the current study, the 
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effects of the co-stimulatory molecules were tested for the ability to induced antigen-specific 
IFN-γ producing T cells. A broad range of immune cells expresses CD40 and it would be 
important to explore the mechanisms of action for CD40L or α-CD40 therapy. Further studies 
to examine CD80/86 up-regulation and IL-12 release from APCs, such as DCs and 
macrophages, would be informative. Similarly, better understanding of the impact of GITRL 
co-delivery could be achieved by studying the changes in the T cell response as well as the 
effect on other T cell subsets, that are important during the induction of long-lasting memory 
responses, such as Treg and Th17 T cells, both of which express high levels of GITR (Shimizu 
et al., 2002, Wang et al., 2012b). 
 
7.4 MPT83 as a candidate antigen for subunit vaccines 
The study of the mycobacterial antigen MPT83 revealed that this membrane glycolipoprotein 
was recognised in both mice and humans during M. tuberculosis infection. Immunisation of 
C57BL/6 mice with either the purified protein with MPAL/DDA or the plasmid DNA encoding 
MPT83 resulted in significant reductions in the bacterial loads in the lungs and the spleen 
compared to the negative controls. Using overlapping peptides, the minimal H-2b-restricted 
CD8+ T cell epitope of MPT83 was identified as MPT83127-135. The defined H-2b-restricted 
CD8+ T cell epitope was used to show differences in the responses against MPT83 in different 
subunit vaccines. Immunisation with the DNA vaccine encoding MPT83 further confirmed the 
ability of DNA-MPT83 to induce CD8+ T cell responses, while immunisation with the 
recombinant protein induced potent T cell responses against the whole protein, but not the H-
2b-restricted CD8+ T cell epitope. These results warrant further evaluation of MPT83 as an 
immunogenic antigen for inclusion in future vaccine for use in humans. 
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While the development of a novel vaccine against TB that is consistently more 
protective than BCG is ideal outcome, subunit vaccines may also provide the option for 
boosting existing immunity in BCG recipients in order to improve the current BCG 
immunisation schedule. To date, at least three anti-TB vaccine candidates based on a small 
number of recombinant mycobacterial proteins with adjuvants are in various stages of phase II 
clinical trials (Kaufmann, 2011). One reason BCG is a potent inducer of T cell responses is the 
fact that this attenuated bacilli still retains a large repertoire of immunogenic mycobacterial 
antigens. Immunisation with recombinant MPT83 demonstrated promising levels of protective 
immunity in mice, similar to the levels reported for antigens included in the current vaccine 
candidates. The formulations for the panel of current anti-TB subunit vaccine candidates in 
clinical trials typically consist of fusions between two to three antigenic proteins (Dietrich and 
Doherty, 2009, Reed et al., 2009, Skeiky et al., 2010). The inclusion of additional effective 
antigens such as MPT83 may increase the protective efficacies of these vaccine candidates. 
The recombinant MPT83 used in this study was expressed using an E. coli expression 
system. While the resultant protein was immunogenic, it lacks the post-translational 
glycosylation and lipidation acquired during native expression of MPT83 by mycobacterial 
species (Michell et al., 2003, Harboe et al., 1998, Vosloo et al., 1997). Expression of 
recombinant MPT83 with its post-translation modifications, for example, using M. smegmatis 
expression systems may result in increased antigenicity. 
The studies presented in this thesis represent different approaches to improving the 
effectiveness of genetic vaccination through the use of recombinant viral vectors, virus-
mediated delivery of mIL-12, DNA-mediated delivery of co-stimulatory molecules and the use 
of a distinct mycobacterial antigen, MPT83. rAAV vectors are unequivocally effective as 
genetic transfer vectors. To further explore if rAAVs are suitable as vaccine vectors, we 
suggest optimising the time frame of the immunisation protocol and time points for the 
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evaluation of the immune response. Alternatively, other AAV serotypes could be investigated 
for their abilities to evade the development of capsid-specific responses, to activate a more 
potent innate immune response following immunisation (Mays et al., 2009) or to induce an 
earlier onset of antigen expression (Zincarelli et al., 2008). The use of multiple AAV serotypes 
in the immunisation protocol for both rAAV vaccines or rAAV2-mIL-12 adjuvants may be a 
method to circumvent the development of rAAV2-specific responses. Future experiments to 
explore the feasibility of co-stimulatory molecules as adjuvants may include studying the 
effects of multimeric soluble CD40L treatment on other immune cells, such as DCs, 
macrophages and B cells. The responses generated following GITRL stimulation may be 
further dissected by investigating the effect on Tregs as well as DCs and effector T cells. 
Alternatively, co-stimulatory molecule-based adjuvants may be improved by developing a 
strategy to express them as membrane proteins in specific cell types, which would preserve 
activation and signal transduction of both the receptor and ligand molecules during 
crosslinking. The immunogenicity and protective efficacy of MPT83 can be tested in other 
vaccine formulations or in larger animal models. Further, if the poly-functional potential of T 
cells can be studied in future experiments. The measurement of multiple cytokines will provide 
a more precise dissection of the immune responses induced following rAAV immunisation, 
CD40L or GITRL treatments, as well as the responses induced by MPT83, and provide a more 
solid indicator for quality and protective potential of the vaccine candidates. 
 
7.5 Conclusions 
This study outlines the importance of vaccine type and formulation in augmenting the signals, 
which influence the induction of vaccine-specific immune response and ultimately protective 
immunity against M. tuberculosis. While rAAV2 provide an attractive genetic transfer vehicle, 
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it did not provide sufficient pro-inflammatory signals (signal 0) to induce potent T cell 
responses or protective immunity. Using the same rAAV vector to deliver mIL-12 (signal 3) 
only resulted in moderate increases in the antigen-specific T cells responses and did not 
influence bacterial burden following intra-pulmonary delivery. Both of these effects may be 
attributed to the levels of transgene expression by rAAVs. While the co-delivery of plasmid 
encoding CD40L or GITRL co-stimulatory molecules (signal 2) with a DNA vaccine provided 
moderately increased T cell responses, this did not translate into increased protective efficacy 
of the DNA vaccine against M. tuberculosis infection. The immunogenicity of the selected 
antigen such as MPT83 (signal 1), remains an important factor in determining the protective 
potential of the vaccine. The protective effect of the secreted lipoprotein, MPT83, as a DNA 
and protein vaccine is encouraging and warrants further application of this protein as a subunit 
vaccine against TB. The study demonstrates that in order to achieve enhanced protective 
efficacy comparable to BCG immunisation, multiple strategies rather than single approaches 
are required to optimise the activation of the signals essential during antigen presentation and T 
cell activation for protection against M. tuberculosis. 
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